0001683168-24-007708.txt : 20241107 0001683168-24-007708.hdr.sgml : 20241107 20241107083600 ACCESSION NUMBER: 0001683168-24-007708 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20240930 FILED AS OF DATE: 20241107 DATE AS OF CHANGE: 20241107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sonoma Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001367083 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 680423298 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33216 FILM NUMBER: 241433377 BUSINESS ADDRESS: STREET 1: 5445 CONESTOGA COURT, SUITE 150 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 800-759-9305 MAIL ADDRESS: STREET 1: 5445 CONESTOGA COURT, SUITE 150 CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: Oculus Innovative Sciences, Inc. DATE OF NAME CHANGE: 20060622 10-Q 1 sonoma_i10q-093024.htm FORM 10-Q FOR SEPTEMBER 2024 SONOMA PHARMACEUTICALS, INC. FORM 10-Q
false --03-31 2025 Q2 0001367083 0001367083 2024-04-01 2024-09-30 0001367083 2024-11-07 0001367083 2024-09-30 0001367083 2024-03-31 0001367083 us-gaap:ConvertiblePreferredStockMember 2024-09-30 0001367083 us-gaap:ConvertiblePreferredStockMember 2024-03-31 0001367083 2024-07-01 2024-09-30 0001367083 2023-07-01 2023-09-30 0001367083 2023-04-01 2023-09-30 0001367083 2023-03-31 0001367083 2023-09-30 0001367083 us-gaap:CommonStockMember 2024-03-31 0001367083 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001367083 us-gaap:RetainedEarningsMember 2024-03-31 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001367083 us-gaap:CommonStockMember 2024-06-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001367083 us-gaap:RetainedEarningsMember 2024-06-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001367083 2024-06-30 0001367083 us-gaap:CommonStockMember 2023-03-31 0001367083 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001367083 us-gaap:RetainedEarningsMember 2023-03-31 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001367083 us-gaap:CommonStockMember 2023-06-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001367083 us-gaap:RetainedEarningsMember 2023-06-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001367083 2023-06-30 0001367083 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001367083 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001367083 2024-04-01 2024-06-30 0001367083 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001367083 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001367083 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001367083 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001367083 2023-04-01 2023-06-30 0001367083 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001367083 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001367083 us-gaap:CommonStockMember 2024-09-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001367083 us-gaap:RetainedEarningsMember 2024-09-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001367083 us-gaap:CommonStockMember 2023-09-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001367083 us-gaap:RetainedEarningsMember 2023-09-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001367083 us-gaap:StockOptionMember 2024-07-01 2024-09-30 0001367083 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001367083 us-gaap:StockOptionMember 2024-04-01 2024-09-30 0001367083 us-gaap:StockOptionMember 2023-04-01 2023-09-30 0001367083 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001367083 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001367083 us-gaap:WarrantMember 2024-04-01 2024-09-30 0001367083 us-gaap:WarrantMember 2023-04-01 2023-09-30 0001367083 SNOA:CommonStockUnitsMember 2024-07-01 2024-09-30 0001367083 SNOA:CommonStockUnitsMember 2023-07-01 2023-09-30 0001367083 SNOA:CommonStockUnitsMember 2024-04-01 2024-09-30 0001367083 SNOA:CommonStockUnitsMember 2023-04-01 2023-09-30 0001367083 SNOA:InsurancePremiumFinancingMember 2024-02-06 0001367083 SNOA:InsurancePremiumFinancingMember 2024-02-05 2024-02-06 0001367083 SNOA:InsurancePremiumFinancingMember 2024-09-30 0001367083 SNOA:InsurancePremiumFinancingMember 2024-03-31 0001367083 SNOA:EquityDistributionAgreementMember 2024-05-13 2024-09-18 0001367083 us-gaap:StockOptionMember 2024-09-30 0001367083 us-gaap:StockOptionMember 2024-04-01 2024-09-30 0001367083 us-gaap:StockOptionMember 2024-03-31 0001367083 us-gaap:RestrictedStockMember 2024-03-31 0001367083 us-gaap:RestrictedStockMember 2024-04-01 2024-09-30 0001367083 us-gaap:RestrictedStockMember 2024-09-30 0001367083 SNOA:HumanCareMember us-gaap:ProductMember 2024-07-01 2024-09-30 0001367083 SNOA:HumanCareMember us-gaap:ProductMember 2023-07-01 2023-09-30 0001367083 SNOA:HumanCareMember us-gaap:ProductMember 2024-04-01 2024-09-30 0001367083 SNOA:HumanCareMember us-gaap:ProductMember 2023-04-01 2023-09-30 0001367083 SNOA:AnimalCareMember us-gaap:ProductMember 2024-07-01 2024-09-30 0001367083 SNOA:AnimalCareMember us-gaap:ProductMember 2023-07-01 2023-09-30 0001367083 SNOA:AnimalCareMember us-gaap:ProductMember 2024-04-01 2024-09-30 0001367083 SNOA:AnimalCareMember us-gaap:ProductMember 2023-04-01 2023-09-30 0001367083 us-gaap:ServiceMember SNOA:ServiceAndRoyaltyMember 2024-07-01 2024-09-30 0001367083 us-gaap:ServiceMember SNOA:ServiceAndRoyaltyMember 2023-07-01 2023-09-30 0001367083 us-gaap:ServiceMember SNOA:ServiceAndRoyaltyMember 2024-04-01 2024-09-30 0001367083 us-gaap:ServiceMember SNOA:ServiceAndRoyaltyMember 2023-04-01 2023-09-30 0001367083 us-gaap:SalesRevenueSegmentMember country:US 2024-07-01 2024-09-30 0001367083 us-gaap:SalesRevenueSegmentMember country:US 2023-07-01 2023-09-30 0001367083 us-gaap:SalesRevenueSegmentMember country:US 2024-04-01 2024-09-30 0001367083 us-gaap:SalesRevenueSegmentMember country:US 2023-04-01 2023-09-30 0001367083 us-gaap:SalesRevenueSegmentMember srt:EuropeMember 2024-07-01 2024-09-30 0001367083 us-gaap:SalesRevenueSegmentMember srt:EuropeMember 2023-07-01 2023-09-30 0001367083 us-gaap:SalesRevenueSegmentMember srt:EuropeMember 2024-04-01 2024-09-30 0001367083 us-gaap:SalesRevenueSegmentMember srt:EuropeMember 2023-04-01 2023-09-30 0001367083 us-gaap:SalesRevenueSegmentMember srt:AsiaMember 2024-07-01 2024-09-30 0001367083 us-gaap:SalesRevenueSegmentMember srt:AsiaMember 2023-07-01 2023-09-30 0001367083 us-gaap:SalesRevenueSegmentMember srt:AsiaMember 2024-04-01 2024-09-30 0001367083 us-gaap:SalesRevenueSegmentMember srt:AsiaMember 2023-04-01 2023-09-30 0001367083 us-gaap:SalesRevenueSegmentMember srt:LatinAmericaMember 2024-07-01 2024-09-30 0001367083 us-gaap:SalesRevenueSegmentMember srt:LatinAmericaMember 2023-07-01 2023-09-30 0001367083 us-gaap:SalesRevenueSegmentMember srt:LatinAmericaMember 2024-04-01 2024-09-30 0001367083 us-gaap:SalesRevenueSegmentMember srt:LatinAmericaMember 2023-04-01 2023-09-30 0001367083 us-gaap:SalesRevenueSegmentMember SNOA:RestOfTheWorldMember 2024-07-01 2024-09-30 0001367083 us-gaap:SalesRevenueSegmentMember SNOA:RestOfTheWorldMember 2023-07-01 2023-09-30 0001367083 us-gaap:SalesRevenueSegmentMember SNOA:RestOfTheWorldMember 2024-04-01 2024-09-30 0001367083 us-gaap:SalesRevenueSegmentMember SNOA:RestOfTheWorldMember 2023-04-01 2023-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerAMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerAMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerAMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerAMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerBMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerBMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerBMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerBMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerCMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerCMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerCMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerCMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerDMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerDMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerDMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-09-30 0001367083 us-gaap:SalesRevenueNetMember SNOA:CustomerDMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-09-30 0001367083 us-gaap:AccountsReceivableMember SNOA:CustomerAMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-09-30 0001367083 us-gaap:AccountsReceivableMember SNOA:CustomerAMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-09-30 0001367083 us-gaap:AccountsReceivableMember SNOA:CustomerCMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-09-30 0001367083 us-gaap:AccountsReceivableMember SNOA:CustomerCMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-09-30 0001367083 us-gaap:AccountsReceivableMember SNOA:CustomerDMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-09-30 0001367083 us-gaap:AccountsReceivableMember SNOA:CustomerDMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024

  

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________ to ______________

 

Commission file number: 001-33216

 

SONOMA PHARMACEUTICALS, INC.

(Name of registrant as specified in its charter)

 

Delaware 68-0423298
(State or other jurisdiction of Incorporation or Organization) (I.R.S. Employer identification No.)

 

5445 Conestoga Court, Suite 150, Boulder, CO 80301
(Address of principal executive offices) (Zip Code)

 

(800) 759-9305

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol Name of Each Exchange on Which Registered
Common Stock, $0.0001 par value SNOA The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒     No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

Large accelerated Filer ☐ Accelerated Filer ☐
Non-accelerated Filer Smaller reporting company
Emerging Growth Company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐    No

 

The number of shares outstanding of the registrant’s common stock, par value $0.0001 per share, as of November 7, 2024 was 1,339,170.

 

 

 

   

 

 

SONOMA PHARMACEUTICALS, INC.

 

Index

 

    Page
   
PART I - FINANCIAL INFORMATION  
Item 1. Unaudited Financial Statements 3
  Condensed Consolidated Balance Sheets 3
  Condensed Consolidated Statements of Comprehensive Loss 4
  Condensed Consolidated Statements of Cash Flows 5
  Condensed Consolidated Statements of Changes in Stockholders’ Equity 6
  Notes to Condensed Consolidated Financial Statements 7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16
Item 3. Quantitative and Qualitative Disclosures About Market Risk 27
Item 4. Controls and Procedures 27
     
PART II - OTHER INFORMATION  
Item 1. Legal Proceedings 29
Item 1A. Risk Factors 29
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 29
Item 3. Defaults Upon Senior Securities 29
Item 4. Mine Safety Disclosures (Not applicable.) 29
Item 5. Other Information 29
Item 6. Exhibits 30
  Signatures 3

 

 

 

 

 

 

 

 

 

 2 

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands, except share amounts)

         
  

September 30,

2024

  

March 31,

2024

 
   (Unaudited)     
ASSETS          
Current assets:          
Cash and cash equivalents  $4,078   $3,128 
Accounts receivable, net   3,157    2,898 
Inventories, net   2,837    2,719 
Prepaid expenses and other current assets   1,929    3,541 
Current portion of deferred consideration, net of discount   220    262 
Total current assets   12,221    12,548 
Property and equipment, net   255    365 
Operating lease, right of use assets   162    286 
Deferred tax asset   792    1,145 
Deferred consideration, net of discount, less current portion   179    330 
Other assets   76    66 
Total assets  $13,685   $14,740 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $770   $607 
Accrued expenses and other current liabilities   2,022    2,113 
Deferred revenue, current portion   319    478 
Short-term debt   82    323 
Operating lease liabilities, current portion   116    198 
Total current liabilities   3,309    3,719 
Deferred revenue, net of current portion   45    87 
Withholding tax payable   4,933    4,710 
Operating lease liabilities, less current portion   46    87 
Total liabilities   8,333    8,603 
Commitments and Contingencies (Note 5)        
Stockholders’ Equity:          
Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at September 30, 2024 and March 31, 2024, respectively, no shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively        
Common stock, $0.0001 par value; 50,000,000 and 24,000,000 shares authorized at September 30, 2024 and March 31, 2024, respectively, 1,338,615 and 780,371 shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively (Note 1) (Note 7)        
Additional paid-in capital   205,651    203,209 
Accumulated deficit   (196,102)   (194,349)
Accumulated other comprehensive loss   (4,197)   (2,723)
Total stockholders’ equity   5,352    6,137 
Total liabilities and stockholders’ equity  $13,685   $14,740 

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

 3 

 

 

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Loss

(In thousands, except per share amounts)

(Unaudited)

                 
  

Three Months Ended

September 30,

  

Six Months Ended

September 30,

 
   2024   2023   2024   2023 
Revenues  $3,579   $2,731   $6,970   $6,158 
Cost of revenues   2,218    1,741    4,303    3,964 
Gross profit   1,361    990    2,667    2,194 
Operating expenses                    
Research and development   506    536    976    861 
Selling, general and administrative   1,705    1,662    3,714    3,781 
Total operating expenses   2,211    2,198    4,690    4,642 
Loss from operations   (850)   (1,208)   (2,023)   (2,448)
Other income (expense), net   387    (90)   563    (301)
Loss from operations before income taxes   (463)   (1,298)   (1,460)   (2,749)
Income tax expense   (147)   (186)   (293)   (153)
Net loss  $(610)  $(1,484)  $(1,753)  $(2,902)
                     
Net loss per share: basic and diluted  $(0.59)  $(5.75)  $(1.86)  $(11.47)
Weighted-average number of shares: basic and diluted   1,034    258    943    253 
                     
Other comprehensive loss                    
Net loss  $(610)  $(1,484)  $(1,753)  $(2,902)
Foreign currency translation adjustments   (593)   (213)   (1,474)   298 
Comprehensive loss  $(1,203)  $(1,697)  $(3,227)  $(2,604)

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

 4 

 

 

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

         
   Six Months Ended 
   September 30, 
   2024   2023 
Cash flows from operating activities:          
Net loss  $(1,753)  $(2,902)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   74    90 
Stock-based compensation   121    307 
Deferred income taxes   188    144 
Changes in operating assets and liabilities:          
Accounts receivable, net   (427)   375 
Inventories, net   (370)   403 
Prepaid expenses and other current assets   1,134    47 
Deferred consideration   99    104 
Operating lease, right-of-use assets   102    79 
Accounts payable   219    132 
Accrued expenses and other current liabilities   62    (353)
Deferred revenue   (128)   (31)
Withholding tax payable   223    238 
Operating lease liabilities   (102)   (79)
Net cash used in operating activities   (558)   (1,446)
           
Cash flows from investing activities:          
Purchases of property and equipment   (31)   (19)
Net cash used in investing activities   (31)   (19)
           
Cash flows from financing activities:          
Proceeds (costs) from issuance of common stock, net of offering expenses   2,289    (5)
Proceeds from exercise of employee stock options   33     
Payments for fractional shares related to reverse-split   (1)    
Principal payments on short-term debt   (241)   (259)
Net cash provided by (used in) financing activities   2,080    (264)
Effect of exchange rate on cash and cash equivalents   (541)   46 
Net increase (decrease) in cash and cash equivalents   950    (1,683)
Cash and cash equivalents, beginning of period   3,128    3,820 
Cash and cash equivalents, end of period  $4,078   $2,137 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $8   $10 

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

 5 

 

 

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Changes in Stockholders’ Equity

For the Six Months ended September 30, 2024 and 2023

(In thousands, except share amounts)

(Unaudited)

                         
   Common Stock
($0.0001 par Value)
   Additional
Paid in
   Accumulated   Accumulated Other Comprehensive     
   Shares   Amount   Capital   Deficit   Loss   Total 
Balance, March 31, 2024   780,371   $   $203,209   $(194,349)  $(2,723)  $6,137 
Proceeds from At-the-Market sale of common stock, net of offering expenses   158,311        748            748 
Proceeds from exercise of employee stock options   2,000        7            7 
Employee stock-based compensation expenses   9,538        107            107 
Foreign currency translation adjustment                   (881)   (881)
Net loss               (1,143)       (1,143)
Balance, June 30, 2024   950,220   $   $204,071   $(195,492)  $(3,604)  $4,975 
Proceeds from At-the-Market sale of common stock, net of offering expenses   381,433        1,541            1,541 
Proceeds from exercise of employee stock options   7,250        26            26 
Payments for fractional shares related to reverse-split   (288)       (1)           (1)
Employee stock-based compensation expenses           14            14 
Foreign currency translation adjustment                   (593)   (593)
Net loss               (610)       (610)
Balance, September 30, 2024   1,338,615   $   $205,651   $(196,102)  $(4,197)  $5,352 

 

                         
   Common Stock
($0.0001 par Value)
   Additional
Paid in
   Accumulated   Accumulated Other Comprehensive     
   Shares   Amount   Capital   Deficit   Loss   Total 
Balance, March 31, 2023   246,678   $   $200,909   $(189,514)  $(3,418)  $7,977 
Cost in connection with ATM           (5)           (5)
Employee stock-based compensation expenses   10,402        177            177 
Foreign currency translation adjustment                   511    511 
Net loss               (1,418)       (1,418)
Balance, June 30, 2023   257,080   $   $201,081   $(190,932)  $(2,907)  $7,242 
Employee stock-based compensation expenses   1,887        130            130 
Foreign currency translation adjustment                   (213)   (213)
Net loss               (1,484)       (1,484)
Balance, September 30, 2023   258,967   $   $201,211   $(192,416)  $(3,120)  $5,675 

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

 

 

 6 

 

 

SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

(Rounded to nearest thousand unless specified)

(Unaudited)

 

 

Note 1. Organization and Recent Developments

 

Organization

 

Sonoma Pharmaceuticals, Inc. (the “Company”) was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware in December 2006. The Company moved its principal office from Petaluma, California to Woodstock, Georgia in June 2020 and to Boulder, Colorado in October 2022. The Company is a global healthcare leader for developing and producing stabilized hypochlorous acid (“HOCl”) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, animal health care, and as a non-toxic disinfectant. The Company’s products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. The Company sells its products either directly or via partners in 55 countries worldwide.

 

Reverse Stock Split

 

Effective August 29, 2024, the Company effected a reverse stock split of its common stock, par value $0.0001 per share. Every twenty shares of common stock were reclassified and combined into one share of common stock. No fractional shares were issued as a result of the reverse stock split. Instead, each fractional share was settled with cash. The reverse stock split reduced the number of shares of the Company’s common stock outstanding from 21,174,693 to 1,058,447. The total number of authorized shares of common stock was not proportionally decreased and the par value per share of the common stock continues to be $0.0001. The reverse stock split has been retroactively applied to all share and per share amounts in the condensed consolidated financial statements and accompanying footnotes.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended March 31, 2024, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on June 17, 2024.

 

 

 

 7 

 

 

 

Note 2. Liquidity and Financial Condition

 

The Company reported a net loss of $610,000 and $1,484,000 for the three months ended September 30, 2024 and 2023, respectively, and $1,753,000 and $2,902,000 for the six months ended September 30, 2024 and 2023, respectively. At September 30, 2024 and March 31, 2024, the Company’s accumulated deficit amounted to $196,102,000 and $194,349,000, respectively. The Company had working capital of $8,912,000 and $8,829,000 as of September 30, 2024 and March 31, 2024, respectively. The cash balance at September 30, 2024 and March 31, 2024 was $4,078,000 and $3,128,000, respectively. During the six months ended September 30, 2024 and 2023, net cash used in operating activities amounted to $558,000 and $1,446,000, respectively.

 

Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed. If the economic climate in the U.S. deteriorates, the Company’s ability to raise additional capital could be negatively impacted. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s continued efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of the Company. This uncertainty along with the Company’s history of losses indicates that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.

 

 

Note 3. Summary of Significant Accounting Policies

  

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.

 

Net Loss per Share

 

The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.

 

The following table provides the net loss for each period along with the computation of basic and diluted net loss per share:

                
  

Three Months Ended

September 30,

  

Six Months Ended

September 30,

 
(In thousands, except per share data)  2024   2023   2024   2023 
Numerator:                
Net loss  $(610)  $(1,484)  $(1,753)  $(2,902)
                     
Denominator:                    
Weighted-average number of common shares outstanding: basic and diluted   1,034    258    943    253 
                     
Net loss per share: basic and diluted  $(0.59)  $(5.75)  $(1.86)  $(11.47)

 

 

 

 8 

 

 

The computation of basic loss per share for the three and six months ended September 30, 2024 and 2023 excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive.

                 
  

Three Months Ended

September 30,

  

Six Months Ended

September 30,

 
(In thousands)  2024   2023   2024   2023 
Stock options   42    26    42    26 
Warrants       5        5 
Common stock units (1)       2        2 
    42    33    42    33 

 

(1) Consists of 1,533 restricted stock units and warrants to purchase 766 shares of common stock.

  

Revenue Recognition

 

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”), Topic 606 Revenue from Contracts with Customers (“Topic 606”). Revenue is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.

 

The Company derives the majority of its revenue through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company has also entered into agreements to license its technology and products.

 

The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled.

 

For all of the Company’s sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able to estimate the amount of product that will be returned.

 

The Company has entered into consignment arrangements, in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company recognizes revenue based on a variable percentage of a fixed price. Revenue recognized varies depending on whether a patient is covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the Company’s rebate program.

 

 

 

 9 

 

 

Sales to stocking distributors are made under terms with fixed pricing and limited rights of return (known as “stock rotation”) of the Company’s products held in their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.

 

The Company evaluates the creditworthiness of new customers and monitors the creditworthiness of its existing customers to determine whether an event or changes in their financial circumstances would raise doubt as to the collectability of a sale at the time in which a sale is made. Payment terms on sales are generally 30 to 90 days.

 

The Company assessed the promised goods and services in the technical support contract with Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and as separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.

 

Accounts Receivable

 

Trade accounts receivable are recorded net of allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based on analysis of contractual terms and historical trends.

 

The Company’s policy is to reserve for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company did not deem it necessary to record an allowance for doubtful accounts for probable credit losses at September 30, 2024 and March 31, 2024. Additionally, at September 30, 2024 and March 31, 2024, the Company has allowances of $66,000 and $27,000, respectively, related to potential discounts, returns, distributor fees and rebates. The allowances are included in Accounts Receivable, net in the accompanying condensed consolidated balance sheets.

 

Inventories

 

Inventories are stated at the lower of cost, cost being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.

 

Due to changing market conditions, estimated future requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value. At September 30, 2024 and March 31, 2024, the Company recorded provisions to reduce the carrying amounts of inventories to their net realizable value in the amounts of $254,000 and $296,000, respectively, which is included in Inventories, net in the accompanying condensed consolidated balance sheets.

 

Recent Accounting Standards

 

Accounting standards that have been issued or proposed by the FASB, the SEC or other standard setting bodies that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption.

 

 

 

 10 

 

 

 

Note 4. Condensed Consolidated Balance Sheet

 

Inventories, net

 

Inventories, net consist of the following:

        
   September 30,   March 31, 
   2024   2024 
Raw materials  $1,670,000   $1,802,000 
Finished goods   1,421,000    1,213,000 
Inventories, gross    3,091,000    3,015,000 
Less: allowance for obsolete and excess inventory   (254,000)   (296,000)
Total inventories, net  $2,837,000   $2,719,000 

 

Leases

 

The Company’s operating leases are comprised primarily of facility leases. Balance sheet information related to the Company’s leases is presented below:

         
   September 30,   March 31, 
   2024   2024 
Operating leases:          
Operating lease right-of-use assets  $162,000   $286,000 
Operating lease liabilities – current   116,000    198,000 
Operating lease liabilities – non-current   46,000    87,000 

 

Other information related to leases is presented below:

 

Six Months Ended September 30, 2024    
Operating lease cost  $186,000 
Other information:     
Operating cash flows from operating leases   (102,000)
Weighted-average remaining lease term – operating leases (in months)   18.7 
Weighted-average discount rate – operating leases   6.00% 

 

As of September 30, 2024, the annual minimum lease payments of our operating lease liabilities were as follows:

     
For Years Ending March 31,    
2025 (excluding the six months ended September 30, 2024)  $87,000 
2026   67,000 
2027   14,000 
2028   9,000 
Total future minimum lease payments, undiscounted   177,000 
Less: imputed interest   (15,000)
Present value of future minimum lease payments  $162,000 

  

 

 

 11 

 

 

 

Note 5. Commitments and Contingencies

 

Legal Matters

 

The Company may be involved in legal matters arising in the ordinary course of business including matters involving proprietary technology from time to time. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation may have a material adverse effect on its business and financial condition of comprehensive loss.

 

Employment Matters

 

The Company has employment agreements in place with two of its key executives. These executive employment agreements provide, among other things, for the payment of up to eighteen months of severance compensation for terminations under certain circumstances.

 

As of September 30, 2024, with respect to these agreements, aggregated annual salaries was $586,000 and potential severance payments to these key executives is $1,300,000, if triggered.

 

 

Note 6. Debt

 

Financing of Insurance Premiums

 

On February 6, 2024, the Company entered into a note agreement for $373,000 with an interest rate of 8.42% per annum with final payment on November 1, 2024. This instrument was issued in connection with financing insurance premiums. The note is payable in nine monthly installment payments of principal and interest of $42,000, with the first installment beginning March 1, 2024. At September 30, 2024 and March 31, 2024, the outstanding principal on the note amounted to $82,000 and $323,000, respectively.

 

 

Note 7. Stockholders’ Equity

 

Authorized Capital

 

Effective August 29, 2024, the Company increased its authorized shares from 24,000,000 to 50,000,000 shares of common stock with a par value of $0.0001 per share.  Additionally, the Company is authorized to issue 714,286 shares of convertible preferred stock with a par value of $0.0001 per share.

 

Sale of Common Stock

 

In connection with the Equity Distribution Agreement that the Company entered into on December 15, 2023 with Maxim Group LLC (“Maxim”), as amended, from May 13, 2024 to September 18, 2024 the Company sold 539,744 shares of its common stock for gross proceeds of $2,490,000 and net proceeds of $2,289,000 after deducting commissions and other offering expenses paid by the Company.

 

 

 

 12 

 

 

 

Note 8. Stock-Based Compensation

 

For the three months ended September 30, 2024 and 2023, the Company incurred $14,000 and $130,000 of stock-based compensation expense, respectively. For the six months ended September 30, 2024 and 2023, the Company incurred $121,000 and $307,000 of stock-based compensation expense, respectively. All stock-based compensation incurred is included in selling, general and administrative expense in the accompanying condensed consolidated statements of comprehensive loss.

 

At September 30, 2024, there was unrecognized compensation costs of $229,000 related to stock options which is expected to be recognized over a weighted-average amortization period of 1.80 years.

 

Stock options award activity is as follows:

        
   Number of
Shares
   Weighted-
Average
Exercise Price
 
Outstanding at April 1, 2024   51,675   $62.60 
Options exercised   (9,250)   3.60 
Options forfeited   (250)   3.60 
Options expired   (10)   2,402 
Outstanding at September 30, 2024   42,165   $75.77 
Exercisable at September 30, 2024   28,335   $107.92 

 

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock, or $3.07 per share at September 30, 2024.

 

Restricted stock award activity is as follows:

          
  

Number of

Shares

  

Weighted

Average Award

Date Fair Value

per Share

 
Unvested restricted stock awards outstanding at April 1, 2024      $ 
Restricted stock awards granted   9,538    4.00 
Restricted stock awards vested   (9,538)   4.00 
Unvested restricted stock awards outstanding at September 30, 2024      $ 

 

The Company issues new shares of common stock upon exercise of stock options or release of restricted stock awards.

 

 

 

 13 

 

 

 

Note 9. Income Taxes

 

At the end of each interim reporting period, the Company determines the income tax provision by using an estimate of the annual effective tax rate, adjusted for discrete items occurring in the quarter.

 

Our effective tax rate for the three and six months ended September 30, 2024 was (31.5)% and (20.5)%, respectively. The Company’s effective tax rate for the three and six months ended September 30, 2024 differed from the federal statutory tax rate of 21% primarily due to the valuation allowance recognized against deferred tax assets in the U.S., and permanent tax adjustment of intercompany interest expense in Mexico and Netherlands.

 

Judgment is required in determining whether deferred tax assets will be realized in full or in part. Management assesses the available positive and negative evidence on a jurisdictional basis to estimate if deferred tax assets will be recognized and when it is more likely than not that all or some deferred tax assets will not be realized, and a valuation allowance must be established. As of September 30, 2024, the Company continues to maintain a valuation allowance in the U.S.

 

 

Note 10. Revenue Disaggregation

 

The Company generates product revenues from products which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services which are provided to medical device manufacturers.

 

The following table presents the Company’s disaggregated revenues by revenue source:

                
   Three Months Ended September 30,   Six Months Ended September 30, 
   2024   2023   2024   2023 
Human Care  $2,957,000   $2,075,000   $5,833,000   $4,825,000 
Animal Care   402,000    489,000    801,000    1,067,000 
Service and Royalty   220,000    167,000    336,000    266,000 
   $3,579,000   $2,731,000   $6,970,000   $6,158,000 

 

The following table shows the Company’s revenues by geographic region:

                  
   Three Months Ended September 30,   Six Months Ended September 30, 
   2024   2023   2024   2023 
United States  $675,000   $590,000   $1,317,000   $1,396,000 
Europe   1,506,000    1,201,000    2,794,000    2,271,000 
Asia   776,000    346,000    1,253,000    1,208,000 
Latin America   465,000    260,000    1,345,000    747,000 
Rest of the World   157,000    334,000    261,000    536,000 
Total  $3,579,000   $2,731,000   $6,970,000   $6,158,000 

 

 

 

 14 

 

 

 

Note 11. Significant Customer Concentrations

 

The following table shows major customers revenues as a percentage of net revenue:

                       
    Three Months Ended September 30,     Six Months Ended September 30,  
    2024     2023     2024     2023  
Customer A     *%       13%       *%       14%  
Customer B     13%       10%       19%       12%  
Customer C     19%       21%       19%       17%  
Customer D     12%       *%       *%       *%  

 

The following table shows major customers accounts receivable balances as a percentage of net accounts receivables:

             
    September 30,  
    2024     2023  
Customer A     16%       11%  
Customer C     11%       13%  
Customer D     20%       20%  

 

* Represents less than 10%

 

 

Note 12. Subsequent Events

 

Management has evaluated subsequent events or transactions occurring through the date the condensed consolidated financial statements were issued. The Company does not have subsequent events to report.

 

 

 

 

 

 

 15 

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and notes to those statements included elsewhere in this Quarterly Report on Form 10-Q as of September 30, 2024 and our audited consolidated financial statements for the year ended March 31, 2024 included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission on June 17, 2024.

 

This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this report, the words “anticipate,” “suggest,” “estimate,” “plan,” “aim,” “seek,” “project,” “continue,” “ongoing,” “potential,” “expect,” “predict,” “believe,” “intend,” “may,” “will,” “should,” “could,” “would,” “likely,” “proposal,” and similar expressions are intended to identify forward-looking statements.

 

Forward-looking statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected. These risks and uncertainties include, but are not limited to the risks described in our Annual Report on Form 10-K including: our ability to become profitable; our dependence on third-party distributors; certain tax impacts of inter-company loans between us and our Mexican subsidiary; the progress and timing of our development programs and regulatory approvals for our products; the benefits and effectiveness of our products; the ability of our products to meet existing or future regulatory standards; the progress and timing of clinical trials and physician studies; our expectations and capabilities relating to the sales and marketing of our current products and our product candidates; our ability to compete with other companies that are developing or selling products that are competitive with our products; the establishment of strategic partnerships for the development or sale of products; the risk our research and development efforts do not lead to new products; the timing of commercializing our products; our ability to penetrate markets through our sales force, distribution network, and strategic business partners to gain a foothold in the market and generate attractive margins; the ability to attain specified revenue goals within a specified time frame, if at all, or to reduce costs; the outcome of discussions with the U.S. Food and Drug Administration, or FDA, and other regulatory agencies; the content and timing of submissions to, and decisions made by, the FDA and other regulatory agencies, including demonstrating to the satisfaction of the FDA the safety and efficacy of our products; our ability to manufacture sufficient amounts of our products for commercialization activities; our ability to protect our intellectual property and operate our business without infringing on the intellectual property of others; our ability to continue to expand our intellectual property portfolio; the risk we may need to indemnify our distributors or other third parties; risks attendant with conducting a significant portion of our business outside the United States; our ability to comply with complex federal and state fraud and abuse laws, including state and federal anti-kickback laws; risks associated with changes to health care laws; our ability to attract and retain qualified directors, officers and employees; our expectations relating to the concentration of our revenue from international sales; our ability to expand to and commercialize products in markets outside the wound care market; our ability to protect our information technology and infrastructure; and the impact of any future changes in accounting regulations or practices in general with respect to public companies. These forward-looking statements speak only as of the date hereof. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

 

Our Business

 

We are a global healthcare leader for developing and producing stabilized hypochlorous acid, or HOCl, products for a wide range of applications, including wound care, eye care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Our products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. We sell our products either directly or via partners in 55 countries worldwide.

 

 

 

 16 

 

 

Business Channels

 

Our core market differentiation is based on being the leading developer and producer of stabilized hypochlorous acid, or HOCl, solutions. We have been in business for over 20 years, and in that time, we have developed significant scientific knowledge of how best to develop and manufacture HOCl products backed by decades of studies and data collection. HOCl is known to be among the safest and most-effective ways to relieve itch, inflammation and burns while stimulating natural healing through increased oxygenation and eliminating persistent microorganisms and biofilms.

 

We sell our products into many markets both in the U.S. and internationally. In international markets, we ship a variety of products to 55 countries. Our core strategy is to work with partners both in the United States and around the world to market and distribute our products. In some cases, we market and sell our own products.

 

Dermatology

 

We have developed unique, differentiated, prescription-strength and safe dermatologic products that support paths to healing among various key dermatologic conditions. Our products are primarily targeted at the treatment of redness and irritation, the management of scars and symptoms of eczema/atopic dermatitis. We are strategically focused on introducing innovative new products that are supported by human clinical data with applications that address specific dermatological procedures currently in demand. In addition, we look for markets where we can provide effective product line extensions and pricing to new product families.

 

In the United States, we sell our prescription and office dispense dermatology products through a distributor, including Epicyn® Facial Cleanser, Levicyn® Antimicrobial Dermal Spray, Levicyn® Gel, Levicyn® Spray Gel, Celacyn® Scar Management Gel, Lasercyn® Dermal Spray and Lasercyn Gel®.

 

In October 2022, we launched two new over-the-counter dermatology products in the United States, Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel for the alleviation of red bumps, rashes, shallow skin fissures, peeling, and symptoms of eczema/atopic dermatitis, and Rejuvacyn® Advanced Skin Repair Cooling Mist for management of minor skin irritations following cosmetic procedures as well as daily skin health and hydration.

 

In June 2022, the Natural Products Association certified Rejuvacyn Advanced as a Natural Personal Care Product. Reliefacyn Advanced received the National Eczema Association Seal of AcceptanceTM in 2023.

 

In January 2023, we launched a line of office dispense products exclusively for skin care professionals, including two new prescription strength dermatology products, Reliefacyn Plus Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn Plus Skin Repair Cooling Mist. These products, along with Regenacyn Plus Scar Gel, are marketed and sold directly to dermatology practices and medical spas.

 

In January 2024, we launched LumacynTM Clarifying Mist, a direct-to-consumer skin care product in the United States. Lumacyn is an all-natural daily toner to soothe skin, reduce redness and irritation, and manage blemishes by reducing infection.

 

Our consumer products are available through Amazon.com, our online store and third-party distributors.

 

We sell dermatology products in Europe and Asia through distributors. In these international markets, we have a network of partners, ranging from country specific distributors to large pharmaceutical companies to full-service sales and marketing companies. We work with our international partners to create products they can market in their home country. Some products we develop and manufacture are custom label while others use branding we have already developed. We have created or co-developed a wide range of products for international markets using our core HOCl technology.

 

 

 

 17 

 

 

First Aid and Wound Care

 

Our HOCl-based wound care products are intended for the treatment of acute and chronic wounds as well as first- and second-degree burns, and as an intraoperative irrigation treatment. They work by first removing foreign material and debris from the skin surface and moistening the skin, thereby improving wound healing. Secondly, our HOCl products assist in the wound healing process by removing microorganisms. HOCl is an important constituent of our innate immune system, formed and released by the macrophages during phagocytosis. Highly organized cell structures such as human tissue can tolerate the action of our wound care solution while single-celled microorganisms cannot, making our products advantageous to other wound-irrigation and antiseptic solutions. Due to its unique chemistry, our wound treatment solution is also much more stable than similar products on the market and therefore maintains much higher levels of hypochlorous acid over its shelf life.

 

In the United States, we sell our wound care products directly to hospitals, physicians, nurses, and other healthcare practitioners and indirectly through non-exclusive distribution arrangements. In Europe, the Middle East and Asia, we sell our wound care products through a diverse network of distributors.

 

In March 2021, we received approval to market and use our HOCl products as biocides under Article 95 of the European Biocidal Products Regulation in France, Germany and Portugal. The approval applies to our products MucoClyns™ for human hygiene to be marketed and commercialized by us, MicrocynAH® for animal heath marketed and commercialized through our partner, Petagon Limited, and MicroSafe for disinfectant use to be marketed and commercialized through our partner, MicroSafe Group DMCC.

 

In June 2022, the Natural Products Association certified Microcyn OTC as a Natural Personal Care Product in the United States.

 

In June 2023, we announced a new application of our HOCl technology for intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures. The intraoperative pulse lavage container is designed to be used in combination with a pulse lavage irrigation device, or flush gun, for abdominal, laparoscopic, orthopedic, and periprosthetic procedures. It is in trial use by hospitals in Europe and launched in the U.S. in November 2023.

 

In April 2024, we announced expansion of our Microcyn Negative Pressure Wound Therapy Solution products line, now available in 250mL, 450mL and 990mL sizes to meet the diverse needs of healthcare professionals and patients.

 

In July 2024, we announced an expansion of our distributor base in Europe through a new partnership with Smart Healthcare Company (SHC) s.r.o. for the distribution of Microdacyn60® wound care products into Ukraine.

 

In August, 2024, we entered into a distribution agreement with Medline Industries, LP, for the marketing and distribution of our wound care products in the United States. The agreement is for an initial term of five years, subject to automatic one-year renewal periods. In October 2024, we entered into an amendment to the agreement which allows Medline to also sell our wound care products in Canada, as well as to sell additional over-the-counter wound care products to retailers in both countries.

 

Eye Care

 

In September 2021, we launched Ocucyn® Eyelid & Eyelash Cleanser, which is sold directly to consumers on Amazon.com, through our online store, and through third party distributors. Ocucyn Eyelid & Eyelash Cleanser, designed for everyday use, is a safe, gentle, and effective solution for good eyelid and eyelash hygiene.

 

Our prescription product Acuicyn® Eyelid & Eyelash Cleanser is a prescription solution for symptoms of blepharitis and the daily hygiene of eyelids and lashes and helps manage red, itchy, crusty and inflamed eyes. It is strong enough to kill the bacteria that causes discomfort, fast enough to provide near instant relief, and gentle enough to use as often as needed.

 

 

 

 18 

 

 

In international markets we rely on distribution partners to sell our eye products. In May 2020, we entered into an expanded license and distribution agreement with our existing partner, Brill International S.L., for our Microdacyn60® Eye Care HOCl-based product. Under the license and distribution agreement, Brill has the right to market and distribute our eye care product under the private label Ocudox in Italy, Germany, Spain, Portugal, France, and the United Kingdom for a period of 10 years, subject to meeting annual minimum sales quantities. In return, Brill paid us a one-time fee, and the agreed upon supply prices. In parts of Asia, Dyamed Biotech markets our eye product under the private label Ocucyn.

  

Oral, Dental and Nasal Care

 

We sell a variety of oral, dental, and nasal products around the world.

 

In international markets, our product Microdacyn60 Oral Care treats mouth and throat infections and thrush. Microdacyn60 assists in reducing inflammation and pain, provides soothing cough relief and does not contain any harmful chemicals. It does not stain teeth, is non-irritating, non-sensitizing, has no contraindications and is ready for use with no mixing or dilution.

 

Our international nasal care product Sinudox™ based on our HOCl technology is an electrolyzed solution intended for nasal irrigation. Sinudox clears and cleans stuffy, runny noses and blocked or inflamed sinuses by ancillary ingredients that may have a local antimicrobial effect. Sinudox is currently sold through Amazon in Europe. In other parts of the world, we partner with distributors to sell Sinudox.

 

Podiatry

 

Our HOCl-based wound care products are also indicated for the treatment of diabetic foot ulcers. In the United States, we sell our wound care products directly to podiatrists as well as hospitals, nurses, and other healthcare practitioners and indirectly through non-exclusive distribution arrangements. In Europe, we sell our wound care products for podiatric use through a diverse network of distributors.

 

In April 2023, we launched PodiacynTM Advanced Everyday Foot Care direct to consumers for over-the-counter use in the United States, intended for management of foot odors, infections, and irritations, as well as daily foot health and hygiene. Podiacyn is available through Amazon.com, our online store and third-party distributors.

 

Animal Health Care

 

MicrocynAH® is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections. It is intended for the safe and rapid treatment of a variety of animal afflictions including cuts, burns, lacerations, rashes, hot spots, rain rot, post-surgical sites, pink eye symptoms and wounds to the outer ear.

 

For our animal health products sold in the U.S. and Canada, we partner with Compana Pet Brands. Compana distributes non-prescription products to national pet-store retail chains and farm animal specialty stores, such as PetSmart, Tractor Supply, Cabela’s, PetExpress, Bass Pro Shops, and Menards. In August 2022, we announced the launch of a MicrocynVS® line of products exclusively for veterinarians for the management of wound, skin, ear and eye afflictions in all animal species.

 

For the Asian and European markets, in May 2019 we partnered with Petagon an international importer and distributor of quality pet food and products for an initial term of five years. We supply Petagon with all MicrocynAH products sold by Petagon. In August 2020, Petagon received a license from the People’s Republic of China for the import of veterinary drug products manufactured by us. This is the highest classification Petagon and Sonoma can receive for animal health products in China.

 

 

 

 19 

 

 

Surface Disinfectants

 

Our HOCl technology has been formulated as a disinfectant and sanitizer solution for our partner MicroSafe and is sold in numerous countries. It is designed to be used to spray in aerosol format in areas and environments likely to serve as a breeding ground for the spread of infectious disease, which could result in epidemics or pandemics. The medical-grade surface disinfectant solution is used in hospitals worldwide to protect doctors and patients. In May 2020, Nanocyn® Disinfectant & Sanitizer received approval to be entered into the Australian Register of Therapeutic Goods, or ARTG for use against the coronavirus SARS-CoV-2, or COVID-19, and was also authorized in Canada for use against COVID-19. Nanocyn has also met the stringent environmental health and social/ethical criteria of Good Environmental Choice Australia, or GECA, becoming one of the very few eco-certified, all-natural disinfectant solutions in Australia.

 

Through our partner MicroSafe, we sell hard surface disinfectant products into Europe, the Middle East and Australia.

 

In July 2021, we granted MicroSafe the non-exclusive right to sell and distribute Nanocyn in the United States provided that MicroSafe secure U.S. EPA approval. In April of 2022, MicroSafe secured the EPA approval for Nanocyn® Disinfectant & Sanitizer, meaning that it can now be sold in the United States as a surface disinfectant, and it was subsequently added to the EPA’s list N for use against COVID-19. In June 2022, the EPA added Nanocyn to List Q as a disinfectant for Emerging Viral Pathogens, including Ebola virus, Mpox, and SARS-CoV-2, and in March 2023 the EPA added Nanocyn to Lists G and H, for use against Methicillin Resistant Staphylococcus Aureus (MRSA), Salmonella, Norovirus, Poliovirus, and as a fungicide. Nanocyn also received the Green Seal® Certification after surpassing a series of rigorous standards that measure environmental health, sustainability and product performance. Nanocyn is currently sold by MicroSafe in Europe, the Middle East and Australia.

 

In August 2024, we announced that the Australian TGA approved extended claims for Nanocyn for use against Candida auris (C. auris) and Clostritium Difficile (C. diff.) in ten minutes.

 

Additional Information

 

Investors and others should note that we announce material financial information using our company website (www.sonomapharma.com), our investor relations website (ir.sonomapharma.com), SEC filings, press releases, public conference calls and webcasts. The information on, or accessible through, our websites is not incorporated by reference in this Quarterly Report on Form 10-Q.

Results of Operations

 

Comparison of the Three Months Ended September 30, 2024 and 2023

 

Revenue

 

The following table shows our consolidated total revenue and revenue by geographic region for the three months ended September 30, 2024 and 2023:

 

  

Three Months Ended

September 30,

         
(In thousands)  2024   2023   $ Change   % Change 
United States  $675   $590   $85    14% 
Europe   1,506    1,201    305    25% 
Asia   776    346    430    124% 
Latin America   465    260    205    79% 
Rest of the World   157    334    (177)   (53%)
Total  $3,579   $2,731   $848    31% 

 

 

 

 20 

 

 

The increase in United States revenue of $85,000 for the three months ended September 30, 2024 was primarily due to increases in eye care and dermatology revenue.

 

The increase in Europe revenue for the three months ended September 30, 2024 of $305,000 was the result of a general increase in demand for our products.

 

The increase in Latin America revenue for the three months ended September 30, 2024 of $205,000 was primarily due to an increase in manufacturing orders.

 

The increase in Asia revenue of $430,000 for the three months ended September 30, 2024 was primarily due to timing of customer orders. The decrease in Rest of World revenue for the three months ended September 30, 2024 of $177,000 was primarily due to timing of customer orders. Revenues from these regions tend to be choppy when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs when ordering larger quantities.

 

Cost of Revenue and Gross Profit

 

The cost of revenue and gross profit metrics for the three months ended September 30, 2024 and 2023 are as follows:

  

  

Three Months Ended

September 30,

         
(In thousands, except for percentages)  2024   2023   $ Change   % Change 
Cost of Revenues  $2,218   $1,741   $477    27% 
Cost of Revenue as a % of Revenues   62%    64%           
Gross Profit  $1,361   $990   $371    37% 
Gross Profit as a % of Revenues   38%    36%           

 

The increase in gross profit of $371,000 for the three months ended September 30, 2024 was primarily due to an increase in revenue as compared to the prior period.

 

Research and Development Expense

 

The research and development expense metrics for the three months ended September 30, 2024 and 2023 are as follows:

 

  

Three Months Ended

September 30,

         
(In thousands, except for percentages)  2024   2023   $ Change   % Change 
Research and Development Expense  $506   $536   $(30)   (6%)
Research and Development Expense as a % of Revenues   14%    20%           

 

Decreases in research and development expenses for the three months ended September 30, 2024 of $30,000 was primarily due to the timing of product development and regulatory efforts.

 

 

 

 21 

 

 

Selling, General and Administrative Expense

 

The selling, general and administrative expense metrics for the three months ended September 30, 2024 and 2023 are as follows:

 

  

Three Months Ended

September 30,

         
(In thousands, except for percentages)  2024   2023   Change   % Change 
Selling, General and Administrative Expense  $1,705   $1,662   $43    3% 
Selling, General and Administrative Expense as a % of Revenues   48%    61%           

 

The increase in selling, general and administrative expenses for the three months ended September 30, 2024 of $43,000 was the result of fluctuations in timing of corporate spending.

 

Other Income (Expense), net

 

Other income (expense), net for the three months ended September 30, 2024 was $387,000 compared to other income (expense), net of $(90,000) for the three months ended September 30, 2023. The change in other income (expense), net primarily relates to exchange rate fluctuations.

 

Income Tax Expense

 

Income tax expense for the three months ended September 30, 2024 and 2023 was $147,000 and $186,000, respectively. The expense for each period is primarily related to the use of our deferred tax asset in Mexico and, to a lesser extent, our deferred tax asset in Netherlands.

 

Net Loss

 

The following table provides the net loss for each period along with the computation of basic and diluted net loss per share:

 

   Three Months Ended September 30, 
(In thousands, except per share data)  2024   2023 
Net loss  $(610)  $(1,484)
           
Weighted-average shares outstanding: basic and diluted   1,034    258 
           
Net loss per share: basic and diluted  $(0.59)  $(5.75)

 

 

 

 22 

 

 

Comparison of the Six Months Ended September 30, 2024 and 2023

 

Revenue

 

The following table shows our consolidated total revenue and revenue by geographic region for the six months ended September 30, 2024 and 2023:

 

  

Six Months Ended

September 30,

         
(In thousands)  2024   2023   $ Change   % Change 
United States  $1,317   $1,396   $(79)   (6%)
Europe   2,794    2,271    523    23% 
Asia   1,253    1,208    45    4% 
Latin America   1,345    747    598    80% 
Rest of the World   261    536    (275)   (51%)
Total  $6,970   $6,158   $812    13% 

 

The decrease in United States revenue of $79,000 for the six months ended September 30, 2024 was primarily the result of fluctuations in timing of orders of over-the-counter animal health care products.

 

The increase in Europe revenue for the six months ended September 30, 2024 of $523,000 was the result of a general increase in demand for our products.

 

The increase in Latin America revenue for the six months ended September 30, 2024 of $598,000 was primarily due to an increase in manufacturing orders.

 

The increase in Asia revenue of $45,000 for the six months ended September 30, 2024 was primarily due to timing of customer orders. The decrease in Rest of World revenue for the six months ended September 30, 2024 of $275,000 was primarily due to timing of customer orders. Revenues from these regions tend to be choppy when viewed on a quarterly basis due to customers placing larger, but less frequent, orders to benefit from quantity discounts and reduced shipping costs when ordering larger quantities.

 

Cost of Revenue and Gross Profit

 

The cost of revenue and gross profit metrics for the six months ended September 30, 2024 and 2023 are as follows:

  

  

Six Months Ended

September 30,

         
(In thousands, except for percentages)  2024   2023   $ Change   % Change 
Cost of Revenues  $4,303   $3,964   $339    9% 
Cost of Revenue as a % of Revenues   62%    64%           
Gross Profit  $2,667   $2,194   $473    22% 
Gross Profit as a % of Revenues   38%    36%           

 

The increase in gross profit of $473,000 for the six months ended September 30, 2024 was primarily due to an increase in revenue, overall product mix, volume as compared to the prior period and transportation in the prior period.

 

 

 

 23 

 

 

Research and Development Expense

 

The research and development expense metrics for the six months ended September 30, 2024 and 2023 are as follows:

 

  

Six Months Ended

September 30,

         
(In thousands, except for percentages)  2024   2023   $ Change   % Change 
Research and Development Expense  $976   $861   $115    13% 
Research and Development Expense as a % of Revenues   14%    14%           

 

Increases in research and development expenses for the six months ended September 30, 2024 of $115,000 was primarily due to increased product development and expanded regulatory efforts in the U.S. and Europe to support new product releases and increases in regulatory demands in Europe.

 

Selling, General and Administrative Expense

 

The selling, general and administrative expense metrics for the six months ended September 30, 2024 and 2023 are as follows:

 

  

Six Months Ended

September 30,

         
(In thousands, except for percentages)  2024   2023   Change   % Change 
Selling, General and Administrative Expense  $3,714   $3,781   $(67)   (2%)
Selling, General and Administrative Expense as a % of Revenues   53%    61%           

 

The decline in selling, general and administrative expenses for the six months ended September 30, 2024 of $67,000 was the result of ongoing efforts to contain expenses across all parts of the company.

 

Other Income (Expense), net

 

Other income (expense), net for the six months ended September 30, 2024 was $563,000 compared to other income (expense), net of $(301,000) for the six months ended September 30, 2023. The change in other income (expense), net primarily relates to exchange rate fluctuations.

 

Income Tax Expense

 

Income tax expense for the six months ended September 30, 2024 and 2023 was $293,000 and $153,000, respectively. The expense for each period is primarily related to the use of our deferred tax asset in Mexico and, to a lesser extent, our deferred tax asset in Netherlands.

 

 

 

 24 

 

 

Net Loss

 

The following table provides the net loss for each period along with the computation of basic and diluted net loss per share:

 

   Six Months Ended September 30, 
(In thousands, except per share data)  2024   2023 
Net loss  $(1,753)  $(2,902)
           
Weighted-average shares outstanding: basic and diluted   943    253 
           
Net loss per share: basic and diluted  $(1.86)  $(11.47)

 

Liquidity and Capital Resources

 

We reported a net loss of $610,000 and $1,484,000 for the three months ended September 30, 2024 and 2023, respectively, and $1,753,000 and $2,902,000 for the six months ended September 30, 2024 and 2023, respectively. At September 30, 2024 and March 31, 2024, our accumulated deficit amounted to $196,102,000 and $194,349,000, respectively. At September 30, 2024 and March 31, 2024, we had cash and cash equivalents of $4,078,000 and $3,128,000, respectively. At September 30, 2024 and March 31, 2024, we had working capital of $8,912,000 and $8,829,000, respectively.

 

Sources of Liquidity

 

Since our inception, substantially all of our operations have been financed through sales of equity securities. Other sources of financing that we have used to date include our revenues, as well as various loans and the sale of certain assets to customers.

 

Since October 1, 2023, substantially all of our operations have been financed through cash on hand and the following transactions:

 

  · Proceeds of $1,446,000, net of offering expenses, from the sale of common stock on October 26, 2023.
  · Proceeds of $343,000, net of offering expenses, from the sale of common stock on January 11, 2024.
  · Proceeds of $2,289,000, net of offering expenses, from the sale of common stock in the six months ended September 30, 2024.

 

Cash Flows

 

The following table presents a summary of our consolidated cash flows for operating, investing and financing activities for the six months ended September 30, 2024 and 2023 as well balances of cash and cash equivalents and working capital:

 

   Six Months Ended September 30, 
(In thousands)  2024   2023 
Net cash provided by (used in):          
Operating activities  $(558)  $(1,446)
Investing activities   (31)   (19)
Financing activities   2,080    (264)
Effect of exchange rates on cash   (541)   46 
Net change in cash and cash equivalents   950    (1,683)
Cash and cash equivalents, beginning of the period   3,128    3,820 
Cash and cash equivalents, end of the period  $4,078   $2,137 
Working capital (1), end of period  $8,912   $8,277 

 

  (1) Defined as current assets minus current liabilities.

 

 

 

 25 

 

 

Net cash used in operating activities during the six months ended September 30, 2024 was $558,000, primarily due to a net loss of $1,753,000 offset by decrease in prepaid expenses of $1,134,000.

 

Net cash used in operating activities during the six months ended September 30, 2023 was $1,446,000, primarily due to a net loss of $2,902,000, offset by a decrease in accounts receivables of $375,000, a decrease in inventory of $403,000 and stock compensation of $307,000.

 

Net cash used in investing activities was $31,000 for six months ended September 30, 2024, primarily related to the purchase of equipment.

 

Net cash used in investing activities was $19,000 for the six months ended September 30, 2023, primarily related to purchases of equipment.

  

Net cash provided by financing activities was $2,080,000 for the six months ended September 30, 2024, primarily due to net proceeds from the sale of common stock of $2,289,000 offset by $241,000 of principal payments on a short-term loan related to financing of insurance premiums.

 

Net cash used in financing activities was $264,000 for the six months ended September 30, 2023, primarily due to principal payments on short-term debt.

 

Material Trends and Uncertainties

 

We rely on certain key customers for a significant portion of our revenues. In the future, a small number of customers may continue to represent a significant portion of our total revenues in any given period. These customers may not consistently purchase our products at a particular rate over any subsequent period.

 

We are exposed to risk from foreign currency devaluation for both the Mexico Peso and the Euro versus the US dollar. Risk related to foreign currency valuation tends to be unpredictable and can be affected by various factors outside of our control.

 

We face a substantial Mexico tax liability, intercompany debt, unpaid technical assistance charges and accrued interest. These amounts are due in 2027. At this time, management believes there are sufficient assets on the balance sheet to more than cover any tax obligation without interrupting our operations or business. We have engaged tax professionals to review all options to limit our exposure to these amounts and to proceed in a manner that is most advantageous to us.

 

We also closely monitor overall economic conditions and consumer sentiment and the prospect of a recession in the United States which may impact our financial results.

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the valuation allowance relating to our deferred tax assets, valuation of equity and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, we evaluate and adjust estimates accordingly.

 

Off-Balance Sheet Transactions

 

We currently have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

 

 

 26 

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

As a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

 

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of our most recent fiscal quarter. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of September 30, 2024 due to the fact that material weaknesses in our internal controls over financial reporting exist at period end.

 

Notwithstanding our ineffective disclosure controls and procedures, management believes the condensed consolidated financial statements included in this Quarterly Report on Form 10-Q present fairly, in all material respects, our financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. generally accepted accounting principles.

 

Evaluation of Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in the Exchange Act Rule 13a-15(f) and 15d-15(f). Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in the 2013 Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation, our management concluded that our internal control over financial reporting was not effective as of September 30, 2024. We determined that there was a lack of separation of duties with preparation and review of the reported numbers, among other things. We believe we have taken steps to correct this, but the controls are currently being tested and have not been working for a sufficient period of time to remove this weakness.

 

 

 

 27 

 

 

Management’s Remediation Measures

 

Management, with oversight from the Audit Committee of our Board of Directors, is actively engaged in remediation efforts to address the material weaknesses identified in the management’s evaluation of internal controls and procedures. Management has taken a number of actions to remediate the material weaknesses described above, including the following:

 

  · Improved monitoring and risk assessment activities to address these control deficiencies.
  · Hired an experienced Chief Financial Officer and Controller in 2023.
  · Separated the preparation of the financial reports from review of the financial reports.
  · Developed and delivered further internal controls training to individuals associated with these control deficiencies and enhanced training provided to all personnel who have financial reporting or internal control responsibilities in these areas. The training includes a review of individual roles and responsibilities related to internal controls, proper oversight and reemphasizes the importance of completing the control procedures.

 

These improvements are targeted at strengthening our internal control over financial reporting and remediating the material weaknesses. We remain committed to an effective internal control environment, and management believes that these actions and the improvements management expects to achieve as a result will effectively remediate the material weaknesses. However, the material weaknesses in our internal control over financial reporting will not be considered remediated until the controls operate for a sufficient period of time and management has concluded, through testing that these controls operate effectively. As of the date of filing this Quarterly Report on Form 10-Q, management is in the process of testing and evaluating these additional controls to determine whether they are operating effectively. We have hired appropriate accounting staff to establish effective internal controls and processes.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting during the three months ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We have not finished testing our controls and sufficient time has not elapsed to make the determination these controls are operating effectively.

 

 

 

 

 

 28 

 

 

PART II - OTHER INFORMATION

 

Item 1. Legal Proceedings

 

On occasion, we may be involved in legal matters arising in the ordinary course of our business including matters involving proprietary technology. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which we are or could become involved in litigation may have a material adverse effect on our business, financial condition or results of comprehensive loss.

 

Item 1A. Risk Factors

 

There have been no material changes from risk factors previously disclosed in our annual report on Form 10-K for the fiscal year ended March 31, 2024, as filed with the SEC June 17, 2024.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

We did not issue any unregistered securities during the quarter ended September 30, 2024 and through November 7, 2024.

 

Item 3. Default Upon Senior Securities

 

We did not default upon any senior securities during the quarter ended September 30, 2024.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

During the quarter ended September 30, 2024, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

 

Amendment to Code of Business Conduct

 

On November 5, 2024, our Board of Directors adopted changes to our Code of Business Conduct (the “Code”). The Code governs the conduct of all our employees, directors and officers, including our management. The changes to the Code were made to update the Code to current best practices. In addition to some clerical changes, the Code now explicitly reflects the definition of “code of ethics” in Item 406 of Regulation S-K. The Code also updates reporting procedures, including updates to our anonymous reporting hotline. No waivers have been granted under the Code to date.

 

A copy of the Code of Business Conduct of Sonoma Pharmaceuticals, Inc., as adopted by the Board of Directors on November 5, 2024, is filed as Exhibit 14.1 to this Quarterly Report on Form 10-Q.

 

Bonus Award to Executive Vice President and Chief Operating Officer

 

On November 5, 2024, the Compensation Committee of our Board of Directors approved a one-time cash bonus of $7,500 to Bruce Thornton, Executive Vice President and Chief Operating Officer of the Company, for contributions in obtaining a new 510(k) clearance for the Company’s products.

 

Approval of Tax Gross-Up

 

On June 16, 2023, the Compensation Committee approved an equity award of 100,000 shares of the Company’s common stock to each of Ms. Trombly and Mr. Thornton, to be issued on June 30, 2023, at a valuation based on the five day weighted-average stock price on the date of grant. In addition, the Compensation Committee approved a one-time cash payment by the Company as reimbursement for estimated taxes payable with respect to such equity awards. On November 5, 2024, the Compensation Committee approved an additional tax payment in the amount of $8,411 to of Ms. Trombly and $10,925 to Mr. Thornton to make up a deficiency in the prior reimbursement.

 

 

 

 29 

 

 

Item 6. Exhibits

 

Exhibit Index

 

Exhibit No. Description
   
3.1 Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., effective January 30, 2006 (included as exhibit 3.1 of the Company’s Annual Report on Form 10-K filed June 20, 2007, and incorporated herein by reference).
3.2 Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., effective October 22, 2008 (included as exhibit A in the Company’s Definitive Proxy Statement on Schedule 14A filed July 21, 2008, and incorporated herein by reference).
3.4 Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective March 29, 2013 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed March 22, 2013, and incorporated herein by reference).
3.5 Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective December 4, 2014 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed December 8, 2014, and incorporated herein by reference).
3.6 Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective October 22, 2015 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed October 27, 2015, and incorporated herein by reference).
3.7 Certificate of Amendment of Restated Certificate of Incorporation of Oculus Innovative Sciences, Inc., as amended, effective June 24, 2016 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 28, 2016, and incorporated herein by reference).
3.8 Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective December 6, 2016 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed December 7, 2016, and incorporated herein by reference).
3.9 Amended and Restated Bylaws, as amended, of Sonoma Pharmaceuticals, Inc., effective December 6, 2016 (included as exhibit 3.2 to the Company’s Current Report on Form 8-K filed December 7, 2016, and incorporated herein by reference).
3.10 Amendment No. 1 to Amended and Restated Bylaws, as amended, of Sonoma Pharmaceuticals, Inc., effective June 14, 2024 (included as exhibit 3.10 to the Company’s Annual Report on Form 10-K filed June 17, 2024, and incorporated herein by reference).
3.11 Certificate of Designation of Preferences, Rights and Limitations of Series A 0% Convertible Preferred Stock, filed with the Delaware Secretary of State on April 24, 2012 (included as exhibit 4.2 to the Company’s Current Report on Form 8-K, filed April 25, 2012, and incorporated herein by reference).
3.12 Certificate of Designation of Series B Preferred Stock, effective October 18, 2016 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed October 21, 2016, and incorporated herein by references).
3.13 Certificate of Amendment of Restated Certificate of Incorporation of Sonoma Pharmaceuticals, Inc., as amended, effective June 19, 2019 (included as exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 19, 2019, and incorporated herein by reference).
4.1 Specimen Common Stock Certificate (included as exhibit 4.1 to the Company’s Annual Report on Form 10-K filed June 28, 2017, and incorporated herein by reference).
4.2 Section 382 Rights Agreement, dated as of October 18, 2016, between Oculus Innovative Sciences, Inc. and Computershare Inc., which includes the Form of Certificate of Designation of Series B Preferred Stock as Exhibit A, the Form of Right Certificate as Exhibit B and the Summary of Rights to Purchase Preferred Stock as Exhibit C (included as exhibit 4.1 to the Company’s Current Report on Form 8-K filed October 21, 2016, and incorporated herein by reference).
10.1 Form of Indemnification Agreement between Oculus Innovative Sciences, Inc. and its officers and directors (included as exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
10.2 Office Lease Agreement, dated May 18, 2006, between Oculus Technologies of Mexico, S.A. de C.V. and Antonio Sergio Arturo Fernandez Valenzuela (translated from Spanish) (included as exhibit 10.10 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
10.3 Office Lease Agreement, dated July 2003, between Oculus Innovative Sciences, B.V. and Artikona Holding B.V. (translated from Dutch) (included as exhibit 10.11 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).

 

 

 

 30 

 

 

10.4 Form of Director Agreement (included as exhibit 10.20 to the Company’s Registration Statement on Form S-1 (File No. 333-135584), as amended, declared effective on January 24, 2007, and incorporated herein by reference).
10.5 Amendment to Office Lease Agreement, effective February 15, 2008, by and between Oculus Innovative Sciences Netherlands B.V. and Artikona Holding B.V. (translated from Dutch) (included as exhibit 10.44 to the Company’s Annual Report on Form 10-K filed June 13, 2008, and incorporated herein by reference).
10.6† Exclusive Sales and Distribution Agreement, dated November 6, 2015, by and between Oculus Innovative Sciences, Inc. and Manna Pro Products, LLC (included as exhibit 10.1 to the Company’s 8-K filed March 23, 2016 and incorporated herein by reference).
10.7† Asset Purchase Agreement dated October 27, 2016, between Oculus Innovative Sciences, Inc. and Invekra, S.A.P.I de C.V. (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed October 31, 2016, and incorporated herein by reference).
10.8† Amendment Agreement to Acquisition Option dated October 27, 2016, by and between More Pharma Corporation S. de R.L. de C.V. and Oculus Technologies of Mexico, S.A. de C.V. (included as exhibit 10.2 to the Company’s Current Report on Form 8-K filed October 31, 2016, and incorporated herein by reference).
10.9 2016 Equity Incentive Plan (included as exhibit A to the Company’s Definitive Proxy Statement on Schedule 14A filed July 29, 2016, and incorporated herein by reference).
10.10⸸+ Asset Purchase Agreement dated May 14, 2019, between Sonoma Pharmaceuticals, Inc. and Petagon, Ltd. (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 22, 2019, and incorporated herein by reference).
10.11⸸+ Asset Purchase Agreement dated February 21, 2020, between Sonoma Pharmaceuticals, Inc. and MicroSafe Group, DMCC (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed February 27, 2020, and incorporated herein by reference.)
10.12⸸+ License, Distribution and Supply Agreement by and between Sonoma Pharmaceuticals, Inc. and Brill International, S.L. dated May 19, 2020 (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 26, 2020, and incorporated herein by reference.)
10.13⸸ Licensing Agreement between Sonoma Pharmaceuticals, Inc. and MicroSafe Group, effective July 27, 2020 (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 6, 2020, and incorporated herein by reference).
10.14⸸ Exclusive Supply and Distribution Agreement between the Company and EMC Pharma, LLC, dated March 26, 2021 (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed March 31, 2021, and incorporated herein by reference).
10.15 2021 Equity Incentive Plan (included as appendix on the Company’s Definitive Proxy Statement on Schedule 14A filed July 29, 2021 and incorporated herein by reference).
10.16+⸸ Exclusive License and Distribution Agreement between the Company and Dyamed Biotech Pte Ltd., dated November 4, 2021 (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed November 9, 2021, and incorporated herein by reference).
10.17+⸸ Exclusive License and Distribution Agreement between Sonoma Pharmaceuticals, Inc. and Anlicare International dated January 18, 2022 (included as exhibit 10.2 to the Company’s Current Report on Form 8-K filed January 20, 2022, and incorporated herein by reference).
10.18 Sonoma Pharmaceuticals, Inc. Non-Employee Director Compensation Program and Stock Ownership Guidelines, revised by the Board of Directors on December 29, 2022 (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed December 30, 2022, and incorporated herein by reference).
10.19 Amended and Restated Employment Agreement by and between the Company and Amy Trombly, dated June 16, 2023 (included as exhibit 10.38 to the Company’s Annual Report on Form 10-K filed June 21, 2023, and incorporated herein by reference).
10.20 Amended and Restated Employment Agreement by and between the Company and Bruce Thornton, dated June 16, 2023 (included as exhibit 10.39 to the Company’s Annual Report on Form 10-K filed June 21, 2023, and incorporated herein by reference).
10.21 First Amendment to the Lease between the Company and Westland Development Services, Inc., dated June 21, 2023 (included as exhibit 10.38 to the Company’s Quarterly Report on Form 10-Q filed November 13, 2023, and incorporated herein by reference).
10.22 Equity Distribution Agreement, by and between Sonoma Pharmaceuticals, Inc. and Maxim Group LLC, dated December 15, 2023 (included as exhibit 1.1 to the Company’s Current Report on Form 8-K filed December 15, 2023, and incorporated herein by reference).
10.23 Offer letter to Jerome Dvonch dated February 7, 2024 (included as exhibit 10.41 to the Company’s Quarterly Report on Form 10-Q filed February 8, 2024, and incorporated herein by reference).
10.24 Offer letter to John Dal Poggetto dated February 7, 2024 (included as exhibit 10.42 to the Company’s Quarterly Report on Form 10-Q filed February 8, 2024 and incorporated herein by reference).

 

 

 

 31 

 

 

10.25 Amendment No. 1 to Equity Distribution Agreement, by and between Sonoma Pharmaceuticals, Inc. and Maxim Group LLC., dated March 8, 2024 (included as exhibit 1.1 to the Company’s Current Report on Form 8-K filed March 8, 2024, and incorporated herein by reference).
10.26⸸+ Distribution Agreement, dated August 19, 2024, by and between Sonoma Pharmaceuticals, Inc. and Medline Industries, LP (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 21, 2024, and incorporated herein by reference).
10.27+ Amendment No. 1 to Distribution Agreement, dated October 17, 2024, by and between Sonoma Pharmaceuticals, Inc. and Medline Industries, LP (included as exhibit 10.1 to the Company’s Current Report on Form 8-K filed October 22, 2024, and incorporated herein by reference).
14.1* Code of Business Conduct, as revised and adopted on November 5, 2024.
21.1 List of Subsidiaries (included as exhibit 21.1 to the Company’s Annual Report on Form 10-K June 28, 2017, and incorporated herein by reference).
31.1* Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2* Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1* Certification of Officers pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted in inline XBRL, and included in exhibit 101).

 

* Filed herewith.
Confidential treatment has been granted with respect to certain portions of this agreement.
Certain portions of the exhibit have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to the SEC upon request.
+ The schedules to the exhibit have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K.  The Company will furnish copies of any such schedules to the SEC upon request.

 

Copies of above exhibits not contained herein are available to any stockholder, upon payment of a reasonable per page fee, upon written request to: Chief Financial Officer, Sonoma Pharmaceuticals, Inc., 5445 Conestoga Court, Suite 150, Boulder, Colorado 80301.

 

 

 

 32 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: November 7, 2024 By: /s/ Amy Trombly  
   

Amy Trombly

President and Chief Executive Officer,

(Principal Executive Officer)

 
       
Date: November 7, 2024 By: /s/ Jerome Dvonch  
    Jerome Dvonch  
    Chief Financial Officer  
   

(Principal Financial and

Principal Accounting Officer)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 33 

 

EX-14.1 2 sonoma_ex1401.htm CODE OF BUSINESS CONDUCT

Exhibit 14.1

 

 

 

Code of Business Conduct
Revised November 5, 2024

Introduction

 

It is the general policy of Sonoma Pharmaceuticals, Inc. (the “Company”) to conduct its business activities and transactions with the highest level of integrity and ethical standards and in accordance with all applicable laws. In carrying out this policy, the Board of Directors of the Company has adopted the following Code of Business Conduct (the “Code”) in order to promote:

 

·honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;

 

·full, fair, accurate, timely, and understandable disclosure in reports and documents that the Company files with, or submits to, the Securities and Exchange Commission (the “SEC”) and in other public communications made by the Company;

 

·compliance with applicable governmental laws, rules and regulations;

 

·the prompt internal reporting of violations of the code to an appropriate person or persons identified in this Code; and

 

·accountability for adherence to this Code.

 

This Code covers a wide range of business practices and procedures. It does not cover every issue that may arise, but it sets out basic principles to guide all employees, officers and directors of the Company. All such persons must conduct themselves accordingly and seek to avoid even the appearance of improper behavior. Those who violate the standards in this Code or who fail to cooperate with management directions given to effect compliance with this Code may be subject to disciplinary action, possibly including termination of employment. For guidance with respect to issues not addressed in this Code, employees should follow the Company’s internal policies and procedures.

 

If you have any questions regarding this Code, you should address these questions to your supervisor, or to the general counsel or other person identified by the Company as its compliance officer (the “Compliance Officer”).

 

 

 

 

 

 1 

 

 

Basic Principles and Practices

 

Honest and Ethical Conduct

 

The Company’s policy is to promote high standards of integrity by conducting its affairs honestly and ethically. Each director, officer and employee must act with integrity and observe the highest ethical standards of business conduct in their dealings with the Company’s customers, suppliers, partners, service providers, competitors, employees and anyone else with whom they have contact in the course of performing their job.

 

Compliance with Laws, Rules and Regulations

 

Company policy requires that our business activities comply with both the letter and the spirit of all applicable laws, rules and regulations. The Company’s products are subject to a variety of laws and regulations that govern healthcare and pharmaceutical products, including marketing approvals, conduct of clinical studies, good manufacturing practices and standards, labeling and advertising/promotion requirements. Although not all employees, directors or officers are expected to know the details of these laws, it is important to know enough to determine when to seek advice from supervisors, managers or other appropriate personnel or counsel.

 

Confidentiality

 

Directors, officers and employees should maintain the confidentiality of information entrusted to them by the Company or by its customers, suppliers or partners, except when disclosure is expressly authorized or legally required. Employees, directors and officers who come into possession of non-public Company information must safeguard the information from the public and not intentionally or inadvertently communicate it to any person (including family members and friends) unless the person has a need to know the information for legitimate, Company-related reasons. This duty of confidentiality is important both as to the Company’s competitive position and with respect to the securities laws applicable to the Company as a public company. Confidential information cannot be disclosed by any employee, director and officer to any third party unless the third party has signed a nondisclosure agreement approved by the Company’s management, and should be divulged only to persons having a need to know the information in order to carry out their job responsibilities. You must also abide by any specific agreements, such as an Employment, Confidential Information and Invention Assignment, regarding confidentiality between you and the Company.

 

Consistent with the foregoing, all employees, directors and officers should be discreet with respect to confidential information about the Company and not discuss it in public places.

 

Confidential information related to the Company can include a variety of materials and information regarding the ongoing operations and plans of the Company, and also includes information that customers or collaborators have provided to the Company. For example, confidential information can include product development plans, clinical and research results, regulatory matters, patents, trademarks, copyrights, laboratory processes, product information, information regarding the financial health of the Company, salary and personnel information and marketing and sales plans.

 

Nothing in this Code shall prevent employees, directors or officers from reporting suspected wrongdoing to the SEC.

 

 

 

 

 2 

 

 

Conflicts of Interest

 

A “conflict of interest” arises when a person’s loyalties or actions are divided between the interests of the Company and those of another, such as a competitor, supplier or customer, or personal business. A conflict of interest can arise when an employee, director or officer (or a member of their family) takes actions or has interests that may make it difficult to perform their work objectively and effectively. A conflict of interest may also arise when an employee, director or officer, or members of their family, receives an improper personal benefit as a result of their position in, or relationship with, the Company. Moreover, the appearance of a conflict of interest alone can adversely affect the Company and its relations with customers, suppliers and employees.

 

Employees, directors and officers are expected to use good judgment, to adhere to high ethical standards and to avoid situations that create an actual or potential conflict of interest. It is almost always a conflict of interest for employees or officers to work simultaneously for a competitor, customer or supplier. In this regard, employees shall not have any undisclosed financial interest in any competitor, supplier, customer, or strategic partner if that interest would create a conflict of interest with the Company. If there is such an interest, the employee should disclose the nature of the interest to the Compliance Officer; provided, however, that employees, directors and officers may maintain small investments in publicly held companies in which such individual has no influence or control.

A conflict of interest can also arise with respect to employment of relatives and persons with close personal relationships. If an employee or someone with whom an employee has a close relationship (e.g., a family member or close companion) has a financial or employment relationship with an actual or potential competitor, supplier or customer, the employee must disclose this fact in writing to the Compliance Officer. The Company may take any action that it deems necessary in its sole discretion to avoid or remedy an actual, prospective or perceived conflict of interest, including a reassignment of some or all of the employee’s duties or change of the employee’s position.

 

Loans by the Company to, or guarantees by the Company of obligations of, employees or their family members are of special concern and could constitute improper personal benefits to the recipients of such loans or guarantees, depending on the facts and circumstances. Loans by the Company to, or guarantees by the Company of obligations of, any director or officer or their family members are expressly prohibited.

 

A conflict of interest may not always be clear; therefore, employees should consult with higher levels of management in case of any questions. Any employee who becomes aware of a conflict or a potential conflict should bring it to the attention of the Compliance Officer. Directors and executive officers must seek determinations and prior authorizations or approvals of potential conflicts of interest exclusively from the Audit Committee.

 

Corporate Opportunities

 

All employees, directors and officers owe a duty to the Company to advance its legitimate interests when the opportunity to do so arises. Employees, directors and officers are prohibited from taking for themselves personally (or for the benefit of friends or family members) opportunities that are discovered through the use of Company assets, property or confidential information or their position without the consent of the Board or its designees. No employee, director or officer may use corporate property, information or their position for improper personal gain (including gain of friends or family members), and no employee, director or officer may compete with the Company directly or indirectly while they are engaged or employed by the Company.

 

Fair Dealing

 

Although the prosperity of our Company depends on our ability to outperform our competitors, the Company is committed to achieving success by fair and ethical means. We seek to maintain a reputation for honesty and fair dealing among our competitors and the public alike. Each employee, director and officer must deal fairly with the Company’s customers, suppliers, competitors, employees, service providers and anyone else with whom they have contact in the course of performing their job. No employee, director or officer should take unfair advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts, or any other unfair business practice.

 

 

 

 3 

 

 

Company personnel are prohibited from receiving a payment or anything of value from a vendor or other entities/individuals in the private sector in exchange for a purchasing decision, subject to exception for gifts or nominal value (e.g. non-lavish meals, marketing materials, t-shirts, caps, etc.).

 

Donations, Gifts, Payments to Customers and Physicians

 

The U.S. and most other countries have laws and regulations that govern the Company’s provision of donations, gifts, or payments to customers or physicians. The Company’s policy is that its employees, directors and officers will comply with all such laws and regulations. The Company will not pay or otherwise remunerate a physician or customer in exchange for ordering, prescribing, purchasing, or recommending the Company’s products. All business courtesies such as meals, transportation, and entertainment provided to a physician or customer must be modest in amount and related to a legitimate business purpose. Donations to customers or organizations closely affiliated with customers shall entail a benefit to society and be made to promote better health care, demonstrate good corporate leadership, or serve a genuine educational function. The Company may enter into legitimate agreements to compensate customers and physicians for consulting, research, or other services rendered, and reasonable costs incurred, where the services have value to the Company and are provided for fair market value. All such agreements must be in writing.

 

Advertising and Promotion

 

The advertising and promotion of the Company’s products are subject to extensive regulation. For example, companies may not promote medical device or drug products or product indications that are not approved by regulatory authorities. These regulations also require that employees, directors and officers represent the Company’s products in a manner consistent with applicable labeling and market approvals. It is the Company’s policy to promote and market its products in a lawful and truthful manner in accordance with the applicable laws and regulations. To help ensure compliance in this area, all promotional materials must be reviewed and approved by the appropriate internal departments prior to distribution.

 

Health and Safety

 

The Company strives to provide a safe and healthy work environment. All employees are responsible for maintaining a safe and healthy workplace for all other employees by following the Company’s safety and health rules, policies and practices and reporting accidents, injuries and unsafe equipment, practices or conditions.

 

Insider Trading

 

No director, officer or employee may purchase or sell any Company securities while in possession of material non-public information regarding the Company, nor may any director, officer or employee purchase or sell another company’s securities while in possession of material non-public information regarding that company. Employees, directors and officers are not permitted to use, share or disseminate confidential information for stock trading purposes or for any other purpose except the conduct of our business. To use confidential information for personal financial benefit or to “tip” others who might make an investment decision on the basis of this information is not only unethical but also illegal.

 

Payments to Government Personnel

 

The United States Foreign Corrupt Practices Act prohibits giving anything of value, directly or indirectly, to officials of foreign governments or foreign political candidates in order to obtain or retain business. It is strictly prohibited to make illegal payments to government officials of any country.

 

In addition, the United States government has a number of laws and regulations regarding business gratuities which may be accepted by U.S. government personnel. The promise, offer or delivery to an official or employee of the U.S. government of a gift, favor, or other gratuity in violation of these rules would not only violate Company policy but could also be a criminal offense. State and local governments, as well as foreign governments, may have similar rules.

 

 

 

 4 

 

 

Protection and Proper Use of Company Assets

 

No secret or unrecorded fund of Company assets or cash shall be established or maintained for any purpose. Anyone spending or obligating Company funds should be certain that the transaction is properly and appropriately documented and that the Company receives appropriate value in return.

 

All employees, directors and officers should endeavor to protect the Company’s assets and ensure their efficient use. Theft, carelessness and waste have a direct impact on the Company’s profitability and are prohibited. Any suspected incident of fraud or theft should be immediately reported for investigation. Company assets should only be used for legitimate Company business, though incidental personal use may be permitted.

 

The obligation to protect Company assets includes the Company’s proprietary information. Proprietary information includes intellectual property such as trade secrets, patents, trademarks, and copyrights, as well as business and marketing plans, engineering and manufacturing ideas, designs, databases, records and any non-public financial data or reports. Unauthorized use or distribution of this information is prohibited and could also be illegal and result in civil or criminal penalties.

 

Record Keeping

 

The Company requires honest and accurate recording and reporting of information in order to make responsible business decisions. If you use a business expense account, expenses to be reimbursed must be documented and recorded accurately. If you are not sure whether an expense is appropriate, ask your supervisor.

 

All of the Company’s books, records, accounts and financial statements must be maintained in reasonable detail, must appropriately reflect the Company’s transactions and must conform both to applicable legal requirements and to the Company’s system of internal controls. All Company business data, records and reports must be prepared truthfully and accurately. The Company’s business records must be maintained for the periods specified in the Company’s applicable record retention policies.

 

Employees, directors and officers who contribute to or prepare the Company’s public filings, submissions or communications should do so in accordance with the following guidelines:

 

  § All accounting records, as well as reports produced from those records, must be prepared in accordance with the laws of each applicable jurisdiction.

 

  § All records must fairly and accurately reflect the transactions or occurrences to which they relate.

 

  § All records must fairly and accurately reflect, in reasonable detail, the Company’s assets, liabilities, revenues and expenses.

 

  § The Company’s accounting records must not contain any false or intentionally misleading entries.

 

  § No transactions should be intentionally misclassified as to accounts, departments or accounting periods.

 

  § All transactions must be supported by accurate documentation in reasonable detail and recorded in the proper account and in the proper accounting period.

 

  § No information should be concealed from the Company’s auditors.

 

  § Compliance with the Company’s system of internal accounting controls is required.

 

 

 

 5 

 

 

Business records and communications often become public, and employees, directors and officers should avoid exaggeration, derogatory remarks, guesswork or inappropriate characterizations of people and companies that can be misunderstood. This applies equally to e-mail, internal memos and formal reports.

 

Disclosure

 

The Company’s periodic reports and other documents filed with the SEC, including all financial statements and other financial information, must comply with applicable federal securities laws and SEC rules.

 

Each director, officer and employee who contributes in any way to the preparation or verification of the Company’s financial statements and other financial information must ensure that the Company’s books, records and accounts are accurately maintained. Each director, officer and employee must cooperate fully with the Company’s accounting and internal audit departments, as well as the Company’s independent public accountants and counsel.

 

Each director, officer and employee who is involved in the Company’s disclosure process must (a) be familiar with and comply with the Company’s disclosure controls and procedures and its internal control over financial reporting; and (b) take all necessary steps to ensure that all filings with the SEC and all other public communications about the financial and business condition of the Company provide full, fair, accurate, timely and understandable disclosure.

 

Implementation

 

All employees, officers and directors must sign a statement certifying that they have read and understand this Code and are aware of the consequences of non-compliance with it; such certification shall be renewed annually. Violations of this Code or of any direction given by management in order to effect the provisions, goals, and aims of this Code may result in disciplinary action, up to and including termination of employment.

 

Waiver

 

Any waiver of this Code for executive officers or directors may be made only in writing (including an explanation of the reason for such waiver) by the Board of Directors, and will be promptly disclosed as required by SEC and Nasdaq rules. Any waiver of this Code for other employees must be approved in writing by the Compliance Officer.

 

Reporting Violations of this Code

 

Employees, directors and officers are responsible for being aware of the corporate policies applicable to their activities and to comply with them fully. If you become aware of a violation of this Code or believe that a violation may take place in the future, you must promptly report the matter. Failure to report a known violation allows misconduct to go unremedied and is itself grounds for discipline. Ordinarily, the report may be made to the employee’s immediate supervisor, the human resources department, the general counsel of the Company or any senior manager of the Company, who, in turn, must report it to the Compliance Officer. If the report pertains to concerns regarding questionable accounting or auditing matters, the employee should direct the report to the Compliance Officer or to the Chair of the Audit Committee of the Board of Directors. Directors and management of the Company shall report any material violations of this Code to the Audit Committee of the Board of Directors. Actions prohibited by this Code involving directors or executive officers must be reported to the Audit Committee. The Audit Committee shall, on a periodic basis review the Code and discuss its implementation and any potential revisions to the Code with the Board of Directors.

 

 

 

 6 

 

 

Reports concerning potential violations of this Code may also be made using the Company’s designated hotline, and may be anonymous, at the employee’s discretion. Contact information is provided at the time of hire and posted in the Company’s offices.

 

After receiving a report of an alleged prohibited action, the Audit Committee or the Compliance Officer must promptly take all appropriate actions necessary to investigate. All directors, officers and employees are expected to cooperate in any internal investigation of misconduct.

 

Employees, directors and officers submitting a report on an anonymous basis are strongly encouraged to keep a copy of the report (if made in writing) and a record of the time and date of their submission, as well as a description of the matter as reported if the report was not in writing.

 

Employees, directors and officers are encouraged to provide as much specific information as possible, including names, dates, places and events that took place, relevant documents and the employee’s perception of why the incident(s) may be misconduct.

 

If possible, the individual should provide a means by which she/he can be contacted in the event that an investigator needs to follow-up or wants to report back to the employee.

 

The Company does not tolerate acts of retaliation against any director, officer or employee who makes a good faith report of known or suspected acts of misconduct or other violations of this Code. We will not allow retaliation against an employee, director or officer for reporting a possible violation of this Code unless it can be shown that the report was knowingly false. Retaliation for reporting a federal offense is illegal under federal law and prohibited under this Code. Such retaliation will result in discipline up to and including termination of employment and may also result in criminal prosecution. The employee, director or officer is protected from retaliation even if the investigator does not agree that there has been a violation. However, if the employee, director or officer making the report was involved in improper activity, the fact that they reported it will not necessarily prevent him or her from being disciplined for their participation in the violation. In these circumstances, the Company may consider the individual’s conduct in promptly reporting the information as a mitigating factor in any disciplinary decision.

 

Enforcement

 

The Company must ensure prompt and consistent action against violations of this Code. If, after investigating a report of an alleged prohibited action by a director or executive officer, the Audit Committee determines that a violation of this Code has occurred, the Audit Committee will report such determination to the Board of Directors.

 

If, after investigating a report of an alleged prohibited action by any other person, the Compliance Officer determines that a violation of this Code has occurred, the Compliance Officer will report such determination to the Audit Committee.

 

Upon receipt of a determination that there has been a violation of this Code, the Board of Directors or the Audit Committee will take such preventative or disciplinary action as it deems appropriate, including, but not limited to, reassignment, demotion, dismissal and, in the event of criminal conduct or other serious violations of the law, notification of appropriate governmental authorities.

  

 

 

 7 

 

 

EX-31.1 3 sonoma_ex3101.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER

Exhibit 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

I, Amy Trombly, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Sonoma Pharmaceuticals, Inc. for the quarter ended September 30, 2024;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  By: /s/ Amy Trombly                               
Date: November 7, 2024   Amy Trombly  
    Chief Executive Officer  
    (Principal Executive Officer)  

 

EX-31.2 4 sonoma_ex3102.htm CERTIFICATION OF CHIEF FINANCIAL OFFICER

Exhibit 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

I, Jerome Dvonch, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Sonoma Pharmaceuticals, Inc. for the quarter ended September 30, 2024;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

  By: /s/ Jerome Dvonch                           
Date: November 7, 2024   Jerome Dvonch  
   

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

 

EX-32.1 5 sonoma_ex3201.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officers of Sonoma Pharmaceuticals, Inc., a Delaware corporation (the “Company”), do hereby certify, to such officers’ knowledge, that:

 

The Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 7, 2024 By: /s/ Amy Trombly                                  
   

Amy Trombly

Chief Executive Officer

(Principal Executive Officer)

 
       
Date: November 7, 2024 By: /s/ Jerome Dvonch                          
   

Jerome Dvonch

Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

 

EX-101.SCH 6 snoa-20240930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 995512 - Disclosure - Organization and Recent Developments link:presentationLink link:calculationLink link:definitionLink 995513 - Disclosure - Liquidity and Financial Condition link:presentationLink link:calculationLink link:definitionLink 995514 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Condensed Consolidated Balance Sheet link:presentationLink link:calculationLink link:definitionLink 995516 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995517 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995518 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 995519 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995520 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995521 - Disclosure - Revenue Disaggregation link:presentationLink link:calculationLink link:definitionLink 995522 - Disclosure - Significant Customer Concentrations link:presentationLink link:calculationLink link:definitionLink 995523 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995524 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995526 - Disclosure - Condensed Consolidated Balance Sheet (Tables) link:presentationLink link:calculationLink link:definitionLink 995527 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995528 - Disclosure - Revenue Disaggregation (Tables) link:presentationLink link:calculationLink link:definitionLink 995529 - Disclosure - Significant Customer Concentrations (Tables) link:presentationLink link:calculationLink link:definitionLink 995530 - Disclosure - Organization and Recent Developments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995531 - Disclosure - Liquidity and Financial Condition (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995532 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share) link:presentationLink link:calculationLink link:definitionLink 995533 - Disclosure - Summary of Significant Accounting Policies (Details - Anti-dilutive shares) link:presentationLink link:calculationLink link:definitionLink 995534 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Condensed Consolidated Balance Sheet (Details - Inventories) link:presentationLink link:calculationLink link:definitionLink 995536 - Disclosure - Condensed Consolidated Balance Sheet (Details - Balance sheet information related to leases) link:presentationLink link:calculationLink link:definitionLink 995537 - Disclosure - Condensed Consolidated Balance Sheet (Details - Minimum lease payments of opearting lease liabilities) link:presentationLink link:calculationLink link:definitionLink 995538 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995539 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995540 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995541 - Disclosure - Stock-Based Compensation (Details - Stock option award activity) link:presentationLink link:calculationLink link:definitionLink 995542 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity) link:presentationLink link:calculationLink link:definitionLink 995543 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995544 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue by source) link:presentationLink link:calculationLink link:definitionLink 995546 - Disclosure - Revenue Disaggregation (Details - Revenue by geographic regions) link:presentationLink link:calculationLink link:definitionLink 995547 - Disclosure - Significant Customer Concentrations (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 snoa-20240930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 snoa-20240930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 snoa-20240930_lab.xml XBRL LABEL FILE Class of Stock [Axis] Convertible Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Antidilutive Securities [Axis] Equity Option [Member] Warrant [Member] Common Stock Units [Member] Short-Term Debt, Type [Axis] Insurance Premium Financing [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Equity Distribution Agreement [Member] Award Type [Axis] Restricted Stock [Member] Segments [Axis] Human Care [Member] Product and Service [Axis] Product [Member] Animal Care [Member] Service [Member] Service And Royalty [Member] Concentration Risk Benchmark [Axis] Revenue, Segment Benchmark [Member] Geographical [Axis] UNITED STATES Europe [Member] Asia [Member] Latin America [Member] Rest Of The World [Member] Revenue Benchmark [Member] Customer [Axis] Customer A [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer B [Member] Customer C [Member] Customer D [Member] Accounts Receivable [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Accounts receivable, net Inventories, net Prepaid expenses and other current assets Current portion of deferred consideration, net of discount Total current assets Property and equipment, net Operating lease, right of use assets Deferred tax asset Deferred consideration, net of discount, less current portion Other assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable Accrued expenses and other current liabilities Deferred revenue, current portion Short-term debt Operating lease liabilities, current portion Total current liabilities Deferred revenue, net of current portion Withholding tax payable Operating lease liabilities, less current portion Total liabilities Commitments and Contingencies (Note 5) Stockholders’ Equity: Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at September 30, 2024 and March 31, 2024, respectively, no shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively Common stock, $0.0001 par value; 50,000,000 and 24,000,000 shares authorized at September 30, 2024 and March 31, 2024, respectively, 1,338,615 and 780,371 shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively (Note 1) (Note 7) Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss Total stockholders’ equity Total liabilities and stockholders’ equity Statement [Table] Statement [Line Items] Convertible preferred stock, par value Convertible preferred stock, shares authorized Convertible preferred stock, shares issued Convertible preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Cost of revenues Gross profit Operating expenses Research and development Selling, general and administrative Total operating expenses Loss from operations Other income (expense), net Loss from operations before income taxes Income tax expense Net loss Net loss per share: basic Net loss per share: diluted Weighted-average number of shares: basic Weighted-average number of shares: diluted Other comprehensive loss Foreign currency translation adjustments Comprehensive loss Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Stock-based compensation Deferred income taxes Changes in operating assets and liabilities: Accounts receivable, net Inventories, net Prepaid expenses and other current assets Deferred consideration Operating lease, right-of-use assets Accounts payable Accrued expenses and other current liabilities Deferred revenue Withholding tax payable Operating lease liabilities Net cash used in operating activities Cash flows from investing activities: Purchases of property and equipment Net cash used in investing activities Cash flows from financing activities: Proceeds (costs) from issuance of common stock, net of offering expenses Proceeds from exercise of employee stock options Payments for fractional shares related to reverse-split Principal payments on short-term debt Net cash provided by (used in) financing activities Effect of exchange rate on cash and cash equivalents Net increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Supplemental disclosure of cash flow information: Cash paid for interest Beginning balance, value Beginning balance, shares Cost in connection with ATM Proceeds from At-the-Market sale of common stock, net of offering expenses Proceeds from At-the-Market sale of common stock, net of offering expenses, shares Proceeds from exercise of employee stock options Proceeds from exercise of employee stock options, shares Payments for fractional shares related to reverse-split Payments for fractional shares related to reverse-split, shares Employee stock-based compensation expenses Employee stock-based compensation expenses, shares Foreign currency translation adjustment Ending balance, value Ending balance, shares Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Recent Developments Liquidity and Financial Condition Accounting Policies [Abstract] Summary of Significant Accounting Policies Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Condensed Consolidated Balance Sheet Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Debt Disclosure [Abstract] Debt Equity [Abstract] Stockholders’ Equity Share-Based Payment Arrangement [Abstract] Stock-Based Compensation Income Tax Disclosure [Abstract] Income Taxes Revenue from Contract with Customer [Abstract] Revenue Disaggregation Risks and Uncertainties [Abstract] Significant Customer Concentrations Subsequent Events [Abstract] Subsequent Events Use of Estimates Net Loss per Share Revenue Recognition Accounts Receivable Inventories Recent Accounting Standards Schedule of computation of basic and diluted net loss per share Schedule of anti-dilutive shares Schedule of inventories, net Schedule of lease information Schedule of minimum lease payments of operating lease liabilities Schedule of stock options award activity Schedule of unvested restricted stock activity Schedule of disaggregated revenue by source Schedule of revenues by geographic region Schedule of customer concentrations of risk Reverse stock split Net loss Accumulated deficit Working capital Liquidity cash balance Net cash used in operating activities Numerator: Denominator: Weighted-average number of common shares outstanding: basic Weighted-average number of common shares outstanding: diluted Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive shares Allowances related to potential discounts, returns, distributor fees and rebates Net realizable value Raw materials Finished goods Inventories, gross  Less: allowance for obsolete and excess inventory Total inventories, net Operating leases: Operating lease right-of-use assets Operating lease liabilities – current Operating lease liabilities – non-current Operating lease cost Operating cash flows from operating leases Weighted-average remaining lease term - operating leases (in months) Weighted-average discount rate - operating leases 2025 (excluding the six months ended September 30, 2024) 2026 2027 2028 Total future minimum lease payments, undiscounted Less: imputed interest Present value of future minimum lease payments Aggregated annual salaries Potential severance payments Short-Term Debt [Table] Short-Term Debt [Line Items] Debt face amount Debt interest rate Final payment date Debt payment terms Periodic payment First installment beginning date Outstanding principal amount Stock, Class of Stock [Table] Class of Stock [Line Items] Stock issued new, shares Proceeds from sale of stock, gross Proceeds from sale of stock, net Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Number of Shares, Outstanding, Beginning Balance Weighted-Average Exercise Price Outstanding, Beginning Balance Number of Shares, Options exercised Weighted-Average Exercise Price, Options exercised Number of Shares, Options forfeited Weighted-Average Exercise Price, Options forfeited Number of Shares, Options expired Weighted-Average Exercise Price, Options expired Number of Shares, Outstanding, Ending Balance Weighted-Average Exercise Price Outstanding, Ending Balance Number of Shares, Exercisable Weighted-average exercise price, exercisable Number of Shares, Unvested restricted stock awards outstanding, beginning balance Weighted Average Award Date Fair Value per Share, Unvested restricted stock awards outstanding, beginning balance Number of Shares, Restricted stock awards granted Weighted Average Award Date Fair Value per Share, Restricted stock awards granted Number of Shares, Restricted stock awards vested Weighted Average Award Date Fair Value per Share, Restricted stock awards vested Number of Shares, Unvested restricted stock awards outstanding, ending balance Weighted Average Award Date Fair Value per Share, Unvested restricted stock awards outstanding, ending balance Stock-based compensation expense Unrecognized compensation costs Weighted average amortization period Aggregate intrinsic value per share Effective tax rate Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Revenues Concentration Risk [Table] Concentration Risk [Line Items] Concentration risk, percentage Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Tax Expense (Benefit) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Increase (Decrease) in Deferred Income Taxes Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Increase (Decrease) in Other Operating Assets Increase (Decrease) in Other Accounts Payable Increase (Decrease) in Other Accounts Payable and Accrued Liabilities IncreaseDecreaseInWithholdingTaxPayable Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities PaymentsForFractionalSharesRelatedToReversesplit Repayments of Other Short-Term Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Shares, Outstanding Stock Issued During Period, Value, Stock Options Exercised Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Inventory, Gross Operating Lease, Right-of-Use Asset, Periodic Reduction Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Revenue from Contract with Customer, Excluding Assessed Tax EX-101.PRE 10 snoa-20240930_pre.xml XBRL PRESENTATION FILE GRAPHIC 11 image_001.jpg GRAPHIC begin 644 image_001.jpg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htm IDEA: XBRL DOCUMENT v3.24.3
Cover - shares
6 Months Ended
Sep. 30, 2024
Nov. 07, 2024
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2024  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2025  
Current Fiscal Year End Date --03-31  
Entity File Number 001-33216  
Entity Registrant Name SONOMA PHARMACEUTICALS, INC.  
Entity Central Index Key 0001367083  
Entity Tax Identification Number 68-0423298  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 5445 Conestoga Court  
Entity Address, Address Line Two Suite 150  
Entity Address, City or Town Boulder  
Entity Address, State or Province CO  
Entity Address, Postal Zip Code 80301  
City Area Code 800  
Local Phone Number 759-9305  
Title of 12(b) Security Common Stock, $0.0001 par value  
Trading Symbol SNOA  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   1,339,170
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2024
Mar. 31, 2024
Current assets:    
Cash and cash equivalents $ 4,078 $ 3,128
Accounts receivable, net 3,157 2,898
Inventories, net 2,837 2,719
Prepaid expenses and other current assets 1,929 3,541
Current portion of deferred consideration, net of discount 220 262
Total current assets 12,221 12,548
Property and equipment, net 255 365
Operating lease, right of use assets 162 286
Deferred tax asset 792 1,145
Deferred consideration, net of discount, less current portion 179 330
Other assets 76 66
Total assets 13,685 14,740
Current liabilities:    
Accounts payable 770 607
Accrued expenses and other current liabilities 2,022 2,113
Deferred revenue, current portion 319 478
Short-term debt 82 323
Operating lease liabilities, current portion 116 198
Total current liabilities 3,309 3,719
Deferred revenue, net of current portion 45 87
Withholding tax payable 4,933 4,710
Operating lease liabilities, less current portion 46 87
Total liabilities 8,333 8,603
Commitments and Contingencies (Note 5)
Stockholders’ Equity:    
Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at September 30, 2024 and March 31, 2024, respectively, no shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively 0 0
Common stock, $0.0001 par value; 50,000,000 and 24,000,000 shares authorized at September 30, 2024 and March 31, 2024, respectively, 1,338,615 and 780,371 shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively (Note 1) (Note 7) 0 0
Additional paid-in capital 205,651 203,209
Accumulated deficit (196,102) (194,349)
Accumulated other comprehensive loss (4,197) (2,723)
Total stockholders’ equity 5,352 6,137
Total liabilities and stockholders’ equity $ 13,685 $ 14,740
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2024
Mar. 31, 2024
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 50,000,000 24,000,000
Common stock, shares issued 1,338,615 780,371
Common stock, shares outstanding 1,338,615 780,371
Convertible Preferred Stock [Member]    
Convertible preferred stock, par value $ 0.0001 $ 0.0001
Convertible preferred stock, shares authorized 714,286 714,286
Convertible preferred stock, shares issued 0 0
Convertible preferred stock, shares outstanding 0 0
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Income Statement [Abstract]        
Revenues $ 3,579 $ 2,731 $ 6,970 $ 6,158
Cost of revenues 2,218 1,741 4,303 3,964
Gross profit 1,361 990 2,667 2,194
Operating expenses        
Research and development 506 536 976 861
Selling, general and administrative 1,705 1,662 3,714 3,781
Total operating expenses 2,211 2,198 4,690 4,642
Loss from operations (850) (1,208) (2,023) (2,448)
Other income (expense), net 387 (90) 563 (301)
Loss from operations before income taxes (463) (1,298) (1,460) (2,749)
Income tax expense (147) (186) (293) (153)
Net loss $ (610) $ (1,484) $ (1,753) $ (2,902)
Net loss per share: basic $ (0.59) $ (5.75) $ (1.86) $ (11.47)
Net loss per share: diluted $ (0.59) $ (5.75) $ (1.86) $ (11.47)
Weighted-average number of shares: basic 1,034 258 943 253
Weighted-average number of shares: diluted 1,034 258 943 253
Other comprehensive loss        
Foreign currency translation adjustments $ (593) $ (213) $ (1,474) $ 298
Comprehensive loss $ (1,203) $ (1,697) $ (3,227) $ (2,604)
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
6 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities:    
Net loss $ (1,753) $ (2,902)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 74 90
Stock-based compensation 121 307
Deferred income taxes 188 144
Changes in operating assets and liabilities:    
Accounts receivable, net (427) 375
Inventories, net (370) 403
Prepaid expenses and other current assets 1,134 47
Deferred consideration 99 104
Operating lease, right-of-use assets 102 79
Accounts payable 219 132
Accrued expenses and other current liabilities 62 (353)
Deferred revenue (128) (31)
Withholding tax payable 223 238
Operating lease liabilities (102) (79)
Net cash used in operating activities (558) (1,446)
Cash flows from investing activities:    
Purchases of property and equipment (31) (19)
Net cash used in investing activities (31) (19)
Cash flows from financing activities:    
Proceeds (costs) from issuance of common stock, net of offering expenses 2,289 (5)
Proceeds from exercise of employee stock options 33 0
Payments for fractional shares related to reverse-split (1) 0
Principal payments on short-term debt (241) (259)
Net cash provided by (used in) financing activities 2,080 (264)
Effect of exchange rate on cash and cash equivalents (541) 46
Net increase (decrease) in cash and cash equivalents 950 (1,683)
Cash and cash equivalents, beginning of period 3,128 3,820
Cash and cash equivalents, end of period 4,078 2,137
Supplemental disclosure of cash flow information:    
Cash paid for interest $ 8 $ 10
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Beginning balance, value at Mar. 31, 2023 $ 200,909 $ (189,514) $ (3,418) $ 7,977
Beginning balance, shares at Mar. 31, 2023 246,678        
Cost in connection with ATM (5) (5)
Employee stock-based compensation expenses 177 177
Employee stock-based compensation expenses, shares 10,402        
Foreign currency translation adjustment 511 511
Net loss (1,418) (1,418)
Ending balance, value at Jun. 30, 2023 201,081 (190,932) (2,907) 7,242
Ending balance, shares at Jun. 30, 2023 257,080        
Beginning balance, value at Mar. 31, 2023 200,909 (189,514) (3,418) 7,977
Beginning balance, shares at Mar. 31, 2023 246,678        
Net loss         (2,902)
Ending balance, value at Sep. 30, 2023 201,211 (192,416) (3,120) 5,675
Ending balance, shares at Sep. 30, 2023 258,967        
Beginning balance, value at Jun. 30, 2023 201,081 (190,932) (2,907) 7,242
Beginning balance, shares at Jun. 30, 2023 257,080        
Employee stock-based compensation expenses 130 130
Employee stock-based compensation expenses, shares 1,887        
Foreign currency translation adjustment (213) (213)
Net loss (1,484) (1,484)
Ending balance, value at Sep. 30, 2023 201,211 (192,416) (3,120) 5,675
Ending balance, shares at Sep. 30, 2023 258,967        
Beginning balance, value at Mar. 31, 2024 203,209 (194,349) (2,723) 6,137
Beginning balance, shares at Mar. 31, 2024 780,371        
Proceeds from At-the-Market sale of common stock, net of offering expenses 748 748
Proceeds from At-the-Market sale of common stock, net of offering expenses, shares 158,311        
Proceeds from exercise of employee stock options 7 7
Proceeds from exercise of employee stock options, shares 2,000        
Employee stock-based compensation expenses 107 107
Employee stock-based compensation expenses, shares 9,538        
Foreign currency translation adjustment (881) (881)
Net loss (1,143) (1,143)
Ending balance, value at Jun. 30, 2024 204,071 (195,492) (3,604) 4,975
Ending balance, shares at Jun. 30, 2024 950,220        
Beginning balance, value at Mar. 31, 2024 203,209 (194,349) (2,723) 6,137
Beginning balance, shares at Mar. 31, 2024 780,371        
Net loss         (1,753)
Ending balance, value at Sep. 30, 2024 205,651 (196,102) (4,197) 5,352
Ending balance, shares at Sep. 30, 2024 1,338,615        
Beginning balance, value at Jun. 30, 2024 204,071 (195,492) (3,604) 4,975
Beginning balance, shares at Jun. 30, 2024 950,220        
Proceeds from At-the-Market sale of common stock, net of offering expenses 1,541 1,541
Proceeds from At-the-Market sale of common stock, net of offering expenses, shares 381,433        
Proceeds from exercise of employee stock options 26 26
Proceeds from exercise of employee stock options, shares 7,250        
Payments for fractional shares related to reverse-split (1) (1)
Payments for fractional shares related to reverse-split, shares (288)        
Employee stock-based compensation expenses 14 14
Foreign currency translation adjustment (593) (593)
Net loss (610) (610)
Ending balance, value at Sep. 30, 2024 $ 205,651 $ (196,102) $ (4,197) $ 5,352
Ending balance, shares at Sep. 30, 2024 1,338,615        
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Sep. 30, 2023
Jun. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure [Table]            
Net Income (Loss) $ (610) $ (1,143) $ (1,484) $ (1,418) $ (1,753) $ (2,902)
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3
Insider Trading Arrangements
3 Months Ended
Sep. 30, 2024
Insider Trading Arrangements [Line Items]  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3
Organization and Recent Developments
6 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Recent Developments

 

Note 1. Organization and Recent Developments

 

Organization

 

Sonoma Pharmaceuticals, Inc. (the “Company”) was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware in December 2006. The Company moved its principal office from Petaluma, California to Woodstock, Georgia in June 2020 and to Boulder, Colorado in October 2022. The Company is a global healthcare leader for developing and producing stabilized hypochlorous acid (“HOCl”) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, animal health care, and as a non-toxic disinfectant. The Company’s products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. The Company sells its products either directly or via partners in 55 countries worldwide.

 

Reverse Stock Split

 

Effective August 29, 2024, the Company effected a reverse stock split of its common stock, par value $0.0001 per share. Every twenty shares of common stock were reclassified and combined into one share of common stock. No fractional shares were issued as a result of the reverse stock split. Instead, each fractional share was settled with cash. The reverse stock split reduced the number of shares of the Company’s common stock outstanding from 21,174,693 to 1,058,447. The total number of authorized shares of common stock was not proportionally decreased and the par value per share of the common stock continues to be $0.0001. The reverse stock split has been retroactively applied to all share and per share amounts in the condensed consolidated financial statements and accompanying footnotes.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended March 31, 2024, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on June 17, 2024.

 

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.3
Liquidity and Financial Condition
6 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Liquidity and Financial Condition

 

Note 2. Liquidity and Financial Condition

 

The Company reported a net loss of $610,000 and $1,484,000 for the three months ended September 30, 2024 and 2023, respectively, and $1,753,000 and $2,902,000 for the six months ended September 30, 2024 and 2023, respectively. At September 30, 2024 and March 31, 2024, the Company’s accumulated deficit amounted to $196,102,000 and $194,349,000, respectively. The Company had working capital of $8,912,000 and $8,829,000 as of September 30, 2024 and March 31, 2024, respectively. The cash balance at September 30, 2024 and March 31, 2024 was $4,078,000 and $3,128,000, respectively. During the six months ended September 30, 2024 and 2023, net cash used in operating activities amounted to $558,000 and $1,446,000, respectively.

 

Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed. If the economic climate in the U.S. deteriorates, the Company’s ability to raise additional capital could be negatively impacted. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s continued efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of the Company. This uncertainty along with the Company’s history of losses indicates that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.

 

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies
6 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

 

Note 3. Summary of Significant Accounting Policies

  

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.

 

Net Loss per Share

 

The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.

 

The following table provides the net loss for each period along with the computation of basic and diluted net loss per share:

                
  

Three Months Ended

September 30,

  

Six Months Ended

September 30,

 
(In thousands, except per share data)  2024   2023   2024   2023 
Numerator:                
Net loss  $(610)  $(1,484)  $(1,753)  $(2,902)
                     
Denominator:                    
Weighted-average number of common shares outstanding: basic and diluted   1,034    258    943    253 
                     
Net loss per share: basic and diluted  $(0.59)  $(5.75)  $(1.86)  $(11.47)

 

The computation of basic loss per share for the three and six months ended September 30, 2024 and 2023 excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive.

                 
  

Three Months Ended

September 30,

  

Six Months Ended

September 30,

 
(In thousands)  2024   2023   2024   2023 
Stock options   42    26    42    26 
Warrants       5        5 
Common stock units (1)       2        2 
    42    33    42    33 

 

(1) Consists of 1,533 restricted stock units and warrants to purchase 766 shares of common stock.

  

Revenue Recognition

 

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”), Topic 606 Revenue from Contracts with Customers (“Topic 606”). Revenue is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.

 

The Company derives the majority of its revenue through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company has also entered into agreements to license its technology and products.

 

The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled.

 

For all of the Company’s sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able to estimate the amount of product that will be returned.

 

The Company has entered into consignment arrangements, in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company recognizes revenue based on a variable percentage of a fixed price. Revenue recognized varies depending on whether a patient is covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the Company’s rebate program.

 

Sales to stocking distributors are made under terms with fixed pricing and limited rights of return (known as “stock rotation”) of the Company’s products held in their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.

 

The Company evaluates the creditworthiness of new customers and monitors the creditworthiness of its existing customers to determine whether an event or changes in their financial circumstances would raise doubt as to the collectability of a sale at the time in which a sale is made. Payment terms on sales are generally 30 to 90 days.

 

The Company assessed the promised goods and services in the technical support contract with Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and as separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.

 

Accounts Receivable

 

Trade accounts receivable are recorded net of allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based on analysis of contractual terms and historical trends.

 

The Company’s policy is to reserve for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company did not deem it necessary to record an allowance for doubtful accounts for probable credit losses at September 30, 2024 and March 31, 2024. Additionally, at September 30, 2024 and March 31, 2024, the Company has allowances of $66,000 and $27,000, respectively, related to potential discounts, returns, distributor fees and rebates. The allowances are included in Accounts Receivable, net in the accompanying condensed consolidated balance sheets.

 

Inventories

 

Inventories are stated at the lower of cost, cost being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.

 

Due to changing market conditions, estimated future requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value. At September 30, 2024 and March 31, 2024, the Company recorded provisions to reduce the carrying amounts of inventories to their net realizable value in the amounts of $254,000 and $296,000, respectively, which is included in Inventories, net in the accompanying condensed consolidated balance sheets.

 

Recent Accounting Standards

 

Accounting standards that have been issued or proposed by the FASB, the SEC or other standard setting bodies that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption.

 

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheet
6 Months Ended
Sep. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Condensed Consolidated Balance Sheet

 

Note 4. Condensed Consolidated Balance Sheet

 

Inventories, net

 

Inventories, net consist of the following:

        
   September 30,   March 31, 
   2024   2024 
Raw materials  $1,670,000   $1,802,000 
Finished goods   1,421,000    1,213,000 
Inventories, gross    3,091,000    3,015,000 
Less: allowance for obsolete and excess inventory   (254,000)   (296,000)
Total inventories, net  $2,837,000   $2,719,000 

 

Leases

 

The Company’s operating leases are comprised primarily of facility leases. Balance sheet information related to the Company’s leases is presented below:

         
   September 30,   March 31, 
   2024   2024 
Operating leases:          
Operating lease right-of-use assets  $162,000   $286,000 
Operating lease liabilities – current   116,000    198,000 
Operating lease liabilities – non-current   46,000    87,000 

 

Other information related to leases is presented below:

 

Six Months Ended September 30, 2024    
Operating lease cost  $186,000 
Other information:     
Operating cash flows from operating leases   (102,000)
Weighted-average remaining lease term – operating leases (in months)   18.7 
Weighted-average discount rate – operating leases   6.00% 

 

As of September 30, 2024, the annual minimum lease payments of our operating lease liabilities were as follows:

     
For Years Ending March 31,    
2025 (excluding the six months ended September 30, 2024)  $87,000 
2026   67,000 
2027   14,000 
2028   9,000 
Total future minimum lease payments, undiscounted   177,000 
Less: imputed interest   (15,000)
Present value of future minimum lease payments  $162,000 

  

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies
6 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

 

Note 5. Commitments and Contingencies

 

Legal Matters

 

The Company may be involved in legal matters arising in the ordinary course of business including matters involving proprietary technology from time to time. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation may have a material adverse effect on its business and financial condition of comprehensive loss.

 

Employment Matters

 

The Company has employment agreements in place with two of its key executives. These executive employment agreements provide, among other things, for the payment of up to eighteen months of severance compensation for terminations under certain circumstances.

 

As of September 30, 2024, with respect to these agreements, aggregated annual salaries was $586,000 and potential severance payments to these key executives is $1,300,000, if triggered.

 

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.3
Debt
6 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Debt

 

Note 6. Debt

 

Financing of Insurance Premiums

 

On February 6, 2024, the Company entered into a note agreement for $373,000 with an interest rate of 8.42% per annum with final payment on November 1, 2024. This instrument was issued in connection with financing insurance premiums. The note is payable in nine monthly installment payments of principal and interest of $42,000, with the first installment beginning March 1, 2024. At September 30, 2024 and March 31, 2024, the outstanding principal on the note amounted to $82,000 and $323,000, respectively.

 

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders’ Equity
6 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Stockholders’ Equity

 

Note 7. Stockholders’ Equity

 

Authorized Capital

 

Effective August 29, 2024, the Company increased its authorized shares from 24,000,000 to 50,000,000 shares of common stock with a par value of $0.0001 per share.  Additionally, the Company is authorized to issue 714,286 shares of convertible preferred stock with a par value of $0.0001 per share.

 

Sale of Common Stock

 

In connection with the Equity Distribution Agreement that the Company entered into on December 15, 2023 with Maxim Group LLC (“Maxim”), as amended, from May 13, 2024 to September 18, 2024 the Company sold 539,744 shares of its common stock for gross proceeds of $2,490,000 and net proceeds of $2,289,000 after deducting commissions and other offering expenses paid by the Company.

 

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-Based Compensation
6 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

 

Note 8. Stock-Based Compensation

 

For the three months ended September 30, 2024 and 2023, the Company incurred $14,000 and $130,000 of stock-based compensation expense, respectively. For the six months ended September 30, 2024 and 2023, the Company incurred $121,000 and $307,000 of stock-based compensation expense, respectively. All stock-based compensation incurred is included in selling, general and administrative expense in the accompanying condensed consolidated statements of comprehensive loss.

 

At September 30, 2024, there was unrecognized compensation costs of $229,000 related to stock options which is expected to be recognized over a weighted-average amortization period of 1.80 years.

 

Stock options award activity is as follows:

        
   Number of
Shares
   Weighted-
Average
Exercise Price
 
Outstanding at April 1, 2024   51,675   $62.60 
Options exercised   (9,250)   3.60 
Options forfeited   (250)   3.60 
Options expired   (10)   2,402 
Outstanding at September 30, 2024   42,165   $75.77 
Exercisable at September 30, 2024   28,335   $107.92 

 

The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock, or $3.07 per share at September 30, 2024.

 

Restricted stock award activity is as follows:

          
  

Number of

Shares

  

Weighted

Average Award

Date Fair Value

per Share

 
Unvested restricted stock awards outstanding at April 1, 2024      $ 
Restricted stock awards granted   9,538    4.00 
Restricted stock awards vested   (9,538)   4.00 
Unvested restricted stock awards outstanding at September 30, 2024      $ 

 

The Company issues new shares of common stock upon exercise of stock options or release of restricted stock awards.

 

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.3
Income Taxes
6 Months Ended
Sep. 30, 2024
Income Tax Disclosure [Abstract]  
Income Taxes

 

Note 9. Income Taxes

 

At the end of each interim reporting period, the Company determines the income tax provision by using an estimate of the annual effective tax rate, adjusted for discrete items occurring in the quarter.

 

Our effective tax rate for the three and six months ended September 30, 2024 was (31.5)% and (20.5)%, respectively. The Company’s effective tax rate for the three and six months ended September 30, 2024 differed from the federal statutory tax rate of 21% primarily due to the valuation allowance recognized against deferred tax assets in the U.S., and permanent tax adjustment of intercompany interest expense in Mexico and Netherlands.

 

Judgment is required in determining whether deferred tax assets will be realized in full or in part. Management assesses the available positive and negative evidence on a jurisdictional basis to estimate if deferred tax assets will be recognized and when it is more likely than not that all or some deferred tax assets will not be realized, and a valuation allowance must be established. As of September 30, 2024, the Company continues to maintain a valuation allowance in the U.S.

 

XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Disaggregation
6 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Disaggregation

 

Note 10. Revenue Disaggregation

 

The Company generates product revenues from products which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services which are provided to medical device manufacturers.

 

The following table presents the Company’s disaggregated revenues by revenue source:

                
   Three Months Ended September 30,   Six Months Ended September 30, 
   2024   2023   2024   2023 
Human Care  $2,957,000   $2,075,000   $5,833,000   $4,825,000 
Animal Care   402,000    489,000    801,000    1,067,000 
Service and Royalty   220,000    167,000    336,000    266,000 
   $3,579,000   $2,731,000   $6,970,000   $6,158,000 

 

The following table shows the Company’s revenues by geographic region:

                  
   Three Months Ended September 30,   Six Months Ended September 30, 
   2024   2023   2024   2023 
United States  $675,000   $590,000   $1,317,000   $1,396,000 
Europe   1,506,000    1,201,000    2,794,000    2,271,000 
Asia   776,000    346,000    1,253,000    1,208,000 
Latin America   465,000    260,000    1,345,000    747,000 
Rest of the World   157,000    334,000    261,000    536,000 
Total  $3,579,000   $2,731,000   $6,970,000   $6,158,000 

 

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.3
Significant Customer Concentrations
6 Months Ended
Sep. 30, 2024
Risks and Uncertainties [Abstract]  
Significant Customer Concentrations

 

Note 11. Significant Customer Concentrations

 

The following table shows major customers revenues as a percentage of net revenue:

                       
    Three Months Ended September 30,     Six Months Ended September 30,  
    2024     2023     2024     2023  
Customer A     *%       13%       *%       14%  
Customer B     13%       10%       19%       12%  
Customer C     19%       21%       19%       17%  
Customer D     12%       *%       *%       *%  

 

The following table shows major customers accounts receivable balances as a percentage of net accounts receivables:

             
    September 30,  
    2024     2023  
Customer A     16%       11%  
Customer C     11%       13%  
Customer D     20%       20%  

 

* Represents less than 10%

 

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.3
Subsequent Events
6 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]  
Subsequent Events

 

Note 12. Subsequent Events

 

Management has evaluated subsequent events or transactions occurring through the date the condensed consolidated financial statements were issued. The Company does not have subsequent events to report.

 

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Policies)
6 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Use of Estimates

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.

 

Net Loss per Share

Net Loss per Share

 

The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.

 

The following table provides the net loss for each period along with the computation of basic and diluted net loss per share:

                
  

Three Months Ended

September 30,

  

Six Months Ended

September 30,

 
(In thousands, except per share data)  2024   2023   2024   2023 
Numerator:                
Net loss  $(610)  $(1,484)  $(1,753)  $(2,902)
                     
Denominator:                    
Weighted-average number of common shares outstanding: basic and diluted   1,034    258    943    253 
                     
Net loss per share: basic and diluted  $(0.59)  $(5.75)  $(1.86)  $(11.47)

 

The computation of basic loss per share for the three and six months ended September 30, 2024 and 2023 excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive.

                 
  

Three Months Ended

September 30,

  

Six Months Ended

September 30,

 
(In thousands)  2024   2023   2024   2023 
Stock options   42    26    42    26 
Warrants       5        5 
Common stock units (1)       2        2 
    42    33    42    33 

 

(1) Consists of 1,533 restricted stock units and warrants to purchase 766 shares of common stock.

  

Revenue Recognition

Revenue Recognition

 

The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”), Topic 606 Revenue from Contracts with Customers (“Topic 606”). Revenue is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.

 

The Company derives the majority of its revenue through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company has also entered into agreements to license its technology and products.

 

The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled.

 

For all of the Company’s sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able to estimate the amount of product that will be returned.

 

The Company has entered into consignment arrangements, in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company recognizes revenue based on a variable percentage of a fixed price. Revenue recognized varies depending on whether a patient is covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the Company’s rebate program.

 

Sales to stocking distributors are made under terms with fixed pricing and limited rights of return (known as “stock rotation”) of the Company’s products held in their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.

 

The Company evaluates the creditworthiness of new customers and monitors the creditworthiness of its existing customers to determine whether an event or changes in their financial circumstances would raise doubt as to the collectability of a sale at the time in which a sale is made. Payment terms on sales are generally 30 to 90 days.

 

The Company assessed the promised goods and services in the technical support contract with Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and as separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.

 

Accounts Receivable

Accounts Receivable

 

Trade accounts receivable are recorded net of allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based on analysis of contractual terms and historical trends.

 

The Company’s policy is to reserve for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company did not deem it necessary to record an allowance for doubtful accounts for probable credit losses at September 30, 2024 and March 31, 2024. Additionally, at September 30, 2024 and March 31, 2024, the Company has allowances of $66,000 and $27,000, respectively, related to potential discounts, returns, distributor fees and rebates. The allowances are included in Accounts Receivable, net in the accompanying condensed consolidated balance sheets.

 

Inventories

Inventories

 

Inventories are stated at the lower of cost, cost being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.

 

Due to changing market conditions, estimated future requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value. At September 30, 2024 and March 31, 2024, the Company recorded provisions to reduce the carrying amounts of inventories to their net realizable value in the amounts of $254,000 and $296,000, respectively, which is included in Inventories, net in the accompanying condensed consolidated balance sheets.

 

Recent Accounting Standards

Recent Accounting Standards

 

Accounting standards that have been issued or proposed by the FASB, the SEC or other standard setting bodies that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption.

 

XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Sep. 30, 2024
Accounting Policies [Abstract]  
Schedule of computation of basic and diluted net loss per share
                
  

Three Months Ended

September 30,

  

Six Months Ended

September 30,

 
(In thousands, except per share data)  2024   2023   2024   2023 
Numerator:                
Net loss  $(610)  $(1,484)  $(1,753)  $(2,902)
                     
Denominator:                    
Weighted-average number of common shares outstanding: basic and diluted   1,034    258    943    253 
                     
Net loss per share: basic and diluted  $(0.59)  $(5.75)  $(1.86)  $(11.47)
Schedule of anti-dilutive shares
                 
  

Three Months Ended

September 30,

  

Six Months Ended

September 30,

 
(In thousands)  2024   2023   2024   2023 
Stock options   42    26    42    26 
Warrants       5        5 
Common stock units (1)       2        2 
    42    33    42    33 

 

(1) Consists of 1,533 restricted stock units and warrants to purchase 766 shares of common stock.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheet (Tables)
6 Months Ended
Sep. 30, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
Schedule of inventories, net
        
   September 30,   March 31, 
   2024   2024 
Raw materials  $1,670,000   $1,802,000 
Finished goods   1,421,000    1,213,000 
Inventories, gross    3,091,000    3,015,000 
Less: allowance for obsolete and excess inventory   (254,000)   (296,000)
Total inventories, net  $2,837,000   $2,719,000 
Schedule of lease information
         
   September 30,   March 31, 
   2024   2024 
Operating leases:          
Operating lease right-of-use assets  $162,000   $286,000 
Operating lease liabilities – current   116,000    198,000 
Operating lease liabilities – non-current   46,000    87,000 

 

Other information related to leases is presented below:

 

Six Months Ended September 30, 2024    
Operating lease cost  $186,000 
Other information:     
Operating cash flows from operating leases   (102,000)
Weighted-average remaining lease term – operating leases (in months)   18.7 
Weighted-average discount rate – operating leases   6.00% 
Schedule of minimum lease payments of operating lease liabilities
     
For Years Ending March 31,    
2025 (excluding the six months ended September 30, 2024)  $87,000 
2026   67,000 
2027   14,000 
2028   9,000 
Total future minimum lease payments, undiscounted   177,000 
Less: imputed interest   (15,000)
Present value of future minimum lease payments  $162,000 
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-Based Compensation (Tables)
6 Months Ended
Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of stock options award activity
        
   Number of
Shares
   Weighted-
Average
Exercise Price
 
Outstanding at April 1, 2024   51,675   $62.60 
Options exercised   (9,250)   3.60 
Options forfeited   (250)   3.60 
Options expired   (10)   2,402 
Outstanding at September 30, 2024   42,165   $75.77 
Exercisable at September 30, 2024   28,335   $107.92 
Schedule of unvested restricted stock activity
          
  

Number of

Shares

  

Weighted

Average Award

Date Fair Value

per Share

 
Unvested restricted stock awards outstanding at April 1, 2024      $ 
Restricted stock awards granted   9,538    4.00 
Restricted stock awards vested   (9,538)   4.00 
Unvested restricted stock awards outstanding at September 30, 2024      $ 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Disaggregation (Tables)
6 Months Ended
Sep. 30, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of disaggregated revenue by source
                
   Three Months Ended September 30,   Six Months Ended September 30, 
   2024   2023   2024   2023 
Human Care  $2,957,000   $2,075,000   $5,833,000   $4,825,000 
Animal Care   402,000    489,000    801,000    1,067,000 
Service and Royalty   220,000    167,000    336,000    266,000 
   $3,579,000   $2,731,000   $6,970,000   $6,158,000 
Schedule of revenues by geographic region
                  
   Three Months Ended September 30,   Six Months Ended September 30, 
   2024   2023   2024   2023 
United States  $675,000   $590,000   $1,317,000   $1,396,000 
Europe   1,506,000    1,201,000    2,794,000    2,271,000 
Asia   776,000    346,000    1,253,000    1,208,000 
Latin America   465,000    260,000    1,345,000    747,000 
Rest of the World   157,000    334,000    261,000    536,000 
Total  $3,579,000   $2,731,000   $6,970,000   $6,158,000 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.3
Significant Customer Concentrations (Tables)
6 Months Ended
Sep. 30, 2024
Risks and Uncertainties [Abstract]  
Schedule of customer concentrations of risk
                       
    Three Months Ended September 30,     Six Months Ended September 30,  
    2024     2023     2024     2023  
Customer A     *%       13%       *%       14%  
Customer B     13%       10%       19%       12%  
Customer C     19%       21%       19%       17%  
Customer D     12%       *%       *%       *%  

 

The following table shows major customers accounts receivable balances as a percentage of net accounts receivables:

             
    September 30,  
    2024     2023  
Customer A     16%       11%  
Customer C     11%       13%  
Customer D     20%       20%  

 

* Represents less than 10%
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.3
Organization and Recent Developments (Details Narrative)
6 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Reverse stock split The reverse stock split reduced the number of shares of the Company’s common stock outstanding from 21,174,693 to 1,058,447. The total number of authorized shares of common stock was not proportionally decreased and the par value per share of the common stock continues to be $0.0001.
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.3
Liquidity and Financial Condition (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Sep. 30, 2023
Jun. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]              
Net loss $ 610 $ 1,143 $ 1,484 $ 1,418 $ 1,753 $ 2,902  
Accumulated deficit 196,102       196,102   $ 194,349
Working capital 8,912       8,912   8,829
Liquidity cash balance $ 4,078       4,078   $ 3,128
Net cash used in operating activities         $ 558 $ 1,446  
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Details - Earnings per share) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Sep. 30, 2023
Jun. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Numerator:            
Net loss $ (610) $ (1,143) $ (1,484) $ (1,418) $ (1,753) $ (2,902)
Denominator:            
Weighted-average number of common shares outstanding: basic 1,034   258   943 253
Weighted-average number of common shares outstanding: diluted 1,034   258   943 253
Net loss per share: basic $ (0.59)   $ (5.75)   $ (1.86) $ (11.47)
Net loss per share: diluted $ (0.59)   $ (5.75)   $ (1.86) $ (11.47)
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Details - Anti-dilutive shares) - shares
shares in Thousands
3 Months Ended 6 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive shares 42 33 42 33
Equity Option [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive shares 42 26 42 26
Warrant [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive shares 0 5 0 5
Common Stock Units [Member]        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Anti-dilutive shares [1] 0 2 0 2
[1] Consists of 1,533 restricted stock units and warrants to purchase 766 shares of common stock.
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.3
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
$ in Thousands
Sep. 30, 2024
Mar. 31, 2024
Accounting Policies [Abstract]    
Allowances related to potential discounts, returns, distributor fees and rebates $ 66 $ 27
Net realizable value $ 254 $ 296
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheet (Details - Inventories) - USD ($)
$ in Thousands
Sep. 30, 2024
Mar. 31, 2024
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]    
Raw materials $ 1,670 $ 1,802
Finished goods 1,421 1,213
Inventories, gross  3,091 3,015
Less: allowance for obsolete and excess inventory (254) (296)
Total inventories, net $ 2,837 $ 2,719
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheet (Details - Balance sheet information related to leases) - USD ($)
$ in Thousands
6 Months Ended
Sep. 30, 2024
Mar. 31, 2024
Operating leases:    
Operating lease right-of-use assets $ 162 $ 286
Operating lease liabilities – current 116 198
Operating lease liabilities – non-current 46 $ 87
Operating lease cost 186  
Operating cash flows from operating leases $ (102)  
Weighted-average remaining lease term - operating leases (in months) 18 months 21 days  
Weighted-average discount rate - operating leases 6.00%  
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Balance Sheet (Details - Minimum lease payments of opearting lease liabilities)
$ in Thousands
Sep. 30, 2024
USD ($)
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
2025 (excluding the six months ended September 30, 2024) $ 87
2026 67
2027 14
2028 9
Total future minimum lease payments, undiscounted 177
Less: imputed interest (15)
Present value of future minimum lease payments $ 162
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.3
Commitments and Contingencies (Details Narrative)
$ in Thousands
6 Months Ended
Sep. 30, 2024
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Aggregated annual salaries $ 586
Potential severance payments $ 1,300
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.3
Debt (Details Narrative) - Insurance Premium Financing [Member] - USD ($)
$ in Thousands
Feb. 06, 2024
Sep. 30, 2024
Mar. 31, 2024
Short-Term Debt [Line Items]      
Debt face amount $ 373    
Debt interest rate 8.42%    
Final payment date Nov. 01, 2024    
Debt payment terms nine monthly installment payments    
Periodic payment $ 42    
First installment beginning date Mar. 01, 2024    
Outstanding principal amount   $ 82 $ 323
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.3
Stockholders’ Equity (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
4 Months Ended 6 Months Ended
Sep. 18, 2024
Sep. 30, 2024
Sep. 30, 2023
Mar. 31, 2024
Class of Stock [Line Items]        
Common stock, shares authorized   50,000,000   24,000,000
Common stock, par value   $ 0.0001   $ 0.0001
Proceeds from sale of stock, net   $ 2,289 $ (5)  
Equity Distribution Agreement [Member]        
Class of Stock [Line Items]        
Stock issued new, shares 539,744      
Proceeds from sale of stock, gross $ 2,490      
Proceeds from sale of stock, net $ 2,289      
Convertible Preferred Stock [Member]        
Class of Stock [Line Items]        
Convertible preferred stock, shares authorized   714,286   714,286
Convertible preferred stock, par value   $ 0.0001   $ 0.0001
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-Based Compensation (Details - Stock option award activity) - Equity Option [Member] - $ / shares
6 Months Ended
Sep. 30, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of Shares, Outstanding, Beginning Balance 51,675
Weighted-Average Exercise Price Outstanding, Beginning Balance $ 62.60
Number of Shares, Options exercised (9,250)
Weighted-Average Exercise Price, Options exercised $ 3.60
Number of Shares, Options forfeited (250)
Weighted-Average Exercise Price, Options forfeited $ 3.60
Number of Shares, Options expired (10)
Weighted-Average Exercise Price, Options expired $ 2,402
Number of Shares, Outstanding, Ending Balance 42,165
Weighted-Average Exercise Price Outstanding, Ending Balance $ 75.77
Number of Shares, Exercisable 28,335
Weighted-average exercise price, exercisable $ 107.92
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-Based Compensation (Details-Restricted stock activity) - Restricted Stock [Member]
6 Months Ended
Sep. 30, 2024
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of Shares, Unvested restricted stock awards outstanding, beginning balance | shares 0
Weighted Average Award Date Fair Value per Share, Unvested restricted stock awards outstanding, beginning balance | $ / shares $ 0
Number of Shares, Restricted stock awards granted | shares 9,538
Weighted Average Award Date Fair Value per Share, Restricted stock awards granted | $ / shares $ 4.00
Number of Shares, Restricted stock awards vested | shares (9,538)
Weighted Average Award Date Fair Value per Share, Restricted stock awards vested | $ / shares $ 4.00
Number of Shares, Unvested restricted stock awards outstanding, ending balance | shares 0
Weighted Average Award Date Fair Value per Share, Unvested restricted stock awards outstanding, ending balance | $ / shares $ 0
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-Based Compensation (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Stock-based compensation expense $ 14 $ 130 $ 121 $ 307
Equity Option [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Unrecognized compensation costs $ 229   $ 229  
Weighted average amortization period     1 year 9 months 18 days  
Aggregate intrinsic value per share     $ 3.07  
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.3
Income Taxes (Details Narrative)
3 Months Ended 6 Months Ended
Sep. 30, 2024
Sep. 30, 2024
Income Tax Disclosure [Abstract]    
Effective tax rate (31.50%) (20.50%)
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Disaggregation (Details - Disaggregation of revenue by source) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Revenues $ 3,579 $ 2,731 $ 6,970 $ 6,158
Human Care [Member] | Product [Member]        
Disaggregation of Revenue [Line Items]        
Revenues 2,957 2,075 5,833 4,825
Animal Care [Member] | Product [Member]        
Disaggregation of Revenue [Line Items]        
Revenues 402 489 801 1,067
Service And Royalty [Member] | Service [Member]        
Disaggregation of Revenue [Line Items]        
Revenues $ 220 $ 167 $ 336 $ 266
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.3
Revenue Disaggregation (Details - Revenue by geographic regions) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Disaggregation of Revenue [Line Items]        
Revenues $ 3,579 $ 2,731 $ 6,970 $ 6,158
Revenue, Segment Benchmark [Member] | UNITED STATES        
Disaggregation of Revenue [Line Items]        
Revenues 675 590 1,317 1,396
Revenue, Segment Benchmark [Member] | Europe [Member]        
Disaggregation of Revenue [Line Items]        
Revenues 1,506 1,201 2,794 2,271
Revenue, Segment Benchmark [Member] | Asia [Member]        
Disaggregation of Revenue [Line Items]        
Revenues 776 346 1,253 1,208
Revenue, Segment Benchmark [Member] | Latin America [Member]        
Disaggregation of Revenue [Line Items]        
Revenues 465 260 1,345 747
Revenue, Segment Benchmark [Member] | Rest Of The World [Member]        
Disaggregation of Revenue [Line Items]        
Revenues $ 157 $ 334 $ 261 $ 536
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.3
Significant Customer Concentrations (Details) - Customer Concentration Risk [Member]
3 Months Ended 6 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue Benchmark [Member] | Customer A [Member]        
Concentration Risk [Line Items]        
Concentration risk, percentage [1] 13.00% [1] 14.00%
Revenue Benchmark [Member] | Customer B [Member]        
Concentration Risk [Line Items]        
Concentration risk, percentage 13.00% 10.00% 19.00% 12.00%
Revenue Benchmark [Member] | Customer C [Member]        
Concentration Risk [Line Items]        
Concentration risk, percentage 19.00% 21.00% 19.00% 17.00%
Revenue Benchmark [Member] | Customer D [Member]        
Concentration Risk [Line Items]        
Concentration risk, percentage 12.00% [1] [1] [1]
Accounts Receivable [Member] | Customer A [Member]        
Concentration Risk [Line Items]        
Concentration risk, percentage     16.00% 11.00%
Accounts Receivable [Member] | Customer C [Member]        
Concentration Risk [Line Items]        
Concentration risk, percentage     11.00% 13.00%
Accounts Receivable [Member] | Customer D [Member]        
Concentration Risk [Line Items]        
Concentration risk, percentage     20.00% 20.00%
[1] Represents less than 10%
EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 132 205 1 true 30 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://sonomapharma.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://sonomapharma.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://sonomapharma.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://sonomapharma.com/role/StatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://sonomapharma.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995512 - Disclosure - Organization and Recent Developments Sheet http://sonomapharma.com/role/OrganizationAndRecentDevelopments Organization and Recent Developments Notes 9 false false R10.htm 995513 - Disclosure - Liquidity and Financial Condition Sheet http://sonomapharma.com/role/LiquidityAndFinancialCondition Liquidity and Financial Condition Notes 10 false false R11.htm 995514 - Disclosure - Summary of Significant Accounting Policies Sheet http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 995515 - Disclosure - Condensed Consolidated Balance Sheet Sheet http://sonomapharma.com/role/BalanceSheet Condensed Consolidated Balance Sheet Notes 12 false false R13.htm 995516 - Disclosure - Commitments and Contingencies Sheet http://sonomapharma.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 995517 - Disclosure - Debt Sheet http://sonomapharma.com/role/Debt Debt Notes 14 false false R15.htm 995518 - Disclosure - Stockholders??? Equity Sheet http://sonomapharma.com/role/StockholdersEquity Stockholders??? Equity Notes 15 false false R16.htm 995519 - Disclosure - Stock-Based Compensation Sheet http://sonomapharma.com/role/Stock-basedCompensation Stock-Based Compensation Notes 16 false false R17.htm 995520 - Disclosure - Income Taxes Sheet http://sonomapharma.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 995521 - Disclosure - Revenue Disaggregation Sheet http://sonomapharma.com/role/RevenueDisaggregation Revenue Disaggregation Notes 18 false false R19.htm 995522 - Disclosure - Significant Customer Concentrations Sheet http://sonomapharma.com/role/SignificantCustomerConcentrations Significant Customer Concentrations Notes 19 false false R20.htm 995523 - Disclosure - Subsequent Events Sheet http://sonomapharma.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 995524 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies 21 false false R22.htm 995525 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies 22 false false R23.htm 995526 - Disclosure - Condensed Consolidated Balance Sheet (Tables) Sheet http://sonomapharma.com/role/BalanceSheetTables Condensed Consolidated Balance Sheet (Tables) Tables http://sonomapharma.com/role/BalanceSheet 23 false false R24.htm 995527 - Disclosure - Stock-Based Compensation (Tables) Sheet http://sonomapharma.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://sonomapharma.com/role/Stock-basedCompensation 24 false false R25.htm 995528 - Disclosure - Revenue Disaggregation (Tables) Sheet http://sonomapharma.com/role/RevenueDisaggregationTables Revenue Disaggregation (Tables) Tables http://sonomapharma.com/role/RevenueDisaggregation 25 false false R26.htm 995529 - Disclosure - Significant Customer Concentrations (Tables) Sheet http://sonomapharma.com/role/SignificantCustomerConcentrationsTables Significant Customer Concentrations (Tables) Tables http://sonomapharma.com/role/SignificantCustomerConcentrations 26 false false R27.htm 995530 - Disclosure - Organization and Recent Developments (Details Narrative) Sheet http://sonomapharma.com/role/OrganizationAndRecentDevelopmentsDetailsNarrative Organization and Recent Developments (Details Narrative) Details http://sonomapharma.com/role/OrganizationAndRecentDevelopments 27 false false R28.htm 995531 - Disclosure - Liquidity and Financial Condition (Details Narrative) Sheet http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative Liquidity and Financial Condition (Details Narrative) Details http://sonomapharma.com/role/LiquidityAndFinancialCondition 28 false false R29.htm 995532 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share) Sheet http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare Summary of Significant Accounting Policies (Details - Earnings per share) Details http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables 29 false false R30.htm 995533 - Disclosure - Summary of Significant Accounting Policies (Details - Anti-dilutive shares) Sheet http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-Anti-dilutiveShares Summary of Significant Accounting Policies (Details - Anti-dilutive shares) Details http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables 30 false false R31.htm 995534 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables 31 false false R32.htm 995535 - Disclosure - Condensed Consolidated Balance Sheet (Details - Inventories) Sheet http://sonomapharma.com/role/BalanceSheetDetails-Inventories Condensed Consolidated Balance Sheet (Details - Inventories) Details http://sonomapharma.com/role/BalanceSheetTables 32 false false R33.htm 995536 - Disclosure - Condensed Consolidated Balance Sheet (Details - Balance sheet information related to leases) Sheet http://sonomapharma.com/role/BalanceSheetDetails-BalanceSheetInformationRelatedToLeases Condensed Consolidated Balance Sheet (Details - Balance sheet information related to leases) Details http://sonomapharma.com/role/BalanceSheetTables 33 false false R34.htm 995537 - Disclosure - Condensed Consolidated Balance Sheet (Details - Minimum lease payments of opearting lease liabilities) Sheet http://sonomapharma.com/role/BalanceSheetDetails-MinimumLeasePaymentsOfOpeartingLeaseLiabilities Condensed Consolidated Balance Sheet (Details - Minimum lease payments of opearting lease liabilities) Details http://sonomapharma.com/role/BalanceSheetTables 34 false false R35.htm 995538 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://sonomapharma.com/role/CommitmentsAndContingencies 35 false false R36.htm 995539 - Disclosure - Debt (Details Narrative) Sheet http://sonomapharma.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://sonomapharma.com/role/Debt 36 false false R37.htm 995540 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://sonomapharma.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://sonomapharma.com/role/StockholdersEquity 37 false false R38.htm 995541 - Disclosure - Stock-Based Compensation (Details - Stock option award activity) Sheet http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity Stock-Based Compensation (Details - Stock option award activity) Details http://sonomapharma.com/role/Stock-basedCompensationTables 38 false false R39.htm 995542 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity) Sheet http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity Stock-Based Compensation (Details-Restricted stock activity) Details http://sonomapharma.com/role/Stock-basedCompensationTables 39 false false R40.htm 995543 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://sonomapharma.com/role/Stock-basedCompensationTables 40 false false R41.htm 995544 - Disclosure - Income Taxes (Details Narrative) Sheet http://sonomapharma.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://sonomapharma.com/role/IncomeTaxes 41 false false R42.htm 995545 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue by source) Sheet http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenueBySource Revenue Disaggregation (Details - Disaggregation of revenue by source) Details http://sonomapharma.com/role/RevenueDisaggregationTables 42 false false R43.htm 995546 - Disclosure - Revenue Disaggregation (Details - Revenue by geographic regions) Sheet http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions Revenue Disaggregation (Details - Revenue by geographic regions) Details http://sonomapharma.com/role/RevenueDisaggregationTables 43 false false R44.htm 995547 - Disclosure - Significant Customer Concentrations (Details) Sheet http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails Significant Customer Concentrations (Details) Details http://sonomapharma.com/role/SignificantCustomerConcentrationsTables 44 false false All Reports Book All Reports snoa-20240930.xsd snoa-20240930_cal.xml snoa-20240930_def.xml snoa-20240930_lab.xml snoa-20240930_pre.xml sonoma_i10q-093024.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sonoma_i10q-093024.htm": { "nsprefix": "SNOA", "nsuri": "http://sonomapharma.com/20240930", "dts": { "schema": { "local": [ "snoa-20240930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "snoa-20240930_cal.xml" ] }, "definitionLink": { "local": [ "snoa-20240930_def.xml" ] }, "labelLink": { "local": [ "snoa-20240930_lab.xml" ] }, "presentationLink": { "local": [ "snoa-20240930_pre.xml" ] }, "inline": { "local": [ "sonoma_i10q-093024.htm" ] } }, "keyStandard": 192, "keyCustom": 13, "axisStandard": 12, "axisCustom": 0, "memberStandard": 18, "memberCustom": 11, "hidden": { "total": 72, "http://fasb.org/us-gaap/2024": 58, "http://sonomapharma.com/20240930": 9, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 132, "entityCount": 1, "segmentCount": 30, "elementCount": 411, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 518, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://sonomapharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R2": { "role": "http://sonomapharma.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R3": { "role": "http://sonomapharma.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "unique": true } }, "R4": { "role": "http://sonomapharma.com/role/StatementsOfComprehensiveLoss", "longName": "00000004 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R5": { "role": "http://sonomapharma.com/role/StatementsOfCashFlows", "longName": "00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "unique": true } }, "R6": { "role": "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity", "longName": "00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2023-03-31_us-gaap_AdditionalPaidInCapitalMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-04-012023-06-30_us-gaap_AdditionalPaidInCapitalMember", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalOther", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R9": { "role": "http://sonomapharma.com/role/OrganizationAndRecentDevelopments", "longName": "995512 - Disclosure - Organization and Recent Developments", "shortName": "Organization and Recent Developments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R10": { "role": "http://sonomapharma.com/role/LiquidityAndFinancialCondition", "longName": "995513 - Disclosure - Liquidity and Financial Condition", "shortName": "Liquidity and Financial Condition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R11": { "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies", "longName": "995514 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R12": { "role": "http://sonomapharma.com/role/BalanceSheet", "longName": "995515 - Disclosure - Condensed Consolidated Balance Sheet", "shortName": "Condensed Consolidated Balance Sheet", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R13": { "role": "http://sonomapharma.com/role/CommitmentsAndContingencies", "longName": "995516 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R14": { "role": "http://sonomapharma.com/role/Debt", "longName": "995517 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R15": { "role": "http://sonomapharma.com/role/StockholdersEquity", "longName": "995518 - Disclosure - Stockholders\u2019 Equity", "shortName": "Stockholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R16": { "role": "http://sonomapharma.com/role/Stock-basedCompensation", "longName": "995519 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R17": { "role": "http://sonomapharma.com/role/IncomeTaxes", "longName": "995520 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R18": { "role": "http://sonomapharma.com/role/RevenueDisaggregation", "longName": "995521 - Disclosure - Revenue Disaggregation", "shortName": "Revenue Disaggregation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R19": { "role": "http://sonomapharma.com/role/SignificantCustomerConcentrations", "longName": "995522 - Disclosure - Significant Customer Concentrations", "shortName": "Significant Customer Concentrations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R20": { "role": "http://sonomapharma.com/role/SubsequentEvents", "longName": "995523 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R21": { "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "995524 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R22": { "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables", "longName": "995525 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R23": { "role": "http://sonomapharma.com/role/BalanceSheetTables", "longName": "995526 - Disclosure - Condensed Consolidated Balance Sheet (Tables)", "shortName": "Condensed Consolidated Balance Sheet (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R24": { "role": "http://sonomapharma.com/role/Stock-basedCompensationTables", "longName": "995527 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R25": { "role": "http://sonomapharma.com/role/RevenueDisaggregationTables", "longName": "995528 - Disclosure - Revenue Disaggregation (Tables)", "shortName": "Revenue Disaggregation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R26": { "role": "http://sonomapharma.com/role/SignificantCustomerConcentrationsTables", "longName": "995529 - Disclosure - Significant Customer Concentrations (Tables)", "shortName": "Significant Customer Concentrations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R27": { "role": "http://sonomapharma.com/role/OrganizationAndRecentDevelopmentsDetailsNarrative", "longName": "995530 - Disclosure - Organization and Recent Developments (Details Narrative)", "shortName": "Organization and Recent Developments (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R28": { "role": "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative", "longName": "995531 - Disclosure - Liquidity and Financial Condition (Details Narrative)", "shortName": "Liquidity and Financial Condition (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "SNOA:WorkingCapital", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "unique": true } }, "R29": { "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare", "longName": "995532 - Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)", "shortName": "Summary of Significant Accounting Policies (Details - Earnings per share)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true }, "uniqueAnchor": null }, "R30": { "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-Anti-dilutiveShares", "longName": "995533 - Disclosure - Summary of Significant Accounting Policies (Details - Anti-dilutive shares)", "shortName": "Summary of Significant Accounting Policies (Details - Anti-dilutive shares)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R31": { "role": "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "995534 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "SNOA:AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "SNOA:AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:ReceivablesPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R32": { "role": "http://sonomapharma.com/role/BalanceSheetDetails-Inventories", "longName": "995535 - Disclosure - Condensed Consolidated Balance Sheet (Details - Inventories)", "shortName": "Condensed Consolidated Balance Sheet (Details - Inventories)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R33": { "role": "http://sonomapharma.com/role/BalanceSheetDetails-BalanceSheetInformationRelatedToLeases", "longName": "995536 - Disclosure - Condensed Consolidated Balance Sheet (Details - Balance sheet information related to leases)", "shortName": "Condensed Consolidated Balance Sheet (Details - Balance sheet information related to leases)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:OperatingLeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "unique": true } }, "R34": { "role": "http://sonomapharma.com/role/BalanceSheetDetails-MinimumLeasePaymentsOfOpeartingLeaseLiabilities", "longName": "995537 - Disclosure - Condensed Consolidated Balance Sheet (Details - Minimum lease payments of opearting lease liabilities)", "shortName": "Condensed Consolidated Balance Sheet (Details - Minimum lease payments of opearting lease liabilities)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:OtherAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R35": { "role": "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "995538 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:OfficersCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-04-01to2024-09-30", "name": "us-gaap:OfficersCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R36": { "role": "http://sonomapharma.com/role/DebtDetailsNarrative", "longName": "995539 - Disclosure - Debt (Details Narrative)", "shortName": "Debt (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2024-02-06_custom_InsurancePremiumFinancingMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-06_custom_InsurancePremiumFinancingMember", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R37": { "role": "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative", "longName": "995540 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-05-132024-09-18_custom_EquityDistributionAgreementMember", "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "unique": true } }, "R38": { "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity", "longName": "995541 - Disclosure - Stock-Based Compensation (Details - Stock option award activity)", "shortName": "Stock-Based Compensation (Details - Stock option award activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2024-03-31_us-gaap_StockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31_us-gaap_StockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R39": { "role": "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity", "longName": "995542 - Disclosure - Stock-Based Compensation (Details-Restricted stock activity)", "shortName": "Stock-Based Compensation (Details-Restricted stock activity)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2024-03-31_us-gaap_RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31_us-gaap_RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R40": { "role": "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative", "longName": "995543 - Disclosure - Stock-Based Compensation (Details Narrative)", "shortName": "Stock-Based Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-04-012024-09-30_us-gaap_StockOptionMember1183002656", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "unique": true } }, "R41": { "role": "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative", "longName": "995544 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } }, "R42": { "role": "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenueBySource", "longName": "995545 - Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue by source)", "shortName": "Revenue Disaggregation (Details - Disaggregation of revenue by source)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30_custom_HumanCareMember_us-gaap_ProductMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "unique": true } }, "R43": { "role": "http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions", "longName": "995546 - Disclosure - Revenue Disaggregation (Details - Revenue by geographic regions)", "shortName": "Revenue Disaggregation (Details - Revenue by geographic regions)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30_us-gaap_SalesRevenueSegmentMember_country_US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "unique": true } }, "R44": { "role": "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails", "longName": "995547 - Disclosure - Significant Customer Concentrations (Details)", "shortName": "Significant Customer Concentrations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerAMember_us-gaap_CustomerConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerAMember_us-gaap_CustomerConcentrationRiskMember", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "sonoma_i10q-093024.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndOtherAccruedLiabilities", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued expenses and other current liabilities", "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other." } } }, "auth_ref": [ "r489" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r42", "r594" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r552" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r737" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r14", "r15", "r63", "r126", "r429", "r461", "r462" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r7", "r15", "r357", "r360", "r385", "r457", "r458", "r718", "r719", "r720", "r726", "r727", "r728", "r729" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r669" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r55" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r473", "r726", "r727", "r728", "r729", "r751", "r790" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r675" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r675" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r675" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r675" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Cost in connection with ATM", "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Employee stock-based compensation expenses", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r34", "r35", "r293" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r640", "r651", "r661", "r686" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r643", "r654", "r664", "r689" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r675" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r682" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "auth_ref": [ "r644", "r655", "r665", "r682", "r690", "r694", "r702" ] }, "SNOA_AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns": { "xbrltype": "monetaryItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns", "crdr": "debit", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Allowances related to potential discounts, returns, distributor fees and rebates" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "SNOA_AnimalCareMember": { "xbrltype": "domainItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "AnimalCareMember", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenueBySource" ], "lang": { "en-us": { "role": { "label": "Animal Care [Member]" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r647" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-Anti-dilutiveShares" ], "lang": { "en-us": { "role": { "label": "Anti-dilutive shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r172" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-Anti-dilutiveShares" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r17" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-Anti-dilutiveShares" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-Anti-dilutiveShares" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r351" ] }, "srt_AsiaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "AsiaMember", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions" ], "lang": { "en-us": { "role": { "label": "Asia [Member]" } } }, "auth_ref": [ "r792", "r793", "r794", "r795" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r95", "r104", "r122", "r148", "r175", "r180", "r197", "r200", "r212", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r352", "r354", "r366", "r425", "r510", "r577", "r578", "r594", "r621", "r747", "r748", "r756" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r117", "r129", "r148", "r212", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r352", "r354", "r366", "r594", "r747", "r748", "r756" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r647" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Exercise Price" } } }, "auth_ref": [ "r697" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r698" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "auth_ref": [ "r693" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r693" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method" } } }, "auth_ref": [ "r693" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r693" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r693" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined" } } }, "auth_ref": [ "r693" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity", "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity", "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Securities" } } }, "auth_ref": [ "r696" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r695" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r694" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r694" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r16", "r120", "r567" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r16", "r73", "r144" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r73" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r673" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://sonomapharma.com/role/BalanceSheetsParenthetical", "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r113", "r123", "r124", "r125", "r148", "r166", "r167", "r169", "r171", "r177", "r178", "r212", "r241", "r243", "r244", "r245", "r248", "r249", "r264", "r265", "r268", "r271", "r278", "r366", "r467", "r468", "r469", "r470", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r498", "r519", "r536", "r545", "r546", "r547", "r548", "r549", "r710", "r724", "r730" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r123", "r124", "r125", "r177", "r264", "r265", "r266", "r268", "r271", "r276", "r278", "r467", "r468", "r469", "r470", "r582", "r710", "r724" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r674" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r674" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Note 5)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r51", "r97", "r426", "r497" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://sonomapharma.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r82", "r237", "r238", "r553", "r740", "r744" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r612", "r613", "r614", "r616", "r617", "r618", "r619", "r726", "r727", "r729", "r751", "r789", "r790" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://sonomapharma.com/role/BalanceSheetsParenthetical", "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r54" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://sonomapharma.com/role/BalanceSheetsParenthetical", "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r54", "r498" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://sonomapharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r54" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://sonomapharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r54", "r498", "r516", "r790", "r791" ] }, "SNOA_CommonStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "CommonStockUnitsMember", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-Anti-dilutiveShares" ], "lang": { "en-us": { "role": { "label": "Common Stock Units [Member]" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.0001 par value; 50,000,000 and 24,000,000 shares authorized at September 30, 2024 and March 31, 2024, respectively, 1,338,615 and 780,371 shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively (Note 1) (Note 7)", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r54", "r428", "r594" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r679" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r678" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r680" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r677" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r36", "r93", "r131", "r133", "r138", "r421", "r436" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions", "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r20", "r21", "r37", "r38", "r206", "r552" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions", "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r20", "r21", "r37", "r38", "r206", "r463", "r552" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r20", "r21", "r37", "r38", "r206", "r552", "r712" ] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrations" ], "lang": { "en-us": { "role": { "label": "Significant Customer Concentrations", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": [ "r77" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r552" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Concentration risk, percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r20", "r21", "r37", "r38", "r206" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r19", "r20", "r21", "r22", "r37", "r94", "r552" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r20", "r21", "r37", "r38", "r206", "r552" ] }, "us-gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockMember", "presentation": [ "http://sonomapharma.com/role/BalanceSheetsParenthetical", "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": [ "r264", "r265", "r268", "r616", "r617", "r618", "r619" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Cost of revenues", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r66", "r67", "r390" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "SNOA_CustomerAMember": { "xbrltype": "domainItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "CustomerAMember", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Customer A [Member]" } } }, "auth_ref": [] }, "SNOA_CustomerBMember": { "xbrltype": "domainItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "CustomerBMember", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Customer B [Member]" } } }, "auth_ref": [] }, "SNOA_CustomerCMember": { "xbrltype": "domainItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "CustomerCMember", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Customer C [Member]" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r78", "r206" ] }, "SNOA_CustomerDMember": { "xbrltype": "domainItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "CustomerDMember", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Customer D [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://sonomapharma.com/role/Debt" ], "lang": { "en-us": { "role": { "label": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r83", "r146", "r230", "r231", "r232", "r233", "r234", "r239", "r240", "r250", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r261", "r262", "r374" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r251", "r374", "r375", "r580", "r581", "r592" ] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://sonomapharma.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt interest rate", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r46", "r259", "r753" ] }, "us-gaap_DebtInstrumentMaturityDateRangeEnd1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDateRangeEnd1", "presentation": [ "http://sonomapharma.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Final payment date", "documentation": "Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r47" ] }, "us-gaap_DebtInstrumentMaturityDateRangeStart1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDateRangeStart1", "presentation": [ "http://sonomapharma.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "First installment beginning date", "documentation": "Earliest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r47" ] }, "us-gaap_DebtInstrumentPaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPaymentTerms", "presentation": [ "http://sonomapharma.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt payment terms", "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment." } } }, "auth_ref": [ "r39", "r48" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://sonomapharma.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Periodic payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r12", "r39" ] }, "SNOA_DeferredConsiderationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "DeferredConsiderationCurrent", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current portion of deferred consideration, net of discount" } } }, "auth_ref": [] }, "SNOA_DeferredConsiderationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "DeferredConsiderationNoncurrent", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred consideration, net of discount, less current portion" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred tax asset", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r328", "r329" ] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred revenue, current portion", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r714" ] }, "us-gaap_DeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueNoncurrent", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred revenue, net of current portion", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r715" ] }, "SNOA_DenominatorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "DenominatorAbstract", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Denominator:" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r5", "r175", "r185", "r200", "r577", "r578" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenueBySource", "http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r289", "r583", "r584", "r585", "r586", "r587", "r588", "r589" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenueBySource", "http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r289", "r583", "r584", "r585", "r586", "r587", "r588", "r589" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of disaggregated revenue by source", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r749" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensation" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r291", "r295", "r322", "r323", "r325", "r590" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r635" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r633", "r635", "r647" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r634" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r622" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r635" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r635" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r668" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r625" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss", "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Net loss per share: basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r139", "r155", "r156", "r157", "r158", "r159", "r160", "r164", "r166", "r169", "r170", "r171", "r174", "r347", "r350", "r364", "r365", "r422", "r437", "r573" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss", "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Net loss per share: diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r139", "r155", "r156", "r157", "r158", "r159", "r160", "r166", "r169", "r170", "r171", "r174", "r347", "r350", "r364", "r365", "r422", "r437", "r573" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Net Loss per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r17", "r18", "r173" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r367" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://sonomapharma.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Effective tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r331", "r591" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized compensation costs", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r324" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average amortization period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r324" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r628" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r624" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r624" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r709" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r624" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r706" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r647" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r624" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r624" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r624" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r624" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r707" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r8", "r114", "r134", "r135", "r136", "r150", "r151", "r152", "r154", "r159", "r161", "r163", "r176", "r213", "r214", "r228", "r279", "r337", "r338", "r344", "r345", "r346", "r348", "r349", "r350", "r356", "r357", "r358", "r359", "r360", "r361", "r363", "r368", "r369", "r370", "r371", "r372", "r373", "r376", "r377", "r385", "r435", "r457", "r458", "r459", "r473", "r536" ] }, "SNOA_EquityDistributionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "EquityDistributionAgreementMember", "presentation": [ "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Distribution Agreement [Member]" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r676" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r640", "r651", "r661", "r686" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r637", "r648", "r658", "r683" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions" ], "lang": { "en-us": { "role": { "label": "Europe [Member]" } } }, "auth_ref": [ "r792", "r793", "r794", "r795" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r682" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r644", "r655", "r665", "r690" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r644", "r655", "r665", "r690" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r644", "r655", "r665", "r690" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r644", "r655", "r665", "r690" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r644", "r655", "r665", "r690" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r64", "r68", "r103", "r148", "r212", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r366", "r575", "r577", "r732", "r733", "r734", "r735", "r736", "r747" ] }, "SNOA_HumanCareMember": { "xbrltype": "domainItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "HumanCareMember", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenueBySource" ], "lang": { "en-us": { "role": { "label": "Human Care [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r65", "r99", "r103", "r423", "r433", "r575", "r577", "r732", "r733", "r734", "r735", "r736" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://sonomapharma.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r149", "r327", "r331", "r332", "r333", "r334", "r335", "r336", "r339", "r341", "r342", "r343", "r472", "r591" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r105", "r111", "r162", "r163", "r175", "r188", "r200", "r330", "r331", "r340", "r438", "r591" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r388", "r722" ] }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredCompensation", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred consideration", "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Deferred income taxes", "label": "Increase (Decrease) in Deferred Income Taxes", "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories, net", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r713", "r722" ] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherAccountsPayable", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Other Accounts Payable", "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Operating lease, right-of-use assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r4" ] }, "SNOA_IncreaseDecreaseInWithholdingTaxPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "IncreaseDecreaseInWithholdingTaxPayable", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Withholding tax payable", "label": "IncreaseDecreaseInWithholdingTaxPayable" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]" } } }, "auth_ref": [ "r644", "r655", "r665", "r682", "r690", "r694", "r702" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r700" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r636", "r705" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r636", "r705" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r636", "r705" ] }, "SNOA_InsurancePremiumFinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "InsurancePremiumFinancingMember", "presentation": [ "http://sonomapharma.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Insurance Premium Financing [Member]" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r140", "r142", "r143" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheetDetails-Inventories": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-Inventories" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r81", "r569" ] }, "us-gaap_InventoryGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryGross", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheetDetails-Inventories": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-Inventories" ], "lang": { "en-us": { "role": { "totalLabel": "Inventories, gross", "label": "Inventory, Gross", "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r716" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://sonomapharma.com/role/BalanceSheetDetails-Inventories": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-Inventories", "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventories, net", "totalLabel": "Total inventories, net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r128", "r568", "r594" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r106", "r119", "r127", "r215", "r216", "r217", "r389", "r571" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheetDetails-Inventories": { "parentTag": "us-gaap_InventoryGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-Inventories" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r81", "r570" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryValuationReserves", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheetDetails-Inventories": { "parentTag": "us-gaap_InventoryNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-Inventories", "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net realizable value", "negatedLabel": "Less: allowance for obsolete and excess inventory", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r81", "r716" ] }, "srt_LatinAmericaMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LatinAmericaMember", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions" ], "lang": { "en-us": { "role": { "label": "Latin America [Member]" } } }, "auth_ref": [ "r792", "r793", "r794", "r795" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://sonomapharma.com/role/BalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of lease information", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r754" ] }, "us-gaap_LeasesOperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesOperatingAbstract", "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-BalanceSheetInformationRelatedToLeases" ], "lang": { "en-us": { "role": { "label": "Operating leases:" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://sonomapharma.com/role/BalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of minimum lease payments of operating lease liabilities", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r755" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheetDetails-MinimumLeasePaymentsOfOpeartingLeaseLiabilities": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-MinimumLeasePaymentsOfOpeartingLeaseLiabilities" ], "lang": { "en-us": { "role": { "totalLabel": "Total future minimum lease payments, undiscounted", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r383" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheetDetails-MinimumLeasePaymentsOfOpeartingLeaseLiabilities": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-MinimumLeasePaymentsOfOpeartingLeaseLiabilities" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r383" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheetDetails-MinimumLeasePaymentsOfOpeartingLeaseLiabilities": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-MinimumLeasePaymentsOfOpeartingLeaseLiabilities" ], "lang": { "en-us": { "role": { "label": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r383" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheetDetails-MinimumLeasePaymentsOfOpeartingLeaseLiabilities": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-MinimumLeasePaymentsOfOpeartingLeaseLiabilities" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r383" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheetDetails-MinimumLeasePaymentsOfOpeartingLeaseLiabilities": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-MinimumLeasePaymentsOfOpeartingLeaseLiabilities" ], "lang": { "en-us": { "role": { "label": "2025 (excluding the six months ended September 30, 2024)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r755" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-MinimumLeasePaymentsOfOpeartingLeaseLiabilities" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r383" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r12", "r43", "r44", "r45", "r49", "r50", "r51", "r52", "r148", "r212", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r353", "r354", "r355", "r366", "r496", "r574", "r621", "r747", "r756", "r757" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r59", "r98", "r431", "r594", "r725", "r739", "r752" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r45", "r118", "r148", "r212", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r353", "r354", "r355", "r366", "r594", "r747", "r756", "r757" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "SNOA_LiquidityCashBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "LiquidityCashBalance", "crdr": "debit", "presentation": [ "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Liquidity cash balance" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r206", "r585", "r604", "r609", "r749", "r760", "r761", "r762", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } }, "auth_ref": [ "r674" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Name" } } }, "auth_ref": [ "r674" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r693" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r701" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "auth_ref": [ "r206", "r585", "r604", "r609", "r749", "r760", "r761", "r762", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r675" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r141" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r141" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative", "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "negatedLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r73", "r74", "r75" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative", "http://sonomapharma.com/role/StatementsOfCashFlows", "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity", "http://sonomapharma.com/role/StatementsOfComprehensiveLoss", "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net Income (Loss)", "negatedLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r69", "r75", "r100", "r116", "r130", "r132", "r136", "r148", "r153", "r155", "r156", "r157", "r158", "r159", "r162", "r163", "r168", "r212", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r347", "r350", "r365", "r366", "r434", "r518", "r534", "r535", "r620", "r747" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r674" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r672" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r671" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r701" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r701" ] }, "SNOA_NumeratorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "NumeratorAbstract", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Numerator:" } } }, "auth_ref": [] }, "us-gaap_OfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OfficersCompensation", "crdr": "debit", "presentation": [ "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregated annual salaries", "documentation": "Amount of expense for salary and wage arising from service rendered by officer. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r721" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r103", "r575", "r732", "r733", "r734", "r735", "r736" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-BalanceSheetInformationRelatedToLeases" ], "lang": { "en-us": { "role": { "label": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r380", "r593" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-MinimumLeasePaymentsOfOpeartingLeaseLiabilities" ], "lang": { "en-us": { "role": { "label": "Present value of future minimum lease payments", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r379" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-BalanceSheetInformationRelatedToLeases", "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities, current portion", "verboseLabel": "Operating lease liabilities \u2013 current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r379" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-BalanceSheetInformationRelatedToLeases", "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities, less current portion", "verboseLabel": "Operating lease liabilities \u2013 non-current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r379" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-BalanceSheetInformationRelatedToLeases", "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease, right of use assets", "verboseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r378" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-BalanceSheetInformationRelatedToLeases" ], "lang": { "en-us": { "role": { "negatedLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r723" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-BalanceSheetInformationRelatedToLeases" ], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate - operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r382", "r593" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://sonomapharma.com/role/BalanceSheetDetails-BalanceSheetInformationRelatedToLeases" ], "lang": { "en-us": { "role": { "label": "Weighted-average remaining lease term - operating leases (in months)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r381", "r593" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://sonomapharma.com/role/OrganizationAndRecentDevelopments" ], "lang": { "en-us": { "role": { "label": "Organization and Recent Developments", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r40", "r92", "r464", "r465" ] }, "us-gaap_OtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsDisclosureTextBlock", "presentation": [ "http://sonomapharma.com/role/BalanceSheet" ], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheet", "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r121" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustments", "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, on foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r3", "r7", "r93" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r3", "r7", "r93" ] }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTaxAbstract", "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive loss" } } }, "auth_ref": [] }, "us-gaap_OtherLongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLongTermDebtCurrent", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Outstanding principal amount", "documentation": "Amount of long-term debt classified as other, payable within one year or the operating cycle, if longer." } } }, "auth_ref": [ "r43", "r44", "r495" ] }, "us-gaap_OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other income (expense), net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r674" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r635" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r642", "r653", "r663", "r688" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Amount" } } }, "auth_ref": [ "r645", "r656", "r666", "r691" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r645", "r656", "r666", "r691" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": [ "r670" ] }, "SNOA_PaymentsForFractionalSharesRelatedToReversesplit": { "xbrltype": "monetaryItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "PaymentsForFractionalSharesRelatedToReversesplit", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments for fractional shares related to reverse-split", "label": "PaymentsForFractionalSharesRelatedToReversesplit" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r71" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r673" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r673" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r672" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name" } } }, "auth_ref": [ "r675" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r671" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r672" ] }, "SNOA_PotentialSeverancePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "PotentialSeverancePayments", "crdr": "debit", "presentation": [ "http://sonomapharma.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Potential severance payments" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r629" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r631" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://sonomapharma.com/role/BalanceSheetsParenthetical", "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r53", "r264" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://sonomapharma.com/role/BalanceSheetsParenthetical", "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r53", "r498" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://sonomapharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Convertible preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r53", "r264" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://sonomapharma.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Convertible preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r53", "r498", "r516", "r790", "r791" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at September 30, 2024 and March 31, 2024, respectively, no shares issued and outstanding at September 30, 2024 and March 31, 2024, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r53", "r427", "r594" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r717" ] }, "SNOA_ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpenses", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Proceeds from At-the-Market sale of common stock, net of offering expenses" } } }, "auth_ref": [] }, "SNOA_ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares": { "xbrltype": "sharesItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "ProceedsFromAtthemarketSaleOfCommonStockNetOfOfferingExpensesShares", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Proceeds from At-the-Market sale of common stock, net of offering expenses, shares" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows", "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds (costs) from issuance of common stock, net of offering expenses", "verboseLabel": "Proceeds from sale of stock, net", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "SNOA_ProceedsFromIssuanceOfCommonStockGross": { "xbrltype": "monetaryItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockGross", "crdr": "debit", "presentation": [ "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of stock, gross" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of employee stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r11" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductMember", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenueBySource" ], "lang": { "en-us": { "role": { "label": "Product [Member]", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r583" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenueBySource" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r203", "r390", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r565", "r583", "r603", "r605", "r606", "r610", "r611", "r745", "r746", "r749", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenueBySource" ], "auth_ref": [ "r203", "r390", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r565", "r583", "r603", "r605", "r606", "r610", "r611", "r745", "r746", "r749", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r384", "r424", "r432", "r594" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r670" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r670" ] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r208", "r209", "r210", "r211", "r738" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": [ "r637", "r648", "r658", "r683" ] }, "us-gaap_RepaymentsOfOtherShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfOtherShortTermDebt", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Principal payments on short-term debt", "label": "Repayments of Other Short-Term Debt", "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing within one year or the operating cycle, if longer." } } }, "auth_ref": [ "r72" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r326", "r563", "r577", "r758" ] }, "SNOA_RestOfTheWorldMember": { "xbrltype": "domainItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "RestOfTheWorldMember", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions" ], "lang": { "en-us": { "role": { "label": "Rest Of The World [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r638", "r649", "r659", "r684" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": [ "r639", "r650", "r660", "r685" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": [ "r646", "r657", "r667", "r692" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r17" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets", "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r56", "r88", "r430", "r460", "r462", "r471", "r499", "r594" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r114", "r150", "r151", "r152", "r154", "r159", "r161", "r163", "r213", "r214", "r228", "r337", "r338", "r344", "r345", "r346", "r348", "r349", "r350", "r356", "r358", "r359", "r361", "r363", "r376", "r377", "r457", "r459", "r473", "r790" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenueBySource", "http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r101", "r102", "r175", "r181", "r182", "r195", "r200", "r203", "r204", "r206", "r288", "r289", "r390" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregation" ], "lang": { "en-us": { "role": { "label": "Revenue Disaggregation", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r112", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r290" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r520", "r564", "r572" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r101", "r102", "r137", "r148", "r175", "r181", "r182", "r195", "r200", "r203", "r204", "r206", "r212", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r366", "r423", "r577", "r747" ] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r701" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r701" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueNetMember", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r206", "r711" ] }, "us-gaap_SalesRevenueSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalesRevenueSegmentMember", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions" ], "lang": { "en-us": { "role": { "label": "Revenue, Segment Benchmark [Member]", "documentation": "Revenue from specified business segment, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [ "r711" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-Anti-dilutiveShares" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of anti-dilutive shares", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of computation of basic and diluted net loss per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r731" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://sonomapharma.com/role/BalanceSheetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of inventories, net", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r13", "r60", "r61", "r62" ] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of unvested restricted stock activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r91" ] }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of revenues by geographic region", "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": [ "r64", "r79" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity", "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity", "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r292", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of stock options award activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r9", "r10", "r90" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://sonomapharma.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r26", "r27", "r28", "r29", "r30", "r31", "r84", "r86", "r87", "r88", "r123", "r124", "r125", "r177", "r264", "r265", "r266", "r268", "r271", "r276", "r278", "r467", "r468", "r469", "r470", "r582", "r710", "r724" ] }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "presentation": [ "http://sonomapharma.com/role/SignificantCustomerConcentrationsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of customer concentrations of risk", "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r19", "r20", "r21", "r22", "r37", "r94" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r623" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r627" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r626" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r632" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenueBySource" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r101", "r102", "r103", "r104", "r175", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r206", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r235", "r236", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r576", "r577", "r578", "r579", "r608", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions" ], "auth_ref": [ "r204", "r205", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r485", "r486", "r487", "r541", "r542", "r543", "r544", "r551", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r566", "r584", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r607", "r614", "r749", "r760", "r761", "r762", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r70" ] }, "SNOA_ServiceAndRoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "ServiceAndRoyaltyMember", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenueBySource" ], "lang": { "en-us": { "role": { "label": "Service And Royalty [Member]" } } }, "auth_ref": [] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenueBySource" ], "lang": { "en-us": { "role": { "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r583" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://sonomapharma.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows", "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" ], "lang": { "en-us": { "role": { "label": "Weighted Average Award Date Fair Value per Share, Restricted stock awards granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r310" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Shares, Unvested restricted stock awards outstanding, beginning balance", "periodEndLabel": "Number of Shares, Unvested restricted stock awards outstanding, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r307", "r308" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted Average Award Date Fair Value per Share, Unvested restricted stock awards outstanding, beginning balance", "periodEndLabel": "Weighted Average Award Date Fair Value per Share, Unvested restricted stock awards outstanding, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r307", "r308" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares, Restricted stock awards vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r311" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" ], "lang": { "en-us": { "role": { "label": "Weighted Average Award Date Fair Value per Share, Restricted stock awards vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r311" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity", "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity", "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r292", "r294", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity" ], "lang": { "en-us": { "role": { "label": "Number of Shares, Exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r301" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity" ], "lang": { "en-us": { "role": { "label": "Weighted-average exercise price, exercisable", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r301" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares, Options expired", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r306" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares, Options forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r750" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity" ], "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, Options forfeited", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r750" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate intrinsic value per share", "documentation": "The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Shares, Outstanding, Beginning Balance", "periodEndLabel": "Number of Shares, Outstanding, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r299", "r300" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted-Average Exercise Price Outstanding, Beginning Balance", "periodEndLabel": "Weighted-Average Exercise Price Outstanding, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r299", "r300" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Employee stock-based compensation expenses, shares", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity", "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity", "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity" ], "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, Options exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r304" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity" ], "lang": { "en-us": { "role": { "label": "Weighted-Average Exercise Price, Options expired", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r306" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-term debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r42", "r96", "r594", "r759" ] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": [ "http://sonomapharma.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://sonomapharma.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r43", "r741", "r742", "r743" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://sonomapharma.com/role/DebtDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r42", "r741", "r742", "r743" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r76", "r145" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r630" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-DisaggregationOfRevenueBySource" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r101", "r102", "r103", "r104", "r115", "r175", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r206", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r229", "r235", "r236", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r576", "r577", "r578", "r579", "r608", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://sonomapharma.com/role/BalanceSheetsParenthetical", "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r113", "r123", "r124", "r125", "r148", "r166", "r167", "r169", "r171", "r177", "r178", "r212", "r241", "r243", "r244", "r245", "r248", "r249", "r264", "r265", "r268", "r271", "r278", "r366", "r467", "r468", "r469", "r470", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r498", "r519", "r536", "r545", "r546", "r547", "r548", "r549", "r710", "r724", "r730" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r54", "r57", "r58", "r114", "r134", "r135", "r136", "r150", "r151", "r152", "r154", "r159", "r161", "r163", "r176", "r213", "r214", "r228", "r279", "r337", "r338", "r344", "r345", "r346", "r348", "r349", "r350", "r356", "r357", "r358", "r359", "r360", "r361", "r363", "r368", "r369", "r370", "r371", "r372", "r373", "r376", "r377", "r385", "r435", "r457", "r458", "r459", "r473", "r536" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r204", "r205", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r485", "r486", "r487", "r541", "r542", "r543", "r544", "r551", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r566", "r584", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r607", "r614", "r749", "r760", "r761", "r762", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://sonomapharma.com/role/BalanceSheetsParenthetical", "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r150", "r151", "r152", "r176", "r377", "r390", "r466", "r484", "r488", "r490", "r491", "r492", "r493", "r494", "r498", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r511", "r512", "r513", "r514", "r515", "r517", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r536", "r615" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://sonomapharma.com/role/BalanceSheetsParenthetical", "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r150", "r151", "r152", "r176", "r207", "r377", "r390", "r466", "r484", "r488", "r490", "r491", "r492", "r493", "r494", "r498", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r511", "r512", "r513", "r514", "r515", "r517", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r536", "r615" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r641", "r652", "r662", "r687" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock issued new, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r53", "r54", "r88", "r467", "r536", "r546" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-restrictedStockActivity" ], "lang": { "en-us": { "role": { "label": "Number of Shares, Restricted stock awards granted", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r8", "r88" ] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Payments for fractional shares related to reverse-split, shares", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity", "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of employee stock options, shares", "negatedLabel": "Number of Shares, Options exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r8", "r53", "r54", "r88", "r304" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from exercise of employee stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r8", "r54", "r57", "r58", "r88" ] }, "SNOA_StockIssuedDuringPeriodValuesReverseStockSplits": { "xbrltype": "monetaryItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "StockIssuedDuringPeriodValuesReverseStockSplits", "crdr": "credit", "presentation": [ "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Payments for fractional shares related to reverse-split" } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": [ "http://sonomapharma.com/role/Stock-basedCompensationDetails-StockOptionAwardActivity", "http://sonomapharma.com/role/Stock-basedCompensationDetailsNarrative", "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-Anti-dilutiveShares" ], "lang": { "en-us": { "role": { "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r614" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets", "http://sonomapharma.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r54", "r57", "r58", "r80", "r500", "r516", "r537", "r538", "r594", "r621", "r725", "r739", "r752", "r790" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://sonomapharma.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r85", "r147", "r263", "r265", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r277", "r279", "r362", "r539", "r540", "r550" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://sonomapharma.com/role/OrganizationAndRecentDevelopmentsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reverse stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r89" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://sonomapharma.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r386", "r387" ] }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": [ "http://sonomapharma.com/role/LiquidityAndFinancialCondition" ], "lang": { "en-us": { "role": { "label": "Liquidity and Financial Condition", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": [ "r41" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://sonomapharma.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List, Table" } } }, "auth_ref": [ "r681" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r673" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r680" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Adoption Date" } } }, "auth_ref": [ "r703" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Arrangement Duration" } } }, "auth_ref": [ "r704" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Expiration Date" } } }, "auth_ref": [ "r704" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r702" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Title" } } }, "auth_ref": [ "r702" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Termination Date" } } }, "auth_ref": [ "r703" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://sonomapharma.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r351" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://sonomapharma.com/role/RevenueDisaggregationDetails-RevenueByGeographicRegions" ], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r699" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r23", "r24", "r25", "r107", "r108", "r109", "r110" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-Anti-dilutiveShares" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r612", "r613", "r616", "r617", "r618", "r619" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss", "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Weighted-average number of shares: diluted", "verboseLabel": "Weighted-average number of common shares outstanding: diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r165", "r171" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://sonomapharma.com/role/StatementsOfComprehensiveLoss", "http://sonomapharma.com/role/SummaryOfSignificantAccountingPoliciesDetails-EarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Weighted-average number of shares: basic", "verboseLabel": "Weighted-average number of common shares outstanding: basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r164", "r171" ] }, "SNOA_WithholdingTaxPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "WithholdingTaxPayable", "crdr": "credit", "calculation": { "http://sonomapharma.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://sonomapharma.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Withholding tax payable" } } }, "auth_ref": [] }, "SNOA_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://sonomapharma.com/20240930", "localname": "WorkingCapital", "crdr": "debit", "presentation": [ "http://sonomapharma.com/role/LiquidityAndFinancialConditionDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Working capital" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://sonomapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r708" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-40/tableOfContent" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(10)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r710": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 64 0001683168-24-007708-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-007708-xbrl.zip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end XML 65 sonoma_i10q-093024_htm.xml IDEA: XBRL DOCUMENT 0001367083 2024-04-01 2024-09-30 0001367083 2024-11-07 0001367083 2024-09-30 0001367083 2024-03-31 0001367083 us-gaap:ConvertiblePreferredStockMember 2024-09-30 0001367083 us-gaap:ConvertiblePreferredStockMember 2024-03-31 0001367083 2024-07-01 2024-09-30 0001367083 2023-07-01 2023-09-30 0001367083 2023-04-01 2023-09-30 0001367083 2023-03-31 0001367083 2023-09-30 0001367083 us-gaap:CommonStockMember 2024-03-31 0001367083 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001367083 us-gaap:RetainedEarningsMember 2024-03-31 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001367083 us-gaap:CommonStockMember 2024-06-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001367083 us-gaap:RetainedEarningsMember 2024-06-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001367083 2024-06-30 0001367083 us-gaap:CommonStockMember 2023-03-31 0001367083 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001367083 us-gaap:RetainedEarningsMember 2023-03-31 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001367083 us-gaap:CommonStockMember 2023-06-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001367083 us-gaap:RetainedEarningsMember 2023-06-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001367083 2023-06-30 0001367083 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001367083 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001367083 2024-04-01 2024-06-30 0001367083 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001367083 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001367083 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001367083 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001367083 2023-04-01 2023-06-30 0001367083 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001367083 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001367083 us-gaap:CommonStockMember 2024-09-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001367083 us-gaap:RetainedEarningsMember 2024-09-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001367083 us-gaap:CommonStockMember 2023-09-30 0001367083 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001367083 us-gaap:RetainedEarningsMember 2023-09-30 0001367083 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001367083 us-gaap:StockOptionMember 2024-07-01 2024-09-30 0001367083 us-gaap:StockOptionMember 2023-07-01 2023-09-30 0001367083 us-gaap:StockOptionMember 2024-04-01 2024-09-30 0001367083 us-gaap:StockOptionMember 2023-04-01 2023-09-30 0001367083 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001367083 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001367083 us-gaap:WarrantMember 2024-04-01 2024-09-30 0001367083 us-gaap:WarrantMember 2023-04-01 2023-09-30 0001367083 SNOA:CommonStockUnitsMember 2024-07-01 2024-09-30 0001367083 SNOA:CommonStockUnitsMember 2023-07-01 2023-09-30 0001367083 SNOA:CommonStockUnitsMember 2024-04-01 2024-09-30 0001367083 SNOA:CommonStockUnitsMember 2023-04-01 2023-09-30 0001367083 SNOA:InsurancePremiumFinancingMember 2024-02-06 0001367083 SNOA:InsurancePremiumFinancingMember 2024-02-05 2024-02-06 0001367083 SNOA:InsurancePremiumFinancingMember 2024-09-30 0001367083 SNOA:InsurancePremiumFinancingMember 2024-03-31 0001367083 SNOA:EquityDistributionAgreementMember 2024-05-13 2024-09-18 0001367083 us-gaap:StockOptionMember 2024-09-30 0001367083 us-gaap:StockOptionMember 2024-04-01 2024-09-30 0001367083 us-gaap:StockOptionMember 2024-03-31 0001367083 us-gaap:RestrictedStockMember 2024-03-31 0001367083 us-gaap:RestrictedStockMember 2024-04-01 2024-09-30 0001367083 us-gaap:RestrictedStockMember 2024-09-30 0001367083 us-gaap:ProductMember SNOA:HumanCareMember 2024-07-01 2024-09-30 0001367083 us-gaap:ProductMember SNOA:HumanCareMember 2023-07-01 2023-09-30 0001367083 us-gaap:ProductMember SNOA:HumanCareMember 2024-04-01 2024-09-30 0001367083 us-gaap:ProductMember SNOA:HumanCareMember 2023-04-01 2023-09-30 0001367083 us-gaap:ProductMember SNOA:AnimalCareMember 2024-07-01 2024-09-30 0001367083 us-gaap:ProductMember SNOA:AnimalCareMember 2023-07-01 2023-09-30 0001367083 us-gaap:ProductMember SNOA:AnimalCareMember 2024-04-01 2024-09-30 0001367083 us-gaap:ProductMember SNOA:AnimalCareMember 2023-04-01 2023-09-30 0001367083 us-gaap:ServiceMember SNOA:ServiceAndRoyaltyMember 2024-07-01 2024-09-30 0001367083 us-gaap:ServiceMember SNOA:ServiceAndRoyaltyMember 2023-07-01 2023-09-30 0001367083 us-gaap:ServiceMember SNOA:ServiceAndRoyaltyMember 2024-04-01 2024-09-30 0001367083 us-gaap:ServiceMember SNOA:ServiceAndRoyaltyMember 2023-04-01 2023-09-30 0001367083 country:US us-gaap:SalesRevenueSegmentMember 2024-07-01 2024-09-30 0001367083 country:US us-gaap:SalesRevenueSegmentMember 2023-07-01 2023-09-30 0001367083 country:US us-gaap:SalesRevenueSegmentMember 2024-04-01 2024-09-30 0001367083 country:US us-gaap:SalesRevenueSegmentMember 2023-04-01 2023-09-30 0001367083 srt:EuropeMember us-gaap:SalesRevenueSegmentMember 2024-07-01 2024-09-30 0001367083 srt:EuropeMember us-gaap:SalesRevenueSegmentMember 2023-07-01 2023-09-30 0001367083 srt:EuropeMember us-gaap:SalesRevenueSegmentMember 2024-04-01 2024-09-30 0001367083 srt:EuropeMember us-gaap:SalesRevenueSegmentMember 2023-04-01 2023-09-30 0001367083 srt:AsiaMember us-gaap:SalesRevenueSegmentMember 2024-07-01 2024-09-30 0001367083 srt:AsiaMember us-gaap:SalesRevenueSegmentMember 2023-07-01 2023-09-30 0001367083 srt:AsiaMember us-gaap:SalesRevenueSegmentMember 2024-04-01 2024-09-30 0001367083 srt:AsiaMember us-gaap:SalesRevenueSegmentMember 2023-04-01 2023-09-30 0001367083 srt:LatinAmericaMember us-gaap:SalesRevenueSegmentMember 2024-07-01 2024-09-30 0001367083 srt:LatinAmericaMember us-gaap:SalesRevenueSegmentMember 2023-07-01 2023-09-30 0001367083 srt:LatinAmericaMember us-gaap:SalesRevenueSegmentMember 2024-04-01 2024-09-30 0001367083 srt:LatinAmericaMember us-gaap:SalesRevenueSegmentMember 2023-04-01 2023-09-30 0001367083 SNOA:RestOfTheWorldMember us-gaap:SalesRevenueSegmentMember 2024-07-01 2024-09-30 0001367083 SNOA:RestOfTheWorldMember us-gaap:SalesRevenueSegmentMember 2023-07-01 2023-09-30 0001367083 SNOA:RestOfTheWorldMember us-gaap:SalesRevenueSegmentMember 2024-04-01 2024-09-30 0001367083 SNOA:RestOfTheWorldMember us-gaap:SalesRevenueSegmentMember 2023-04-01 2023-09-30 0001367083 SNOA:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001367083 SNOA:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001367083 SNOA:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-09-30 0001367083 SNOA:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-09-30 0001367083 SNOA:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001367083 SNOA:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001367083 SNOA:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-09-30 0001367083 SNOA:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-09-30 0001367083 SNOA:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001367083 SNOA:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001367083 SNOA:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-09-30 0001367083 SNOA:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-09-30 0001367083 SNOA:CustomerDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001367083 SNOA:CustomerDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001367083 SNOA:CustomerDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-09-30 0001367083 SNOA:CustomerDMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-09-30 0001367083 SNOA:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-09-30 0001367083 SNOA:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-09-30 0001367083 SNOA:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-09-30 0001367083 SNOA:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-09-30 0001367083 SNOA:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-04-01 2024-09-30 0001367083 SNOA:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-09-30 iso4217:USD shares iso4217:USD shares pure false --03-31 2025 Q2 0001367083 10-Q true 2024-09-30 false 001-33216 SONOMA PHARMACEUTICALS, INC. DE 68-0423298 5445 Conestoga Court Suite 150 Boulder CO 80301 800 759-9305 Common Stock, $0.0001 par value SNOA NASDAQ Yes Yes Non-accelerated Filer true false false 1339170 4078000 3128000 3157000 2898000 2837000 2719000 1929000 3541000 220000 262000 12221000 12548000 255000 365000 162000 286000 792000 1145000 179000 330000 76000 66000 13685000 14740000 770000 607000 2022000 2113000 319000 478000 82000 323000 116000 198000 3309000 3719000 45000 87000 4933000 4710000 46000 87000 8333000 8603000 0.0001 0.0001 714286 714286 0 0 0 0 0 0 0.0001 0.0001 50000000 24000000 1338615 1338615 780371 780371 0 0 205651000 203209000 -196102000 -194349000 -4197000 -2723000 5352000 6137000 13685000 14740000 3579000 2731000 6970000 6158000 2218000 1741000 4303000 3964000 1361000 990000 2667000 2194000 506000 536000 976000 861000 1705000 1662000 3714000 3781000 2211000 2198000 4690000 4642000 -850000 -1208000 -2023000 -2448000 387000 -90000 563000 -301000 -463000 -1298000 -1460000 -2749000 147000 186000 293000 153000 -610000 -1484000 -1753000 -2902000 -0.59 -0.59 -5.75 -5.75 -1.86 -1.86 -11.47 -11.47 1034000 1034000 258000 258000 943000 943000 253000 253000 -610000 -1484000 -1753000 -2902000 -593000 -213000 -1474000 298000 -1203000 -1697000 -3227000 -2604000 -1753000 -2902000 74000 90000 121000 307000 -188000 -144000 427000 -375000 370000 -403000 -1134000 -47000 99000 104000 -102000 -79000 219000 132000 62000 -353000 -128000 -31000 223000 238000 -102000 -79000 -558000 -1446000 31000 19000 -31000 -19000 2289000 -5000 33000 0 1000 -0 241000 259000 2080000 -264000 -541000 46000 950000 -1683000 3128000 3820000 4078000 2137000 8000 10000 780371 203209000 -194349000 -2723000 6137000 158311 748000 748000 2000 7000 7000 9538 107000 107000 -881000 -881000 -1143000 -1143000 950220 204071000 -195492000 -3604000 4975000 381433 1541000 1541000 7250 26000 26000 -288 -1000 -1000 14000 14000 -593000 -593000 -610000 -610000 1338615 205651000 -196102000 -4197000 5352000 246678 200909000 -189514000 -3418000 7977000 -5000 -5000 10402 177000 177000 511000 511000 -1418000 -1418000 257080 201081000 -190932000 -2907000 7242000 1887 130000 130000 -213000 -213000 -1484000 -1484000 258967 201211000 -192416000 -3120000 5675000 <p id="xdx_801_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zz7HOii8gpJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1.</b></span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_zO2hg6S8BGk1">Organization and Recent Developments</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Organization</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sonoma Pharmaceuticals, Inc. (the “Company”) was incorporated under the laws of the State of California in April 1999 and was reincorporated under the laws of the State of Delaware in December 2006. The Company moved its principal office from Petaluma, California to Woodstock, Georgia in June 2020 and to Boulder, Colorado in October 2022. The Company is a global healthcare leader for developing and producing stabilized hypochlorous acid (“HOCl”) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, animal health care, and as a non-toxic disinfectant. The Company’s products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. The Company sells its products either directly or via partners in 55 countries worldwide.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Reverse Stock Split</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective August 29, 2024, the Company effected a reverse stock split of its common stock, par value $0.0001 per share. Every twenty shares of common stock were reclassified and combined into one share of common stock. No fractional shares were issued as a result of the reverse stock split. Instead, each fractional share was settled with cash. <span id="xdx_905_eus-gaap--StockholdersEquityReverseStockSplit_c20240401__20240930_zJnNgqJ6Xayg" title="Reverse stock split">The reverse stock split reduced the number of shares of the Company’s common stock outstanding from 21,174,693 to 1,058,447. The total number of authorized shares of common stock was not proportionally decreased and the par value per share of the common stock continues to be $0.0001.</span> The reverse stock split has been retroactively applied to all share and per share amounts in the condensed consolidated financial statements and accompanying footnotes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis of Presentation</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial statements and are in the form prescribed by the Securities and Exchange Commission (the “SEC”) in instructions to Form 10-Q and Rule 10-01 of Regulation S-X. The accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair statement of the Company’s financial position, results of operations and cash flows for the periods indicated. All material intercompany accounts and transactions have been eliminated in consolidation. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended March 31, 2024, and notes thereto included in the Company’s annual report on Form 10-K, which was filed with the SEC on June 17, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> The reverse stock split reduced the number of shares of the Company’s common stock outstanding from 21,174,693 to 1,058,447. The total number of authorized shares of common stock was not proportionally decreased and the par value per share of the common stock continues to be $0.0001. <p id="xdx_805_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zQ1oXb0n3Vl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2.</b></span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_824_zGbRB3sf9iJi">Liquidity and Financial Condition</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reported a net loss of $<span id="xdx_90E_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20240701__20240930_z8pjUuyBSjMg" title="Net loss">610,000</span> and $<span id="xdx_906_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20230701__20230930_zETJdYk0rGij" title="Net loss">1,484,000</span> for the three months ended September 30, 2024 and 2023, respectively, and $<span id="xdx_90F_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20240401__20240930_zh1JLng3jY2g" title="Net loss">1,753,000</span> and $<span id="xdx_901_eus-gaap--NetIncomeLoss_iN_pn3d_di_c20230401__20230930_ztCy0vzqAGya" title="Net loss">2,902,000</span> for the six months ended September 30, 2024 and 2023, respectively. At September 30, 2024 and March 31, 2024, the Company’s accumulated deficit amounted to $<span id="xdx_90C_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3d_di_c20240930_zUFo2CNkvY0e" title="Accumulated deficit">196,102,000 </span>and $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3d_di_c20240331_zLHrForMsbs9" title="Accumulated deficit">194,349,000</span>, respectively. The Company had working capital of $<span id="xdx_900_ecustom--WorkingCapital_iI_pn3d_c20240930_zPJZ6ueNl6Ba" title="Working capital">8,912,000</span> and $<span id="xdx_90E_ecustom--WorkingCapital_iI_pn3d_c20240331_ziymUCa2Cjf8" title="Working capital">8,829,000</span> as of September 30, 2024 and March 31, 2024, respectively. The cash balance at September 30, 2024 and March 31, 2024 was $<span id="xdx_90C_ecustom--LiquidityCashBalance_iI_pn3d_c20240930_zzSiALJKjCwa" title="Liquidity cash balance">4,078,000</span> and $<span id="xdx_902_ecustom--LiquidityCashBalance_iI_pn3d_c20240331_zABOeHfNaVwe" title="Liquidity cash balance">3,128,000</span>, respectively. During the six months ended September 30, 2024 and 2023, net cash used in operating activities amounted to $<span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3d_di_c20240401__20240930_zYesHSg7Rgs3" title="Net cash used in operating activities">558,000 </span>and $<span id="xdx_905_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3d_di_c20230401__20230930_zmgbkczcb1J" title="Net cash used in operating activities">1,446,000</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management believes that the Company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means; however, the Company cannot provide any assurance that other new financings will be available on commercially acceptable terms, if needed. If the economic climate in the U.S. deteriorates, the Company’s ability to raise additional capital could be negatively impacted. If the Company is unable to secure additional capital, it may be required to take additional measures to reduce costs in order to conserve its cash in amounts sufficient to sustain operations and meet its obligations. These measures could cause significant delays in the Company’s continued efforts to commercialize its products, which is critical to the realization of its business plan and the future operations of the Company. This uncertainty along with the Company’s history of losses indicates that there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> -610000 -1484000 -1753000 -2902000 -196102000 -194349000 8912000 8829000 4078000 3128000 -558000 -1446000 <p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_z9JOoEvIx4tf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3.</b></span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82F_zg4rOJcRqGda">Summary of Significant Accounting Policies</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> <b><i> </i></b></p> <p id="xdx_84C_eus-gaap--UseOfEstimates_z1elHG8SIoji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zD48YVLKPbB1">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zZZA0jQLK883" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_868_ztqPmLabPoTi">Net Loss per Share</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides the net loss for each period along with the computation of basic and diluted net loss per share:</p> <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zL26z3HmK2Y8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zN6HMzueYCb3" style="display: none">Schedule of computation of basic and diluted net loss per share</span></td><td> </td> <td colspan="2" id="xdx_491_20240701__20240930_zZOBuPExR7Ih" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_495_20230701__20230930_zSrLE0bpK7fe" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20240401__20240930_zNUNECfChrkj" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_491_20230401__20230930_zb4jdGMyY0g8" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six Months Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_ecustom--NumeratorAbstract_iB_zkVXSRJUIx9g" style="vertical-align: bottom"> <td>Numerator:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--NetIncomeLoss_zNTZUDcJUT68" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(610</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,484</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,753</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(2,902</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DenominatorAbstract_iB_zBTUR7hLhPM5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted-average number of common shares outstanding: basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20240930_z7PpRTDKaly1" title="Weighted-average number of common shares outstanding: basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240701__20240930_zJybcouVIhAe" title="Weighted-average number of common shares outstanding: diluted">1,034</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20230930_zsERZP2mzm36" title="Weighted-average number of common shares outstanding: basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20230930_zafqD03MLb9g" title="Weighted-average number of common shares outstanding: diluted">258</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240401__20240930_zmMIXIhpD8X8" title="Weighted-average number of common shares outstanding: basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240401__20240930_zjWZndBMUtg" title="Weighted-average number of common shares outstanding: diluted">943</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230401__20230930_zNPdvG38NE7e" title="Weighted-average number of common shares outstanding: basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230401__20230930_ztng2L4jqItd" title="Weighted-average number of common shares outstanding: diluted">253</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pip0_c20240701__20240930_zKcEJHme1Vej" title="Net loss per share: basic"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pip0_c20240701__20240930_zeGHyqpMgD22" title="Net loss per share: diluted">(0.59</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pip0_c20230701__20230930_z4aFQ3QSxuRk" title="Net loss per share: basic"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20230930_zEmNalWniXfd" title="Net loss per share: diluted">(5.75</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pip0_c20240401__20240930_zJLFvn3worA4" title="Net loss per share: basic"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pip0_c20240401__20240930_z9vWc2T0nm46" title="Net loss per share: diluted">(1.86</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_pip0_c20230401__20230930_z9GZBn4mGXQl" title="Net loss per share: basic"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pip0_c20230401__20230930_zsUkyUQkQJl1" title="Net loss per share: diluted">(11.47</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A1_zO8eby9OIfQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The computation of basic loss per share for the three and six months ended September 30, 2024 and 2023 excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive.</p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zq2a2A30XUjb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Anti-dilutive shares)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B0_zMoylVPK0NDk" style="display: none">Schedule of anti-dilutive shares</span> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six Months Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-style: italic; text-align: justify">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: justify">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zcxHWnFcgGi2" style="width: 11%; text-align: right" title="Anti-dilutive shares">42</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zvKlhmIgK0rk" style="width: 11%; text-align: right" title="Anti-dilutive shares">26</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zrvi2XFQ6BE3" style="width: 11%; text-align: right" title="Anti-dilutive shares">42</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zz7acqSHGGyd" style="width: 11%; text-align: right" title="Anti-dilutive shares">26</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zJjPaaGNnUDh" style="text-align: right" title="Anti-dilutive shares">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqeOomk2fyo6" style="text-align: right" title="Anti-dilutive shares">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240401__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs8zTtNyiqqf" style="text-align: right" title="Anti-dilutive shares">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zCTI0QuE0eOh" style="text-align: right" title="Anti-dilutive shares">5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 1pt">Common stock units (1)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zOec5orLyyug" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zl1OwnlrsHhe" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">2</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240401__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_z0tg2LYPaHyk" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zTaVFrLU7Fy1" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">2</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240701__20240930_znTLmJqUkEUa" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">42</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930_zOFhEbxAGqsc" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20240930_zyLhhzpvkyjg" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">42</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20230930_z6VX3uQ0Oksh" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%"><span id="xdx_F0E_zSWhVvSENMN9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="width: 95%; text-align: justify"><span id="xdx_F1A_zSLyF9SUUHC1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 1,533 restricted stock units and warrants to purchase 766 shares of common stock.</span></td></tr> </table> <p id="xdx_8A2_zqPJ2plqtw2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b> </p> <p id="xdx_849_eus-gaap--RevenueRecognitionPolicyTextBlock_zH4h0SvHGV9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_ziSx4XRaimgh">Revenue Recognition</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”), Topic 606 Revenue from Contracts with Customers (“Topic 606”). Revenue is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company derives the majority of its revenue through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company has also entered into agreements to license its technology and products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For all of the Company’s sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able to estimate the amount of product that will be returned.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has entered into consignment arrangements, in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company recognizes revenue based on a variable percentage of a fixed price. Revenue recognized varies depending on whether a patient is covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the Company’s rebate program.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales to stocking distributors are made under terms with fixed pricing and limited rights of return (known as “stock rotation”) of the Company’s products held in their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates the creditworthiness of new customers and monitors the creditworthiness of its existing customers to determine whether an event or changes in their financial circumstances would raise doubt as to the collectability of a sale at the time in which a sale is made. Payment terms on sales are generally 30 to 90 days.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company assessed the promised goods and services in the technical support contract with Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and as separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--ReceivablesPolicyTextBlock_ziFdsg0M6t42" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zT34h1d5uDq3">Accounts Receivable</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable are recorded net of allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based on analysis of contractual terms and historical trends.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s policy is to reserve for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company did not deem it necessary to record an allowance for doubtful accounts for probable credit losses at September 30, 2024 and March 31, 2024. Additionally, at September 30, 2024 and March 31, 2024, the Company has allowances of $<span id="xdx_904_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_pn3d_c20240930_z3yAiJQEGks7" title="Allowances related to potential discounts, returns, distributor fees and rebates">66,000</span> and $<span id="xdx_904_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_pn3d_c20240331_zV1zr2boLtN5" title="Allowances related to potential discounts, returns, distributor fees and rebates">27,000</span>, respectively, related to potential discounts, returns, distributor fees and rebates. The allowances are included in Accounts Receivable, net in the accompanying condensed consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p id="xdx_843_eus-gaap--InventoryPolicyTextBlock_zxorT21NzfG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_z31FBld4Goqd">Inventories</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower of cost, cost being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to changing market conditions, estimated future requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value. At September 30, 2024 and March 31, 2024, the Company recorded provisions to reduce the carrying amounts of inventories to their net realizable value in the amounts of $<span id="xdx_904_eus-gaap--InventoryValuationReserves_iI_pn3d_c20240930_zxsUNTnPzTB2" title="Net realizable value">254,000 </span>and $<span id="xdx_90E_eus-gaap--InventoryValuationReserves_iI_pn3d_c20240331_zPTpGjGUax1e" title="Net realizable value">296,000</span>, respectively, which is included in Inventories, net in the accompanying condensed consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p> <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zDmO9d7mMa5l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zwnQAUis8LWk">Recent Accounting Standards</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounting standards that have been issued or proposed by the FASB, the SEC or other standard setting bodies that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_eus-gaap--UseOfEstimates_z1elHG8SIoji" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86C_zD48YVLKPbB1">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_840_eus-gaap--EarningsPerSharePolicyTextBlock_zZZA0jQLK883" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i><span id="xdx_868_ztqPmLabPoTi">Net Loss per Share</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company computes basic net loss per share by dividing net loss per share available to common stockholders by the weighted average number of common shares outstanding for the period and excludes the effects of any potentially dilutive securities. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides the net loss for each period along with the computation of basic and diluted net loss per share:</p> <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zL26z3HmK2Y8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zN6HMzueYCb3" style="display: none">Schedule of computation of basic and diluted net loss per share</span></td><td> </td> <td colspan="2" id="xdx_491_20240701__20240930_zZOBuPExR7Ih" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_495_20230701__20230930_zSrLE0bpK7fe" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20240401__20240930_zNUNECfChrkj" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_491_20230401__20230930_zb4jdGMyY0g8" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six Months Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_ecustom--NumeratorAbstract_iB_zkVXSRJUIx9g" style="vertical-align: bottom"> <td>Numerator:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--NetIncomeLoss_zNTZUDcJUT68" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(610</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,484</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,753</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(2,902</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DenominatorAbstract_iB_zBTUR7hLhPM5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted-average number of common shares outstanding: basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20240930_z7PpRTDKaly1" title="Weighted-average number of common shares outstanding: basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240701__20240930_zJybcouVIhAe" title="Weighted-average number of common shares outstanding: diluted">1,034</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20230930_zsERZP2mzm36" title="Weighted-average number of common shares outstanding: basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20230930_zafqD03MLb9g" title="Weighted-average number of common shares outstanding: diluted">258</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240401__20240930_zmMIXIhpD8X8" title="Weighted-average number of common shares outstanding: basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240401__20240930_zjWZndBMUtg" title="Weighted-average number of common shares outstanding: diluted">943</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230401__20230930_zNPdvG38NE7e" title="Weighted-average number of common shares outstanding: basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230401__20230930_ztng2L4jqItd" title="Weighted-average number of common shares outstanding: diluted">253</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pip0_c20240701__20240930_zKcEJHme1Vej" title="Net loss per share: basic"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pip0_c20240701__20240930_zeGHyqpMgD22" title="Net loss per share: diluted">(0.59</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pip0_c20230701__20230930_z4aFQ3QSxuRk" title="Net loss per share: basic"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20230930_zEmNalWniXfd" title="Net loss per share: diluted">(5.75</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pip0_c20240401__20240930_zJLFvn3worA4" title="Net loss per share: basic"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pip0_c20240401__20240930_z9vWc2T0nm46" title="Net loss per share: diluted">(1.86</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_pip0_c20230401__20230930_z9GZBn4mGXQl" title="Net loss per share: basic"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pip0_c20230401__20230930_zsUkyUQkQJl1" title="Net loss per share: diluted">(11.47</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8A1_zO8eby9OIfQc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The computation of basic loss per share for the three and six months ended September 30, 2024 and 2023 excludes the potentially dilutive securities summarized in the table below because their inclusion would be anti-dilutive.</p> <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zq2a2A30XUjb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Anti-dilutive shares)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B0_zMoylVPK0NDk" style="display: none">Schedule of anti-dilutive shares</span> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six Months Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-style: italic; text-align: justify">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: justify">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zcxHWnFcgGi2" style="width: 11%; text-align: right" title="Anti-dilutive shares">42</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zvKlhmIgK0rk" style="width: 11%; text-align: right" title="Anti-dilutive shares">26</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zrvi2XFQ6BE3" style="width: 11%; text-align: right" title="Anti-dilutive shares">42</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zz7acqSHGGyd" style="width: 11%; text-align: right" title="Anti-dilutive shares">26</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zJjPaaGNnUDh" style="text-align: right" title="Anti-dilutive shares">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqeOomk2fyo6" style="text-align: right" title="Anti-dilutive shares">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240401__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs8zTtNyiqqf" style="text-align: right" title="Anti-dilutive shares">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zCTI0QuE0eOh" style="text-align: right" title="Anti-dilutive shares">5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 1pt">Common stock units (1)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zOec5orLyyug" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zl1OwnlrsHhe" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">2</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240401__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_z0tg2LYPaHyk" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zTaVFrLU7Fy1" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">2</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240701__20240930_znTLmJqUkEUa" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">42</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930_zOFhEbxAGqsc" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20240930_zyLhhzpvkyjg" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">42</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20230930_z6VX3uQ0Oksh" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%"><span id="xdx_F0E_zSWhVvSENMN9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="width: 95%; text-align: justify"><span id="xdx_F1A_zSLyF9SUUHC1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 1,533 restricted stock units and warrants to purchase 766 shares of common stock.</span></td></tr> </table> <p id="xdx_8A2_zqPJ2plqtw2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b> </p> <table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zL26z3HmK2Y8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Earnings per share)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B7_zN6HMzueYCb3" style="display: none">Schedule of computation of basic and diluted net loss per share</span></td><td> </td> <td colspan="2" id="xdx_491_20240701__20240930_zZOBuPExR7Ih" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_495_20230701__20230930_zSrLE0bpK7fe" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_49E_20240401__20240930_zNUNECfChrkj" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_491_20230401__20230930_zb4jdGMyY0g8" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six Months Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-style: italic; text-align: justify">(In thousands, except per share data)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_ecustom--NumeratorAbstract_iB_zkVXSRJUIx9g" style="vertical-align: bottom"> <td>Numerator:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--NetIncomeLoss_zNTZUDcJUT68" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: left">Net loss</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(610</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,484</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(1,753</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right">(2,902</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--DenominatorAbstract_iB_zBTUR7hLhPM5" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -10pt; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Weighted-average number of common shares outstanding: basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240701__20240930_z7PpRTDKaly1" title="Weighted-average number of common shares outstanding: basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240701__20240930_zJybcouVIhAe" title="Weighted-average number of common shares outstanding: diluted">1,034</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230701__20230930_zsERZP2mzm36" title="Weighted-average number of common shares outstanding: basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230701__20230930_zafqD03MLb9g" title="Weighted-average number of common shares outstanding: diluted">258</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_907_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20240401__20240930_zmMIXIhpD8X8" title="Weighted-average number of common shares outstanding: basic"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20240401__20240930_zjWZndBMUtg" title="Weighted-average number of common shares outstanding: diluted">943</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pn3n3_c20230401__20230930_zNPdvG38NE7e" title="Weighted-average number of common shares outstanding: basic"><span id="xdx_902_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pn3n3_c20230401__20230930_ztng2L4jqItd" title="Weighted-average number of common shares outstanding: diluted">253</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share: basic and diluted</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90A_eus-gaap--EarningsPerShareBasic_pip0_c20240701__20240930_zKcEJHme1Vej" title="Net loss per share: basic"><span id="xdx_902_eus-gaap--EarningsPerShareDiluted_pip0_c20240701__20240930_zeGHyqpMgD22" title="Net loss per share: diluted">(0.59</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_pip0_c20230701__20230930_z4aFQ3QSxuRk" title="Net loss per share: basic"><span id="xdx_906_eus-gaap--EarningsPerShareDiluted_pip0_c20230701__20230930_zEmNalWniXfd" title="Net loss per share: diluted">(5.75</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--EarningsPerShareBasic_pip0_c20240401__20240930_zJLFvn3worA4" title="Net loss per share: basic"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_pip0_c20240401__20240930_z9vWc2T0nm46" title="Net loss per share: diluted">(1.86</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90C_eus-gaap--EarningsPerShareBasic_pip0_c20230401__20230930_z9GZBn4mGXQl" title="Net loss per share: basic"><span id="xdx_90A_eus-gaap--EarningsPerShareDiluted_pip0_c20230401__20230930_zsUkyUQkQJl1" title="Net loss per share: diluted">(11.47</span></span></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> -610000 -1484000 -1753000 -2902000 1034000 1034000 258000 258000 943000 943000 253000 253000 -0.59 -0.59 -5.75 -5.75 -1.86 -1.86 -11.47 -11.47 <table cellpadding="0" cellspacing="0" id="xdx_89D_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zq2a2A30XUjb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Summary of Significant Accounting Policies (Details - Anti-dilutive shares)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B0_zMoylVPK0NDk" style="display: none">Schedule of anti-dilutive shares</span> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Six Months Ended </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>September 30,</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-style: italic; text-align: justify">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 40%; text-align: justify">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zcxHWnFcgGi2" style="width: 11%; text-align: right" title="Anti-dilutive shares">42</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zvKlhmIgK0rk" style="width: 11%; text-align: right" title="Anti-dilutive shares">26</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zrvi2XFQ6BE3" style="width: 11%; text-align: right" title="Anti-dilutive shares">42</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zz7acqSHGGyd" style="width: 11%; text-align: right" title="Anti-dilutive shares">26</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zJjPaaGNnUDh" style="text-align: right" title="Anti-dilutive shares">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zqeOomk2fyo6" style="text-align: right" title="Anti-dilutive shares">5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240401__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zs8zTtNyiqqf" style="text-align: right" title="Anti-dilutive shares">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zCTI0QuE0eOh" style="text-align: right" title="Anti-dilutive shares">5</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 1pt">Common stock units (1)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240701__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zOec5orLyyug" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zl1OwnlrsHhe" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">2</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_d0_c20240401__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_z0tg2LYPaHyk" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">–</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockUnitsMember_fKDEp_zTaVFrLU7Fy1" style="border-bottom: Black 1pt solid; text-align: right" title="Anti-dilutive shares">2</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240701__20240930_znTLmJqUkEUa" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">42</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230701__20230930_zOFhEbxAGqsc" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20240401__20240930_zyLhhzpvkyjg" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">42</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn3n3_c20230401__20230930_z6VX3uQ0Oksh" style="border-bottom: Black 2.5pt double; text-align: right" title="Anti-dilutive shares">33</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 5%"><span id="xdx_F0E_zSWhVvSENMN9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="width: 95%; text-align: justify"><span id="xdx_F1A_zSLyF9SUUHC1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists of 1,533 restricted stock units and warrants to purchase 766 shares of common stock.</span></td></tr> </table> 42000 26000 42000 26000 0 5000 0 5000 0 2000 0 2000 42000 33000 42000 33000 <p id="xdx_849_eus-gaap--RevenueRecognitionPolicyTextBlock_zH4h0SvHGV9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86E_ziSx4XRaimgh">Revenue Recognition</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue in accordance with Accounting Standards Codification (“ASC”), Topic 606 Revenue from Contracts with Customers (“Topic 606”). Revenue is recognized when the Company transfers promised goods or services to the customer, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under the agreement, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company derives the majority of its revenue through sales of its products directly to end users and to distributors. The Company also sells products to a customer base, including hospitals, medical centers, doctors, pharmacies, distributors and wholesalers. The Company has also entered into agreements to license its technology and products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be the contracts with a customer. For each contract, the Company considers the promise to transfer products, each of which are distinct, to be the identified performance obligations. In determining the transaction price the Company evaluates whether the price is subject to refund or adjustment to determine the net consideration to which it expects to be entitled.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For all of the Company’s sales to non-consignment distribution channels, revenue is recognized when control of the product is transferred to the customer (i.e. when its performance obligation is satisfied), which typically occurs when title passes to the customer upon shipment but could occur when the customer receives the product based on the terms of the agreement with the customer. For product sales to its value-added resellers, non-stocking distributors and end-user customers, the Company grants return privileges to its customers, and because the Company has a long history with its customers, the Company is able to estimate the amount of product that will be returned.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has entered into consignment arrangements, in which goods are left in the possession of another party to sell. As products are sold from the customer to third parties, the Company recognizes revenue based on a variable percentage of a fixed price. Revenue recognized varies depending on whether a patient is covered by insurance or is not covered by insurance. In addition, the Company may incur a revenue deduction related to the use of the Company’s rebate program.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Sales to stocking distributors are made under terms with fixed pricing and limited rights of return (known as “stock rotation”) of the Company’s products held in their inventory. Revenue from sales to distributors is recognized upon the transfer of control to the distributor.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates the creditworthiness of new customers and monitors the creditworthiness of its existing customers to determine whether an event or changes in their financial circumstances would raise doubt as to the collectability of a sale at the time in which a sale is made. Payment terms on sales are generally 30 to 90 days.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company assessed the promised goods and services in the technical support contract with Invekra for a ten-year period as being a distinct service that Invekra can benefit from on its own and as separately identifiable from any other promises within the contract. Given that the distinct service is not substantially the same as other goods and services within the Invekra contract, the Company accounted for the distinct service as a performance obligation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--ReceivablesPolicyTextBlock_ziFdsg0M6t42" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_868_zT34h1d5uDq3">Accounts Receivable</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable are recorded net of allowances for cash discounts for prompt payment, doubtful accounts, and sales returns. Estimates for cash discounts and sales returns are based on analysis of contractual terms and historical trends.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s policy is to reserve for uncollectible accounts based on its best estimate of the amount of probable credit losses in its existing accounts receivable. The Company periodically reviews its accounts receivable to determine whether an allowance for doubtful accounts is necessary based on an analysis of past due accounts and other factors that may indicate that the realization of an account may be in doubt. Other factors that the Company considers include its existing contractual obligations, historical payment patterns of its customers and individual customer circumstances, an analysis of days sales outstanding by customer and geographic region, and a review of the local economic environment and its potential impact on government funding and reimbursement practices. Account balances deemed to be uncollectible are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. The Company did not deem it necessary to record an allowance for doubtful accounts for probable credit losses at September 30, 2024 and March 31, 2024. Additionally, at September 30, 2024 and March 31, 2024, the Company has allowances of $<span id="xdx_904_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_pn3d_c20240930_z3yAiJQEGks7" title="Allowances related to potential discounts, returns, distributor fees and rebates">66,000</span> and $<span id="xdx_904_ecustom--AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns_iI_pn3d_c20240331_zV1zr2boLtN5" title="Allowances related to potential discounts, returns, distributor fees and rebates">27,000</span>, respectively, related to potential discounts, returns, distributor fees and rebates. The allowances are included in Accounts Receivable, net in the accompanying condensed consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> 66000 27000 <p id="xdx_843_eus-gaap--InventoryPolicyTextBlock_zxorT21NzfG5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_z31FBld4Goqd">Inventories</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inventories are stated at the lower of cost, cost being determined on a standard cost basis (which approximates actual cost on a first-in, first-out basis), or net realizable value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Due to changing market conditions, estimated future requirements, age of the inventories on hand and production of new products, the Company regularly reviews inventory quantities on hand and records a provision to write down excess and obsolete inventory to its estimated net realizable value. At September 30, 2024 and March 31, 2024, the Company recorded provisions to reduce the carrying amounts of inventories to their net realizable value in the amounts of $<span id="xdx_904_eus-gaap--InventoryValuationReserves_iI_pn3d_c20240930_zxsUNTnPzTB2" title="Net realizable value">254,000 </span>and $<span id="xdx_90E_eus-gaap--InventoryValuationReserves_iI_pn3d_c20240331_zPTpGjGUax1e" title="Net realizable value">296,000</span>, respectively, which is included in Inventories, net in the accompanying condensed consolidated balance sheets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p> 254000 296000 <p id="xdx_84D_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zDmO9d7mMa5l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_867_zwnQAUis8LWk">Recent Accounting Standards</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Accounting standards that have been issued or proposed by the FASB, the SEC or other standard setting bodies that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_807_eus-gaap--OtherAssetsDisclosureTextBlock_zQZwK8gQErG" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4.</b></span></td> <td style="width: 94%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_823_z8Mh4g8Ou6jb">Condensed Consolidated Balance Sheet</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Inventories, net</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.5pt"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Inventories, net consist of the following:</p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z4khUsFXhoI8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Condensed Consolidated Balance Sheet (Details - Inventories)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BB_zf9HXnwgq7Pc" style="display: none">Schedule of inventories, net</span></td><td> </td> <td colspan="2" id="xdx_49C_20240930_zDTqjhisSX58" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_494_20240331_zGz5nh2RfBgl" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pn3p0_maIGzA0w_z40CRiCZHFuk" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,670,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,802,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3p0_maIGzA0w_zAW23kGkdUce" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,421,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,213,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InventoryGross_iTI_pn3p0_mtIGzA0w_maINzHEX_ztYPCjtB9JX4" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><b style="display: none">Inventories, gross</b> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,091,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,015,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InventoryValuationReserves_iNI_pn3p0_di_msINzHEX_zAMXUO4ZmQRl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: allowance for obsolete and excess inventory</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(254,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(296,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--InventoryNet_iTI_pn3p0_mtINzHEX_zdrGbcIgrH37" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,837,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,719,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zNmX63zDOx6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Leases</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s operating leases are comprised primarily of facility leases. Balance sheet information related to the Company’s leases is presented below:</p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_pn3n3_zJ4mPc33Vk07" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Condensed Consolidated Balance Sheet (Details - Balance sheet information related to leases)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B9_zBkBrl70Hqte" style="display: none">Schedule of lease information</span> </td><td> </td> <td colspan="2" id="xdx_497_20240930_zCzu79xQOb44" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_495_20240331_z0ogmW26QMre" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--LeasesOperatingAbstract_iB_zjRDdGpwAXM" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: justify">Operating leases:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3p0_zPNJGu8fWlZ2" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: justify">Operating lease right-of-use assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">162,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">286,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3p0_zRUBU68cUUje" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Operating lease liabilities – current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">198,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3p0_zOEGPwJe9n22" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Operating lease liabilities – non-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,000</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other information related to leases is presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Six Months Ended September 30, 2024</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: left">Operating lease cost</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseCost_pn3p0_c20240401__20240930_zCeliOvatP39" style="width: 13%; text-align: right" title="Operating lease cost">186,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: 9.3pt">Operating cash flows from operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pn3p0_di_c20240401__20240930_zam67Pek9jM1" style="text-align: right" title="Operating cash flows from operating leases">(102,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 9.3pt">Weighted-average remaining lease term – operating leases (in months)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240930_zzoqyNdcVZjb" title="Weighted-average remaining lease term - operating leases (in months)">18.7</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: 9.3pt">Weighted-average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20240930_zSDCuB7wQat" title="Weighted-average discount rate - operating leases">6.00</span>%</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A2_zhlnB8YRPMM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 180.1pt 0 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of September 30, 2024, the annual minimum lease payments of our operating lease liabilities were as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_z75k3mSRK3O8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Condensed Consolidated Balance Sheet (Details - Minimum lease payments of opearting lease liabilities)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BF_zXcqSsrPRZf6" style="display: none">Schedule of minimum lease payments of operating lease liabilities</span> </td><td> </td> <td colspan="2" id="xdx_491_20240930_zUq1PpcEzUkl" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">For Years Ending March 31,</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3p0_maLOLLPzr9e_z8DCsyUlOoV1" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%">2025 (excluding the six months ended September 30, 2024)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">87,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3p0_maLOLLPzr9e_zR6VZMhukCHk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">67,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3p0_maLOLLPzr9e_zz4aZn15sDd7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3p0_maLOLLPzr9e_zuBbbF0TIhO5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2028</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3p0_mtLOLLPzr9e_zLPKrTLuuP3b" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">177,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3p0_di_zITnxH3Qd4Tf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iI_pn3p0_zO8omezqn5L6" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of future minimum lease payments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">162,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zBg9UiowmLF3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_z4khUsFXhoI8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Condensed Consolidated Balance Sheet (Details - Inventories)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BB_zf9HXnwgq7Pc" style="display: none">Schedule of inventories, net</span></td><td> </td> <td colspan="2" id="xdx_49C_20240930_zDTqjhisSX58" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_494_20240331_zGz5nh2RfBgl" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--InventoryRawMaterialsNetOfReserves_iI_pn3p0_maIGzA0w_z40CRiCZHFuk" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,670,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,802,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_pn3p0_maIGzA0w_zAW23kGkdUce" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Finished goods</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,421,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,213,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--InventoryGross_iTI_pn3p0_mtIGzA0w_maINzHEX_ztYPCjtB9JX4" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td><b style="display: none">Inventories, gross</b> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,091,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,015,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--InventoryValuationReserves_iNI_pn3p0_di_msINzHEX_zAMXUO4ZmQRl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: allowance for obsolete and excess inventory</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(254,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(296,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--InventoryNet_iTI_pn3p0_mtINzHEX_zdrGbcIgrH37" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,837,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,719,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1670000 1802000 1421000 1213000 3091000 3015000 254000 296000 2837000 2719000 <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--LeaseCostTableTextBlock_pn3n3_zJ4mPc33Vk07" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Condensed Consolidated Balance Sheet (Details - Balance sheet information related to leases)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B9_zBkBrl70Hqte" style="display: none">Schedule of lease information</span> </td><td> </td> <td colspan="2" id="xdx_497_20240930_zCzu79xQOb44" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2" id="xdx_495_20240331_z0ogmW26QMre" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--LeasesOperatingAbstract_iB_zjRDdGpwAXM" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: justify">Operating leases:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pn3p0_zPNJGu8fWlZ2" style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: justify">Operating lease right-of-use assets</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">162,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">286,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn3p0_zRUBU68cUUje" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Operating lease liabilities – current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">198,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pn3p0_zOEGPwJe9n22" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Operating lease liabilities – non-current</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,000</td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other information related to leases is presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Six Months Ended September 30, 2024</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%; text-align: left">Operating lease cost</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--OperatingLeaseCost_pn3p0_c20240401__20240930_zCeliOvatP39" style="width: 13%; text-align: right" title="Operating lease cost">186,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other information:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: 9.3pt">Operating cash flows from operating leases</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pn3p0_di_c20240401__20240930_zam67Pek9jM1" style="text-align: right" title="Operating cash flows from operating leases">(102,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 9.3pt">Weighted-average remaining lease term – operating leases (in months)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20240930_zzoqyNdcVZjb" title="Weighted-average remaining lease term - operating leases (in months)">18.7</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: 9.3pt">Weighted-average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pip0_dp_c20240930_zSDCuB7wQat" title="Weighted-average discount rate - operating leases">6.00</span>%</td><td style="text-align: left"> </td></tr> </table> 162000 286000 116000 198000 46000 87000 186000 102000 P18M21D 0.0600 <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_pn3n3_z75k3mSRK3O8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Condensed Consolidated Balance Sheet (Details - Minimum lease payments of opearting lease liabilities)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8BF_zXcqSsrPRZf6" style="display: none">Schedule of minimum lease payments of operating lease liabilities</span> </td><td> </td> <td colspan="2" id="xdx_491_20240930_zUq1PpcEzUkl" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">For Years Ending March 31,</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pn3p0_maLOLLPzr9e_z8DCsyUlOoV1" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 83%">2025 (excluding the six months ended September 30, 2024)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">87,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pn3p0_maLOLLPzr9e_zR6VZMhukCHk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">67,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pn3p0_maLOLLPzr9e_zz4aZn15sDd7" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">2027</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pn3p0_maLOLLPzr9e_zuBbbF0TIhO5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">2028</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pn3p0_mtLOLLPzr9e_zLPKrTLuuP3b" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">177,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pn3p0_di_zITnxH3Qd4Tf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less: imputed interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(15,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--OperatingLeaseLiability_iI_pn3p0_zO8omezqn5L6" style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of future minimum lease payments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">162,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 87000 67000 14000 9000 177000 15000 162000 <p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zzVqTc1V3ulc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5.</b></span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_822_zcws14aXF0Ld">Commitments and Contingencies</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Legal Matters</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company may be involved in legal matters arising in the ordinary course of business including matters involving proprietary technology from time to time. While management believes that such matters are currently insignificant, matters arising in the ordinary course of business for which the Company is or could become involved in litigation may have a material adverse effect on its business and financial condition of comprehensive loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Employment Matters</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has employment agreements in place with two of its key executives. These executive employment agreements provide, among other things, for the payment of up to eighteen months of severance compensation for terminations under certain circumstances.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2024, with respect to these agreements, aggregated annual salaries was $<span id="xdx_90F_eus-gaap--OfficersCompensation_pn3d_c20240401__20240930_z9GoHoPfmlOc" title="Aggregated annual salaries">586,000</span> and potential severance payments to these key executives is $<span id="xdx_900_ecustom--PotentialSeverancePayments_iI_pn3d_c20240930_zxj47exFCsCi" title="Potential severance payments">1,300,000</span>, if triggered.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 586000 1300000 <p id="xdx_80E_eus-gaap--DebtDisclosureTextBlock_zAatIYiA84h1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6.</b></span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_823_z7c1YiIHVDP3">Debt</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Financing of Insurance Premiums</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 6, 2024, the Company entered into a note agreement for $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pn3d_c20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_z0eDGgxF7E93" title="Debt face amount">373,000</span> with an interest rate of <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pip0_dp_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zQRVkrSMKbmc" title="Debt interest rate">8.42</span>% per annum with final payment on <span id="xdx_909_eus-gaap--DebtInstrumentMaturityDateRangeEnd1_dd_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zOPz9xXyVcMj" title="Final payment date">November 1, 2024</span>. This instrument was issued in connection with financing insurance premiums. The note is payable in <span id="xdx_905_eus-gaap--DebtInstrumentPaymentTerms_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember" title="Debt payment terms">nine monthly installment payments</span> of principal and interest of $<span id="xdx_909_eus-gaap--DebtInstrumentPeriodicPayment_pn3d_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_z7B8N70fWzUf" title="Periodic payment">42,000</span>, with the first installment beginning <span id="xdx_90F_eus-gaap--DebtInstrumentMaturityDateRangeStart1_dd_c20240205__20240206__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zlUOhzdlqOol" title="First installment beginning date">March 1, 2024</span>. At September 30, 2024 and March 31, 2024, the outstanding principal on the note amounted to $<span id="xdx_904_eus-gaap--OtherLongTermDebtCurrent_iI_pn3d_c20240930__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zsZIkjJ10zQf" title="Outstanding principal amount">82,000</span> and $<span id="xdx_902_eus-gaap--OtherLongTermDebtCurrent_iI_pn3d_c20240331__us-gaap--ShortTermDebtTypeAxis__custom--InsurancePremiumFinancingMember_zqaDRW9Cu9Hd" title="Outstanding principal amount">323,000</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 373000 0.0842 2024-11-01 nine monthly installment payments 42000 2024-03-01 82000 323000 <p id="xdx_805_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z0WYUbTVq0E" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7.</b></span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_zxzmzZmkliZ9">Stockholders’ Equity</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Authorized Capital</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective August 29, 2024, the Company increased its authorized shares from <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20240331_zKOqCcvVaPyb" title="Common stock, shares authorized">24,000,000</span> to <span id="xdx_904_eus-gaap--CommonStockSharesAuthorized_iI_pip0_c20240930_z9n2cWmpPFFd" title="Common stock, shares authorized">50,000,000</span> shares of common stock with a par value of $<span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pip0_c20240930_zynnzE8KmkVb" title="Common stock, par value">0.0001</span> per share.  Additionally, the Company is authorized to issue <span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pip0_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zmiydM9kGbme" title="Convertible preferred stock, shares authorized">714,286</span> shares of convertible preferred stock with a par value of $<span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pip0_c20240930__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zPXcf0qmFhYa" title="Convertible preferred stock, par value">0.0001</span> per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Sale of Common Stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Equity Distribution Agreement that the Company entered into on December 15, 2023 with Maxim Group LLC (“Maxim”), as amended, from May 13, 2024 to September 18, 2024 the Company sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pip0_c20240513__20240918__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zH26DMty3d0f" title="Stock issued new, shares">539,744</span> shares of its common stock for gross proceeds of $<span id="xdx_905_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn3d_c20240513__20240918__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zEw3N96VjGMi" title="Proceeds from sale of stock, gross">2,490,000</span> and net proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn3d_c20240513__20240918__us-gaap--TypeOfArrangementAxis__custom--EquityDistributionAgreementMember_zoW36zA6PGqd" title="Proceeds from sale of stock, net">2,289,000</span> after deducting commissions and other offering expenses paid by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 24000000 50000000 0.0001 714286 0.0001 539744 2490000 2289000 <p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zTRYE7Yll7k1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8.</b></span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82B_zroWnFuQKrV1">Stock-Based Compensation</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended September 30, 2024 and 2023, the Company incurred $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_pn3d_c20240701__20240930_zfk11EAE0JJd" title="Stock-based compensation expense">14,000</span> and $<span id="xdx_903_eus-gaap--ShareBasedCompensation_pn3d_c20230701__20230930_zK4Sijnk65gc" title="Stock-based compensation expense">130,000</span> of stock-based compensation expense, respectively. For the six months ended September 30, 2024 and 2023, the Company incurred $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pn3d_c20240401__20240930_zvzzAvvOwvw8" title="Stock-based compensation expense">121,000</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pn3d_c20230401__20230930_zdfVWhUHZEzb" title="Stock-based compensation expense">307,000</span> of stock-based compensation expense, respectively. All stock-based compensation incurred is included in selling, general and administrative expense in the accompanying condensed consolidated statements of comprehensive loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2024, there was unrecognized compensation costs of $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn3p0_c20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zMZfQsZWEL4a" title="Unrecognized compensation costs">229,000</span> related to stock options which is expected to be recognized over a weighted-average amortization period of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJwhSbUItpEc" title="Weighted average amortization period">1.80</span> years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Stock options award activity is as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_z8NYwZY0DrQb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details - Stock option award activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B1_zREnmieT3dKf" style="display: none">Schedule of stock options award activity</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Outstanding at April 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCd1DCnJQnff" style="width: 13%; text-align: right" title="Number of Shares, Outstanding, Beginning Balance">51,675</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJec9LmozFWf" style="width: 13%; text-align: right" title="Weighted-Average Exercise Price Outstanding, Beginning Balance">62.60</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z84GdTRGln47" style="text-align: right" title="Number of Shares, Options exercised">(9,250</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJgg526H9117" style="text-align: right" title="Weighted-Average Exercise Price, Options exercised">3.60</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Options forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pip0_di_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSyegUUCsj52" style="text-align: right" title="Number of Shares, Options forfeited">(250</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRMZbx0whun6" style="text-align: right" title="Weighted-Average Exercise Price, Options forfeited">3.60</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pip0_di_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKYNpU9Hz56d" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Options expired">(10</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuRLKgNI0Rm1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Options expired">2,402</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfYoWzomI1Ee" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Outstanding, Ending Balance">42,165</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4blB50TswOb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price Outstanding, Ending Balance">75.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOvUJXQVLVGd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Exercisable">28,335</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zeF3RqgCn7t6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, exercisable">107.92</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_z4KzmNdIHwL2" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company’s common stock, or $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOVRjI7ENZBb" title="Aggregate intrinsic value per share">3.07</span> per share at September 30, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Restricted stock award activity is as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_pn3n3_zbW3jn2Mo9xc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)"> <tr style="vertical-align: bottom"> <td> <span id="xdx_8B3_zxW9gP99ueC2" style="display: none">Schedule of unvested restricted stock activity</span> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Number of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Average Award</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Date Fair Value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>per Share</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Unvested restricted stock awards outstanding at April 1, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pip0_d0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHiHH9QRdjI7" style="text-align: right" title="Number of Shares, Unvested restricted stock awards outstanding, beginning balance">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_d0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQ5PiKTz2p9b" style="text-align: right" title="Weighted Average Award Date Fair Value per Share, Unvested restricted stock awards outstanding, beginning balance">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">Restricted stock awards granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpwgW70ekN8f" style="width: 13%; text-align: right" title="Number of Shares, Restricted stock awards granted">9,538</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zg9cVeKQsCae" style="width: 13%; text-align: right" title="Weighted Average Award Date Fair Value per Share, Restricted stock awards granted">4.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Restricted stock awards vested</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pip0_di_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoL14oUETuQ" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Restricted stock awards vested">(9,538</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zg8MSrAY2A8g" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Award Date Fair Value per Share, Restricted stock awards vested">4.00</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Unvested restricted stock awards outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pip0_d0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zSF2sxUWYYF2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Unvested restricted stock awards outstanding, ending balance">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_d0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrj9bdLF1kl7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Award Date Fair Value per Share, Unvested restricted stock awards outstanding, ending balance">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zlpQ1IkLBonb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company issues new shares of common stock upon exercise of stock options or release of restricted stock awards.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 14000 130000 121000 307000 229000 P1Y9M18D <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_pn3n3_z8NYwZY0DrQb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details - Stock option award activity)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B1_zREnmieT3dKf" style="display: none">Schedule of stock options award activity</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 66%">Outstanding at April 1, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zCd1DCnJQnff" style="width: 13%; text-align: right" title="Number of Shares, Outstanding, Beginning Balance">51,675</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJec9LmozFWf" style="width: 13%; text-align: right" title="Weighted-Average Exercise Price Outstanding, Beginning Balance">62.60</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Options exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pip0_di_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z84GdTRGln47" style="text-align: right" title="Number of Shares, Options exercised">(9,250</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJgg526H9117" style="text-align: right" title="Weighted-Average Exercise Price, Options exercised">3.60</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Options forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pip0_di_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zSyegUUCsj52" style="text-align: right" title="Number of Shares, Options forfeited">(250</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRMZbx0whun6" style="text-align: right" title="Weighted-Average Exercise Price, Options forfeited">3.60</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Options expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pip0_di_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zKYNpU9Hz56d" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Options expired">(10</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zuRLKgNI0Rm1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Options expired">2,402</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfYoWzomI1Ee" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Outstanding, Ending Balance">42,165</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z4blB50TswOb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price Outstanding, Ending Balance">75.77</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pip0_c20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOvUJXQVLVGd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Exercisable">28,335</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pip0_c20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zeF3RqgCn7t6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-average exercise price, exercisable">107.92</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 51675 62.60 9250 3.60 250 3.60 10 2402 42165 75.77 28335 107.92 3.07 <table cellpadding="0" cellspacing="0" id="xdx_896_eus-gaap--ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_pn3n3_zbW3jn2Mo9xc" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Stock-Based Compensation (Details-Restricted stock activity)"> <tr style="vertical-align: bottom"> <td> <span id="xdx_8B3_zxW9gP99ueC2" style="display: none">Schedule of unvested restricted stock activity</span> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Number of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Shares</b></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Average Award</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>Date Fair Value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 1.8pt 0 0; text-align: center"><b>per Share</b></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Unvested restricted stock awards outstanding at April 1, 2024</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pip0_d0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHiHH9QRdjI7" style="text-align: right" title="Number of Shares, Unvested restricted stock awards outstanding, beginning balance">–</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pip0_d0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zQ5PiKTz2p9b" style="text-align: right" title="Weighted Average Award Date Fair Value per Share, Unvested restricted stock awards outstanding, beginning balance">–</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left">Restricted stock awards granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpwgW70ekN8f" style="width: 13%; text-align: right" title="Number of Shares, Restricted stock awards granted">9,538</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zg9cVeKQsCae" style="width: 13%; text-align: right" title="Weighted Average Award Date Fair Value per Share, Restricted stock awards granted">4.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Restricted stock awards vested</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pip0_di_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zoL14oUETuQ" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Restricted stock awards vested">(9,538</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pip0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zg8MSrAY2A8g" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Award Date Fair Value per Share, Restricted stock awards vested">4.00</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Unvested restricted stock awards outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pip0_d0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zSF2sxUWYYF2" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Unvested restricted stock awards outstanding, ending balance">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pip0_d0_c20240401__20240930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zrj9bdLF1kl7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Award Date Fair Value per Share, Unvested restricted stock awards outstanding, ending balance">–</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0 0 9538 4.00 9538 4.00 0 0 <p id="xdx_80D_eus-gaap--IncomeTaxDisclosureTextBlock_z5aboWXF1Sb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9.</b></span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_820_zYkWlWSDKyl9">Income Taxes</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At the end of each interim reporting period, the Company determines the income tax provision by using an estimate of the annual effective tax rate, adjusted for discrete items occurring in the quarter.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our effective tax rate for the three and six months ended September 30, 2024 was <span id="xdx_90F_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp_c20240701__20240930_z18PWsvILnt4" title="Effective tax rate">(31.5</span>)% and <span id="xdx_904_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pip0_dp_c20240401__20240930_zevbtC1sBOb8" title="Effective tax rate">(20.5</span>)%, respectively. The Company’s effective tax rate for the three and six months ended September 30, 2024 differed from the federal statutory tax rate of 21% primarily due to the valuation allowance recognized against deferred tax assets in the U.S., and permanent tax adjustment of intercompany interest expense in Mexico and Netherlands.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Judgment is required in determining whether deferred tax assets will be realized in full or in part. Management assesses the available positive and negative evidence on a jurisdictional basis to estimate if deferred tax assets will be recognized and when it is more likely than not that all or some deferred tax assets will not be realized, and a valuation allowance must be established. As of September 30, 2024, the Company continues to maintain a valuation allowance in the U.S.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> -0.315 -0.205 <p id="xdx_805_eus-gaap--RevenueFromContractWithCustomerTextBlock_z4XtbbynmC4c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10. </b></span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82E_zDG7qKxycPl8">Revenue Disaggregation</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company generates product revenues from products which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services which are provided to medical device manufacturers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table presents the Company’s disaggregated revenues by revenue source:</p> <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--DisaggregationOfRevenueTableTextBlock_pn3n3_ztzy80mLr2K4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue by source)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B0_zkcqc3EeKQC4" style="display: none">Schedule of disaggregated revenue by source</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 32%; text-align: justify">Human Care</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zfeR89F8zPS2" style="width: 13%; text-align: right" title="Revenues">2,957,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zzF7t6Qptyj5" style="width: 13%; text-align: right" title="Revenues">2,075,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z7iJDxkmJtta" style="width: 13%; text-align: right" title="Revenues">5,833,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zvfX7w9128c2" style="width: 13%; text-align: right" title="Revenues">4,825,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Animal Care</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zlyqruq5jbfk" style="text-align: right" title="Revenues">402,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zR3qdAChgZ74" style="text-align: right" title="Revenues">489,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zh5bZ4iPO1X5" style="text-align: right" title="Revenues">801,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_ztHdiuYswI9f" style="text-align: right" title="Revenues">1,067,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 1pt">Service and Royalty</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_ztSa9x2PWyKe" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">220,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_zAst5JSxp1Ih" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">167,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_z0IxzmhIJHl5" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">336,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_zh3nXJUGxJ6d" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">266,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930_zczsdvRPMNC" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">3,579,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930_zS2OGngW1BRa" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">2,731,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930_zmFuW4gNEII6" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">6,970,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930_zDVGBkfn8EL3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">6,158,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zclxKg11ZHBb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows the Company’s revenues by geographic region:</p> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_pn3n3_zExLQKTrNN7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Revenue by geographic regions)"> <tr style="vertical-align: bottom"> <td> <span id="xdx_8BE_zPiIwiAVQU06" style="display: none">Schedule of revenues by geographic region</span> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 32%; text-align: justify">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_z1vehWf2dB91" style="width: 13%; text-align: right" title="Revenues">675,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_zT44DEJy127a" style="width: 13%; text-align: right" title="Revenues">590,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_z4FFShOZ9ckc" style="width: 13%; text-align: right" title="Revenues">1,317,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_zwHrBKDBTQL2" style="width: 13%; text-align: right" title="Revenues">1,396,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Europe</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_z36UoCD2hEaa" style="text-align: right" title="Revenues">1,506,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zIN3Uhu5fVgg" style="text-align: right" title="Revenues">1,201,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zAsjwxnfy7Rj" style="text-align: right" title="Revenues">2,794,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zk1aP9KxWNw4" style="text-align: right" title="Revenues">2,271,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Asia</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zoFJCjxBcKHg" style="text-align: right" title="Revenues">776,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zydo6KttX9Dc" style="text-align: right" title="Revenues">346,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zNHyPTQKRqyi" style="text-align: right" title="Revenues">1,253,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_z93VioKZNg97" style="text-align: right" title="Revenues">1,208,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Latin America</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zAuPb1Yg0hNg" style="text-align: right" title="Revenues">465,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zQanhDPVaesi" style="text-align: right" title="Revenues">260,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zupNvJLfdYT7" style="text-align: right" title="Revenues">1,345,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zTTChssHxax8" style="text-align: right" title="Revenues">747,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 1pt">Rest of the World</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_zSYRlRFv2Wu6" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">157,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_z1GOBf6qsL0a" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">334,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_zWUOxLd16obf" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">261,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_zYLGM1zuyMLc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">536,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930_z8fX0fCEZ96k" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">3,579,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930_zdFAUOqUb42f" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">2,731,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930_ztl7ty3rjWb6" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">6,970,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930_z5AsTYMhvBXe" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">6,158,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zIVhkI8Q4E1b" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--DisaggregationOfRevenueTableTextBlock_pn3n3_ztzy80mLr2K4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Disaggregation of revenue by source)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B0_zkcqc3EeKQC4" style="display: none">Schedule of disaggregated revenue by source</span></td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 32%; text-align: justify">Human Care</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zfeR89F8zPS2" style="width: 13%; text-align: right" title="Revenues">2,957,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zzF7t6Qptyj5" style="width: 13%; text-align: right" title="Revenues">2,075,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_z7iJDxkmJtta" style="width: 13%; text-align: right" title="Revenues">5,833,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--HumanCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zvfX7w9128c2" style="width: 13%; text-align: right" title="Revenues">4,825,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Animal Care</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zlyqruq5jbfk" style="text-align: right" title="Revenues">402,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zR3qdAChgZ74" style="text-align: right" title="Revenues">489,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_zh5bZ4iPO1X5" style="text-align: right" title="Revenues">801,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__us-gaap--StatementBusinessSegmentsAxis__custom--AnimalCareMember__srt--ProductOrServiceAxis__us-gaap--ProductMember_ztHdiuYswI9f" style="text-align: right" title="Revenues">1,067,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 1pt">Service and Royalty</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_ztSa9x2PWyKe" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">220,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_zAst5JSxp1Ih" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">167,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_z0IxzmhIJHl5" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">336,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__srt--ProductOrServiceAxis__us-gaap--ServiceMember__us-gaap--StatementBusinessSegmentsAxis__custom--ServiceAndRoyaltyMember_zh3nXJUGxJ6d" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">266,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930_zczsdvRPMNC" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">3,579,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930_zS2OGngW1BRa" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">2,731,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930_zmFuW4gNEII6" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">6,970,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930_zDVGBkfn8EL3" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">6,158,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 2957000 2075000 5833000 4825000 402000 489000 801000 1067000 220000 167000 336000 266000 3579000 2731000 6970000 6158000 <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_pn3n3_zExLQKTrNN7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Revenue Disaggregation (Details - Revenue by geographic regions)"> <tr style="vertical-align: bottom"> <td> <span id="xdx_8BE_zPiIwiAVQU06" style="display: none">Schedule of revenues by geographic region</span> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Six Months Ended September 30,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 32%; text-align: justify">United States</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_z1vehWf2dB91" style="width: 13%; text-align: right" title="Revenues">675,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_zT44DEJy127a" style="width: 13%; text-align: right" title="Revenues">590,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_z4FFShOZ9ckc" style="width: 13%; text-align: right" title="Revenues">1,317,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__country--US_zwHrBKDBTQL2" style="width: 13%; text-align: right" title="Revenues">1,396,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Europe</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_z36UoCD2hEaa" style="text-align: right" title="Revenues">1,506,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zIN3Uhu5fVgg" style="text-align: right" title="Revenues">1,201,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zAsjwxnfy7Rj" style="text-align: right" title="Revenues">2,794,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--EuropeMember_zk1aP9KxWNw4" style="text-align: right" title="Revenues">2,271,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify">Asia</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zoFJCjxBcKHg" style="text-align: right" title="Revenues">776,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zydo6KttX9Dc" style="text-align: right" title="Revenues">346,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_zNHyPTQKRqyi" style="text-align: right" title="Revenues">1,253,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--AsiaMember_z93VioKZNg97" style="text-align: right" title="Revenues">1,208,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Latin America</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zAuPb1Yg0hNg" style="text-align: right" title="Revenues">465,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zQanhDPVaesi" style="text-align: right" title="Revenues">260,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zupNvJLfdYT7" style="text-align: right" title="Revenues">1,345,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__srt--LatinAmericaMember_zTTChssHxax8" style="text-align: right" title="Revenues">747,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: justify; padding-bottom: 1pt">Rest of the World</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_zSYRlRFv2Wu6" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">157,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_z1GOBf6qsL0a" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">334,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_zWUOxLd16obf" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">261,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueSegmentMember__srt--StatementGeographicalAxis__custom--RestOfTheWorldMember_zYLGM1zuyMLc" style="border-bottom: Black 1pt solid; text-align: right" title="Revenues">536,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240701__20240930_z8fX0fCEZ96k" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">3,579,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230701__20230930_zdFAUOqUb42f" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">2,731,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20240401__20240930_ztl7ty3rjWb6" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">6,970,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20230401__20230930_z5AsTYMhvBXe" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenues">6,158,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 675000 590000 1317000 1396000 1506000 1201000 2794000 2271000 776000 346000 1253000 1208000 465000 260000 1345000 747000 157000 334000 261000 536000 3579000 2731000 6970000 6158000 <p id="xdx_804_eus-gaap--ConcentrationRiskDisclosureTextBlock_zLjWHwuWetO6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 8%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11.</b></span></td> <td style="text-indent: 10pt; width: 92%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span><span id="xdx_822_zI6CKyyt4ab6">Significant Customer Concentrations</span></span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.5pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows major customers revenues as a percentage of net revenue:</p> <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zWXFCVrtBzqb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Significant Customer Concentrations (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B5_z1nbZdzlRweb" style="display: none">Schedule of customer concentrations of risk</span></td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended September 30,</b></span></td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months Ended September 30,</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #D1D1D1"> <td style="width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer A</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____zluGXwIsZvL2" style="display: none" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0985">–</span></span>*%</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1sqkwFqD1fk" title="Concentration risk, percentage">13</span>%</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____zv4f1MQzAc6h" style="display: none" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0989">–</span></span>*%</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ze5FQgu4sGD4" title="Concentration risk, percentage">14</span>%</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer B</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQRq0eFO50og" title="Concentration risk, percentage">13</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zelPUQ2IcDi1" title="Concentration risk, percentage">10</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLdNjQkUKLc8" title="Concentration risk, percentage">19</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKIw24CDZI52" title="Concentration risk, percentage">12</span>%</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #D1D1D1"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer C</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zB8J9aGE9jGe" title="Concentration risk, percentage">19</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUPusgjI5dTf" title="Concentration risk, percentage">21</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUe26LKCXG5d" title="Concentration risk, percentage">19</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQ3sA5Y3Uata" title="Concentration risk, percentage">17</span>%</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer D</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z55BQAouDyo5" title="Concentration risk, percentage">12</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____zNQGWsIBNrId" style="display: none" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1011">–</span></span>*%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____zAMd8zBV2HGf" style="display: none" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1013">–</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____z48CqvQaEsDk" style="display: none" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1015">–</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows major customers accounts receivable balances as a percentage of net accounts receivables:</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #D1D1D1"> <td style="width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer A</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoVaqrLEDJCf" title="Concentration risk, percentage">16</span>%</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEOHU6l0Jvzb" title="Concentration risk, percentage">11</span>%</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer C</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zA6zRQxRCLj8" title="Concentration risk, percentage">11</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8FLm9SpAb1c" title="Concentration risk, percentage">13</span>%</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #D1D1D1"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer D</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zV9myxFLqHw1" title="Concentration risk, percentage">20</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ze16PFfbTdRg" title="Concentration risk, percentage">20</span>%</span></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"><span id="xdx_F05_zLnQgcSyzGqf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="width: 98%"><span id="xdx_F12_zfRrrInFQ5R5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents less than 10%</span></td></tr> </table> <p id="xdx_8A5_zWE73hsIxA45" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_zWXFCVrtBzqb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Significant Customer Concentrations (Details)"> <tr style="vertical-align: bottom"> <td><span id="xdx_8B5_z1nbZdzlRweb" style="display: none">Schedule of customer concentrations of risk</span></td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Three Months Ended September 30,</b></span></td> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Six Months Ended September 30,</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #D1D1D1"> <td style="width: 36%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer A</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____zluGXwIsZvL2" style="display: none" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0985">–</span></span>*%</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1sqkwFqD1fk" title="Concentration risk, percentage">13</span>%</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____zv4f1MQzAc6h" style="display: none" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl0989">–</span></span>*%</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ze5FQgu4sGD4" title="Concentration risk, percentage">14</span>%</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer B</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQRq0eFO50og" title="Concentration risk, percentage">13</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zelPUQ2IcDi1" title="Concentration risk, percentage">10</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zLdNjQkUKLc8" title="Concentration risk, percentage">19</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerBMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKIw24CDZI52" title="Concentration risk, percentage">12</span>%</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #D1D1D1"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer C</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zB8J9aGE9jGe" title="Concentration risk, percentage">19</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUPusgjI5dTf" title="Concentration risk, percentage">21</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUe26LKCXG5d" title="Concentration risk, percentage">19</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQ3sA5Y3Uata" title="Concentration risk, percentage">17</span>%</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer D</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z55BQAouDyo5" title="Concentration risk, percentage">12</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____zNQGWsIBNrId" style="display: none" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1011">–</span></span>*%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____zAMd8zBV2HGf" style="display: none" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1013">–</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_fKg_____z48CqvQaEsDk" style="display: none" title="Concentration risk, percentage"><span style="-sec-ix-hidden: xdx2ixbrl1015">–</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*%</span></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table shows major customers accounts receivable balances as a percentage of net accounts receivables:</p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30,</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2024</b></span></td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #D1D1D1"> <td style="width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer A</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoVaqrLEDJCf" title="Concentration risk, percentage">16</span>%</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerAMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEOHU6l0Jvzb" title="Concentration risk, percentage">11</span>%</span></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer C</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zA6zRQxRCLj8" title="Concentration risk, percentage">11</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerCMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8FLm9SpAb1c" title="Concentration risk, percentage">13</span>%</span></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #D1D1D1"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer D</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20240401__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zV9myxFLqHw1" title="Concentration risk, percentage">20</span>%</span></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pip0_dp_c20230401__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerDMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ze16PFfbTdRg" title="Concentration risk, percentage">20</span>%</span></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 2%"><span id="xdx_F05_zLnQgcSyzGqf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="width: 98%"><span id="xdx_F12_zfRrrInFQ5R5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents less than 10%</span></td></tr> </table> 0.13 0.14 0.13 0.10 0.19 0.12 0.19 0.21 0.19 0.17 0.12 0.16 0.11 0.11 0.13 0.20 0.20 <p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_z02xi8gkq8k1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 6%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12.</b></span></td> <td style="width: 94%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_826_zJU8yuNiYMjg">Subsequent Events</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has evaluated subsequent events or transactions occurring through the date the condensed consolidated financial statements were issued. The Company does not have subsequent events to report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> false false false false Consists of 1,533 restricted stock units and warrants to purchase 766 shares of common stock. Represents less than 10%